



# 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

## The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)

**Authors/Task Force members:** Perry M. Elliott\* (Chairperson) (UK) Aris Anastasakis (Greece), Michael A. Borger (Germany), Martin Borggrefe (Germany), Franco Cecchi (Italy), Philippe Charron (France), Albert Alain Hagege (France), Antoine Lafont (France), Giuseppe Limongelli (Italy), Heiko Mahrholdt (Germany), William J. McKenna (UK), Jens Mogensen (Denmark), Petros Nihoyannopoulos (UK), Stefano Nistri (Italy), Petronella G. Pieper (Netherlands), Burkert Pieske (Austria), Claudio Rapezzi (Italy), Frans H. Rutten (Netherlands), Christoph Tillmanns (Germany), Hugh Watkins (UK).

**Additional Contributor:** Constantinos O'Mahony (UK).

**ESC Committee for Practice Guidelines (CPG):** Jose Luis Zamorano (Chairperson) (Spain), Stephan Achenbach (Germany), Helmut Baumgartner (Germany), Jeroen J. Bax (Netherlands), Héctor Bueno (Spain), Veronica Dean (France), Christi Deaton (UK), Çetin Erol (Turkey), Robert Fagard (Belgium), Roberto Ferrari (Italy), David Hasdai (Israel), Arno W. Hoes (Netherlands), Paulus Kirchhof (Germany/UK), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Patrizio Lancellotti (Belgium), Ales Linhart (Czech Republic), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Per Anton Sirnes (Norway), Juan Luis Tamargo (Spain), Michal Tendera (Poland), Adam Torbicki (Poland), William Wijns (Belgium), Stephan Windecker (Switzerland).

**Document Reviewers:** David Hasdai (Israel) (CPG Review Coordinator), Piotr Ponikowski (Poland) (CPG Review Coordinator), Stephan Achenbach (Germany), Fernando Alfonso (Spain), Cristina Basso (Italy), Nuno Miguel Cardim (Portugal), Juan Ramón Gimeno (Spain), Stephane Heymans (Netherlands), Per Johan Holm (Sweden), Andre Keren

\* Corresponding author: Perry M. Elliott, Cardiology Department, The Heart Hospital, 16-18 Westmoreland Street, London W1G 8PH, United Kingdom, Tel: +44 203 456 7898, Email: [perry.elliott@ucl.ac.uk](mailto:perry.elliott@ucl.ac.uk)

**Other ESC entities having participated in the development of this document:**

**Associations:** European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association of the ESC (HFA).

**Working Groups:** Cardiovascular Pharmacology and Drug Therapy, Working Group on Cardiovascular Surgery, Working Group on Developmental Anatomy and Pathology, Working Group on Grown-up Congenital Heart Disease, Working Group on Myocardial and Pericardial Diseases.

**Councils:** Cardiology Practice, Cardiovascular Primary Care.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

**Disclaimer:** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relationship to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

**National Cardiac Societies document reviewers:** listed in Appendix 1

©The European Society of Cardiology 2014. All rights reserved. For permissions please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

(Israel), Paulus Kirchhof (Germany/UK), Philippe Kolh (Belgium), Christos Lionis (Greece), Claudio Muneretto (Italy), Silvia Priori (Italy), Maria Jesus Salvador (Spain), Christian Wolpert (Germany), Jose Luis Zamorano (Spain).

The disclosure forms of the authors and reviewers are available on the ESC website [www.escardio.org/guidelines](http://www.escardio.org/guidelines)

**Keywords**

Guideline • Diagnosis • Cardiac imaging • Genetics • Symptoms • Heart failure • Arrhythmia • Left ventricular outflow tract obstruction • Sudden cardiac death • Implantable cardioverter defibrillators • Pregnancy • Athletes • Hypertension • Valve disease

**Table of Contents**

Abbreviations and acronyms . . . . .	3	6. Genetic testing and family screening . . . . .	15
1. Preamble . . . . .	4	6.1 Counselling in probands . . . . .	16
2. Introduction . . . . .	5	6.2 Methods for molecular genetic screening in probands . . . . .	16
2.1 Definition . . . . .	5	6.3 Indications for genetic testing in probands . . . . .	16
2.2 Scope of Guidelines . . . . .	5	6.4 Genetic and clinical screening of relatives . . . . .	17
3. Epidemiology . . . . .	6	6.4.1 Families with definite disease causing genetic mutations . . . . .	17
4. Aetiology . . . . .	6	6.4.2 Families without definite disease causing genetic mutations . . . . .	17
4.1 Sarcomere protein gene mutations . . . . .	6	6.5 Clinical and genetic screening of children . . . . .	18
4.2 Metabolic disorders . . . . .	6	6.6 Follow-up of mutation carriers without a phenotype . . . . .	19
4.3 Mitochondrial cardiomyopathies . . . . .	6	6.7 Pre-implantation and pre-natal genetic testing . . . . .	19
4.4 Neuromuscular disease . . . . .	6	7. Delivery of care . . . . .	19
4.5 Malformation syndromes . . . . .	6	7.1 Education and training . . . . .	20
4.6 Infiltrative disease/inflammation . . . . .	6	8. Assessment of symptoms . . . . .	20
4.7 Endocrine disorders . . . . .	6	8.1 Chest pain . . . . .	20
4.8 Drugs . . . . .	7	8.2 Heart failure . . . . .	20
5. Diagnosis . . . . .	7	8.2.1 Invasive pressure studies . . . . .	21
5.1 Diagnostic criteria . . . . .	7	8.2.2 Cardiopulmonary exercise testing . . . . .	21
5.1.1 Adults . . . . .	7	8.3 Syncope . . . . .	21
5.1.2 Children . . . . .	7	8.4 Palpitations . . . . .	22
5.1.3 Relatives . . . . .	8	8.5 Role of electrophysiological testing . . . . .	22
5.2 History and physical examination . . . . .	8	9. Management of symptoms and complications . . . . .	23
5.3 Resting and ambulatory electrocardiography . . . . .	10	9.1 Left ventricular outflow tract obstruction . . . . .	23
5.4 Echocardiography . . . . .	10	9.1.1 General measures . . . . .	23
5.4.1 Assessment of left ventricular wall thickness . . . . .	10	9.1.2 Drug therapy . . . . .	23
5.4.2 Associated abnormalities of the mitral valve and left ventricular outflow tract . . . . .	10	9.1.3 Invasive treatment of left ventricular outflow tract obstruction . . . . .	24
5.4.3 Assessment of latent obstruction . . . . .	11	9.1.3.1 Surgery . . . . .	24
5.4.4 Left atrial enlargement . . . . .	11	9.1.3.2 Septal alcohol ablation . . . . .	24
5.4.5 Assessment of diastolic function . . . . .	12	9.1.3.3 Surgery vs. alcohol ablation . . . . .	25
5.4.6 Systolic function . . . . .	12	9.1.3.4 Minimum activity requirements . . . . .	25
5.4.7 Value of echocardiography in differential diagnosis . . . . .	12	9.1.3.5 Dual chamber pacing . . . . .	26
5.4.8 Contrast echocardiography . . . . .	12	9.2 Left ventricular mid-cavity obstruction and apical aneurysms . . . . .	27
5.4.9 Transoesophageal echocardiography . . . . .	12	9.3 Management of symptoms in patients without left ventricular outflow tract obstruction . . . . .	27
5.5 Cardiovascular magnetic resonance imaging . . . . .	13	9.3.1 Heart failure . . . . .	27
5.5.1 Assessment of ventricular morphology and function . . . . .	13	9.3.1.1 Drug therapy . . . . .	27
5.5.2 Myocardial fibrosis . . . . .	14	9.3.1.2 Cardiac resynchronization therapy . . . . .	28
5.5.3 Late Gadolinium Enhancement and Prognosis . . . . .	14	9.3.1.3 Cardiac transplantation . . . . .	28
5.5.4 Differential diagnosis . . . . .	14	9.3.1.4 Left ventricular assist devices . . . . .	28
5.6 Nuclear imaging and computerized tomography . . . . .	15	9.3.2 Angina . . . . .	28
5.7 Endomyocardial biopsy . . . . .	15		
5.8 Laboratory tests . . . . .	15		

9.4 Atrial tachyarrhythmia . . . . .	29
9.4.1 Acute treatment . . . . .	30
9.4.2 Thromboembolism prophylaxis . . . . .	30
9.4.3 Ventricular rate control . . . . .	30
9.4.4 Rhythm control . . . . .	30
9.5 Sudden cardiac death . . . . .	31
9.5.1 Clinical risk assessment . . . . .	31
9.5.2 Models for estimating sudden cardiac death risk . . . . .	32
9.5.3 Prevention of sudden cardiac death . . . . .	33
9.5.3.1 Exercise restriction . . . . .	33
9.5.3.2 Anti-arrhythmic drugs . . . . .	33
9.5.3.3 Implantable cardioverter defibrillators . . . . .	33
9.5.3.3.1 Secondary prophylaxis . . . . .	33
9.5.3.3.2 Primary prophylaxis . . . . .	33
9.5.3.3.3 Practical aspects of ICD therapy . . . . .	35
9.5.4 Risk of sudden death in children . . . . .	35
9.6 Symptomatic bradycardia and atrioventricular block . . . . .	36
9.7 Ventricular tachycardia . . . . .	36
10. Recommendations for routine follow-up . . . . .	36
11. Reproduction and contraception . . . . .	37
11.1 Introduction . . . . .	37
11.2 Contraception and termination of pregnancy . . . . .	37
11.3 Infertility treatment . . . . .	37
11.4 Pre-conception counselling . . . . .	37
11.5 Management of pregnancy and delivery . . . . .	38
12. Special issues . . . . .	39
12.1. Diagnosis of hypertrophic cardiomyopathy in athletes . . . . .	39
12.2 Hypertension . . . . .	39
12.2.1 Imaging . . . . .	39
12.2.2 Electrocardiogram . . . . .	39
12.3 Isolated basal septal hypertrophy (sigmoid septum) in elderly people . . . . .	39
12.4 Diagnosis and management of valve disease in patients with hypertrophic cardiomyopathy . . . . .	40
12.4.1 Aortic valve disease . . . . .	40
12.4.2 Mitral valve disease . . . . .	40
12.4.3 Endocarditis prophylaxis . . . . .	40
13. Living with cardiomyopathy: advice to patients . . . . .	41
14. Appendix . . . . .	41
References . . . . .	42

## Abbreviations and acronyms

2D	two-dimensional
99mTc-DPD	99mTechnetium-3,3-diphosphono-1,2-propanodi-carboxylic acid
ACE	angiotensin-converting enzyme
AF	atrial fibrillation
AL	amyloid light chain
AR	aortic regurgitation
ARB	angiotensin receptor blocker
ATTR	amyloidosis-transferrin type
AV	atrioventricular
BiVAD	biventricular assist device

BNP	brain natriuretic peptide
BPM	Beats per minute
CCS	Canadian Cardiovascular Society
CFC	cardiofacialcutaneous
CHA <sub>2</sub> DS <sub>2</sub> -VASc	Congestive Heart failure, hypertension, Age $\geq$ 75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female)
CMR	cardiac magnetic resonance
CRT	cardiac resynchronization therapy
CRT-D	cardiac resynchronization therapy-defibrillator
CRT-P	Cardiac resynchronization therapy with a pacemaker
CT	computed tomography
DC	direct current
DNA	deoxyribonucleic acid
E/A	ratio of mitral peak velocity of early filling (E) to mitral peak velocity of late filling (A)
E/e'	ratio of early transmitral flow velocity (E) to early mitral annulus velocity (e')
EACTS	European Association for Cardio-Thoracic Surgery
ECG	electrocardiogram
EF	ejection fraction
EPS	electrophysiological study
ESC	European Society of Cardiology
FDA	(US) Food and Drug Administration
FHL1	four and a half LIM domains 1
HAS-BLED	hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (> 65 years), drugs/alcohol concomitantly
HCM	hypertrophic cardiomyopathy
hs-cTnT	high sensitivity cardiac troponin T
HTS	high throughput sequencing
ICD	implantable cardioverter defibrillator
ILR	implantable loop recorder
INR	international normalized ratio
IUD	intrauterine device
LA	left atrium
LAMP-2	lysosome-associated membrane protein 2
LBBS	left bundle branch block
LEOPARD	Lentiginos, ECG abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth, and sensory-neural Deafness
LGE	late gadolinium enhancement
LV	left ventricular
LVAD	left ventricular assist device
LVH	left ventricular hypertrophy
LVOTO	left ventricular outflow tract obstruction
MADIT-RIT	Multicenter Automatic Defibrillator Implantation Trial—Reduce Inappropriate Therapy
MAPK	mitogen activated protein kinase
MELAS	mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
MERFF	myoclonic epilepsy with ragged red fibres

MRA	mineralocorticoid receptor antagonist
MYBPC3	myosin-binding protein C, cardiac-type
MYH7	myosin-7 ( $\beta$ -myosin heavy chain)
MYL3	myosin light chain 3
NOAC	new oral anticoagulants
NSVT	non-sustained ventricular tachycardia
NT-proBNP	N-terminal pro brain natriuretic peptide
NYHA	New York Heart Association
OAC	oral anticoagulants
o.d.	omni die (every day)
PC-CMR	phase contrast cardiac magnetic resonance
PDE <sub>5</sub>	phosphodiesterase type 5
PET	positron emission tomography
PRKAG2	gamma-2 sub-unit of the adenosine monophosphate-activated protein kinase
RAAS	renin angiotensin aldosterone system
RV	right ventricular
SAM	systolic anterior motion
SCD	sudden cardiac death
SAA	septal alcohol ablation
S-ICD <sup>TM</sup>	Subcutaneous lead implantable cardioverter defibrillator
SPECT	single photon emission computed tomography
SSFP	steady-state free precession
SVT	supraventricular tachycardia
TOE	transoesophageal echocardiography
TNNI3	troponin I, cardiac muscle
TNNT2	troponin T, cardiac muscle
TPM1	tropomyosin alpha-1 chain
TTE	transthoracic echocardiography
TTR	transthyretin
VF	ventricular fibrillation
VKA	vitamin K antagonist
VT	ventricular tachycardia
WHO	World Health Organization

## 1. Preamble

Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk-benefit-ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help the health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines

can be found on the ESC website (<http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx>). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed including assessment of the risk-benefit-ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of recommendation of particular management options were weighed and graded according to predefined scales, as outlined in *Tables 1 and 2*.

The experts of the writing and reviewing panels filled in declarations of interest forms which might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (<http://www.escardio.org/guidelines>). Any changes in declarations of interest that arise during the writing period must be notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from healthcare industry.

The ESC CPG supervises and coordinates the preparation of new Guidelines produced by Task Forces, expert groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions it is approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publication in the *European Heart Journal*. It was developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC Guidelines covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. To implement the guidelines, condensed pocket guidelines versions, summary slides, booklets with essential messages, summary cards for non-specialists, electronic version for digital applications (smartphones etc) are produced. These versions are abridged and, thus, if needed, one should always refer to the full text version which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse, translate and implement the ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice.

Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive,

**Table 1** Classes of recommendations

Classes of Recommendations	Definition	Suggested wording to use
<b>Class I</b>	<b>Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.</b>	<b>Is recommended/is indicated</b>
<b>Class II</b>	<b>Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.</b>	
<i>Class IIa</i>	<i>Weight of evidence/opinion is in favour of usefulness/efficacy.</i>	<b>Should be considered</b>
<i>Class IIb</i>	<i>Usefulness/efficacy is less well established by evidence/opinion.</i>	<b>May be considered</b>
<b>Class III</b>	<b>Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.</b>	<b>Is not recommended</b>

**Table 2** Levels of evidence

<b>Level of Evidence A</b>	<b>Data derived from multiple randomized clinical trials or meta-analyses.</b>
<b>Level of Evidence B</b>	<b>Data derived from a single randomized clinical trial or large non-randomized studies.</b>
<b>Level of Evidence C</b>	<b>Consensus of opinion of the experts and/or small studies, retrospective studies, registries.</b>

diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

## 2. Introduction

### 2.1 Definition

Cardiomyopathies are defined by structural and functional abnormalities of the ventricular myocardium that are unexplained by flow-limiting coronary artery disease or abnormal loading conditions.<sup>1</sup> Historically, this group of disorders has been subdivided into primary disease, in which the heart is the only involved organ, and

secondary forms where the cardiomyopathy is a manifestation of a systemic disorder. These Guidelines adopt a classification system proposed in a recent ESC position statement, in which cardiomyopathies are defined by specific morphological and functional criteria and then grouped into familial/genetic and non-familial/non-genetic subtypes, irrespective of the presence of extra-cardiac disease.<sup>1</sup>

*Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness that is not solely explained by abnormal loading conditions.*

This definition applies to children and adults and makes no *a priori* assumptions about aetiology or myocardial pathology. While this approach broadens the scope of the Guidelines and makes some recommendations more complex, it aligns with everyday clinical practice and is more likely to improve diagnostic accuracy and treatment.

### 2.2 Scope of Guidelines

Uniquely for a common cardiovascular disease, there are very few randomized, controlled, clinical trials in patients with HCM.<sup>2</sup> For this reason, the majority of the recommendations in this document are based on observational cohort studies and expert consensus opinion. The aim is to provide healthcare professionals with a practical diagnostic and treatment framework for patients of all ages and, as the majority of patients have a genetic cause for their disease, the Guidelines also consider the implications of a diagnosis for families and provide specific advice on reproduction and contraception.

Adoption of a purely morphological disease definition means that the number of possible aetiologies is considerable, particularly in young children. As it is impractical to provide an exhaustive compendium of all possible causes of HCM, the Guidelines focus on the most common genetic and non-genetic subtypes, but additional references for less common disorders are provided. Similarly,

treatment recommendations focus largely on generic management issues but make reference to rare diseases when appropriate.

### 3. Epidemiology

A number of methodologically diverse studies in North America, Europe, Asia and Africa report a prevalence of unexplained increase in LV thickness in the range of 0.02–0.23% in adults (*Web Table 1*).<sup>3–12</sup> Many show an age-related prevalence, with much lower rates in patients diagnosed under the age of 25 years.<sup>9</sup> In paediatric registries, the prevalence of HCM in children is unknown, but population-based studies report an annual incidence of 0.3 to 0.5 per 100,000<sup>13,14</sup> (*Web Table 1*). While HCM is most frequently transmitted as an autosomal-dominant trait (see section 6: Genetic testing and family screening) most studies report a small male preponderance (*Web Table 1*). This finding remains unexplained but might reflect bias in screening strategies as well as genetic and hormonal modifiers. The prevalence of HCM in different racial groups is similar.<sup>3–12</sup>

### 4. Aetiology

*In up to 60% of adolescents and adults with HCM, the disease is an autosomal dominant trait caused by mutations in cardiac sarcomere protein genes.*<sup>15–19</sup>

Five to ten percent of adult cases are caused by other genetic disorders including inherited metabolic and neuromuscular diseases, chromosome abnormalities and genetic syndromes (*Figure 1; Web Tables 2 and 3*).<sup>20,21</sup> Some patients have non-genetic disorders that mimic genetic forms of the disease, for example, senile (TTR) and (AL) amyloidosis.<sup>22,23</sup>

#### 4.1 Sarcomere protein gene mutations

Mutations in the genes encoding beta-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3) account for the majority of cases; less commonly affected genes include cardiac troponin I and T (TNNT3, TNNT2), tropomyosin alpha-1 chain (TPM1) and myosin light chain 3 (MYL3). In general, patients with a sarcomere protein mutation present earlier and report a higher prevalence of family history of HCM and sudden cardiac death (SCD) than those without a mutation.<sup>19,24</sup> They also tend to have more severe hypertrophy, microvascular dysfunction and myocardial fibrosis.<sup>25</sup> Several studies have suggested that some sarcomeric protein mutations are associated with a poorer prognosis than others, but these observations are based on small numbers of affected individuals, are sometimes inconsistent between studies, and are limited by the rarity of individual mutations.<sup>26–32</sup> This situation should improve as better data are collected on individual mutations in international databases such as ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>). Multiple sarcomeric protein mutations are present in up to 5% of individuals and tend to present earlier with a more severe phenotype.<sup>33–35</sup>

#### 4.2 Metabolic disorders

Many inherited metabolic diseases are associated with LV hypertrophy. Most are inherited as autosomal recessive traits, but a few are X-linked (*Figure 1; Web Table 3*).<sup>21</sup> The most common metabolic disorders in adults with HCM are Anderson-Fabry disease, with a prevalence of around 0.5–1% in patients older than 35–40 years,<sup>36</sup>

and disease caused by mutations in the gene encoding the  $\gamma_2$  sub-unit of the adenosine monophosphate-activated protein kinase (PRKAG2), with a prevalence of approximately 1%.<sup>37</sup> The reported prevalence of lysosome-associated membrane protein 2 (LAMP-2) mutations that cause Danon disease ranges from 0.7–2.7%.<sup>38</sup> Although still rare, metabolic disorders account for a greater proportion of HCM in children and adolescents.

#### 4.3 Mitochondrial cardiomyopathies

Primary mitochondrial disorders are caused by mutations in nuclear or mitochondrial DNA that are transmitted as autosomal dominant, autosomal recessive, X-linked and maternally inherited traits.<sup>39</sup> The most frequent are those caused by mutations in genes that code for the respiratory chain protein complexes (*Web Table 3*).<sup>21</sup> The clinical presentation of mitochondrial disease typically varies in age at onset and in the range and severity of organ involvement.

#### 4.4 Neuromuscular disease

With the exception of Friedreich's ataxia,<sup>40,41</sup> HCM is a rare manifestation of neuromuscular disease (*Figure 1; Web Table 3*).<sup>21</sup> It is reported in some muscular dystrophies and congenital skeletal myopathies (e.g. nemaline myopathy)<sup>42</sup> (*Web Table 3*)<sup>21</sup> and in association with muscle weakness and contractures caused by mutations in the four-and-half LIM domain-1 (FHL-1) gene.<sup>43</sup> Desmin gene mutations typically cause dilated and restrictive cardiomyopathies, but can present with HCM and atrioventricular (AV) block.<sup>44</sup>

#### 4.5 Malformation syndromes


Several malformation syndromes are associated with HCM (*Web table 3*). The most common are those caused by mutations in genes that code for proteins of the Ras/mitogen activated protein kinase (MAPK) pathway including Noonan,<sup>45</sup> LEOPARD (Lentiginos, ECG abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth, and sensorineural Deafness)<sup>46,47</sup> and Costello syndromes.<sup>48</sup> Most are diagnosed in childhood, but some milder forms (particularly Noonan syndrome) escape early detection and are identified later in life.

#### 4.6 Infiltrative disease/inflammation

Cardiac amyloidosis results in a progressive increase in the thickness of the left and right ventricular myocardium, interatrial septum and AV valves.<sup>49</sup> Light chain (AL) and hereditary transthyretin (TTR)-related amyloidoses can affect the heart in isolation or with multi-organ involvement, whereas wild type (senile) TTR amyloidosis predominantly affects the heart and the carpal tunnel ligament. Myocardial oedema and cellular infiltration in acute myocarditis can mimic HCM, but this is usually a transient phenomenon, accompanied by other clinical and laboratory findings suggestive of the diagnosis.<sup>50,51</sup>

#### 4.7 Endocrine disorders

Transient ventricular hypertrophy is seen in infants of mothers with diabetes, even after good diabetic control during pregnancy.<sup>52</sup> In adults, left ventricular hypertrophy (LVH) is reported in association with pheochromocytoma<sup>53</sup> and acromegaly,<sup>54</sup> but treatment of the underlying endocrine disorder usually results in resolution of hypertrophy.



**Figure 1** Diverse aetiology of hypertrophic cardiomyopathy.

## 4.8 Drugs

Chronic use of some drugs, including anabolic steroids, tacrolimus and hydroxychloroquine, can cause LVH although they rarely result in a left ventricular wall thickness  $\geq 1.5$  cm.<sup>55–57</sup>

## 5. Diagnosis

The diagnosis of HCM rests on the detection of increased LV wall thickness by any imaging modality, but the disease phenotype also includes myocardial fibrosis, morphologic abnormalities of the mitral valve apparatus, abnormal coronary microcirculatory function and electrocardiographic abnormalities. Due to the diverse aetiology of the disease, detection of increased LV wall thickness that is unexplained by loading conditions should prompt a systematic search for its underlying cause. In many patients, this work-up should include specialized laboratory testing and, in some circumstances, genetic analysis (Figure 2).

### 5.1 Diagnostic criteria

#### 5.1.1 Adults

In an adult, HCM is defined by a wall thickness  $\geq 15$  mm in one or more LV myocardial segments—as measured by any imaging technique

(*echocardiography, cardiac magnetic resonance imaging (CMR) or computed tomography (CT)*)—that is not explained solely by loading conditions.


Genetic and non-genetic disorders can present with lesser degrees of wall thickening (13–14 mm); in these cases, the diagnosis of HCM requires evaluation of other features including family history, non-cardiac symptoms and signs, electrocardiogram (ECG) abnormalities, laboratory tests and multi-modality cardiac imaging.

Common diagnostic challenges include the following:

- Presentation in the late phase of the disease with a dilated and/or hypokinetic left ventricle and LV wall thinning (see section 8.2).
- Physiological hypertrophy caused by intense athletic training (see section 12.1).
- Patients with co-existent pathologies (see section 12.2 on hypertension and section 12.4 on diagnosis and management of valve disease)
- Isolated basal septal hypertrophy in elderly people (see section 12.3).

#### 5.1.2 Children

As in adults, the diagnosis of HCM requires an LV wall thickness more than two standard deviations greater than the predicted mean (z-score  $> 2$ , where a z-score is defined as the number of standard deviations from the population mean).<sup>58</sup>



**Figure 2** Schematic summarising the general approach to the diagnosis of hypertrophic cardiomyopathy. Notes: 1. Counselling is essential before and after testing for genetic disease. 2. Genetic testing is recommended in patients fulfilling diagnostic criteria for HCM to enable cascade genetic screening of their relatives. 3. For recommendations on individual investigations see relevant sections. ECG = electrocardiogram.

### 5.1.3 Relatives

The clinical diagnosis of HCM in first-degree relatives of patients with unequivocal disease (LVH  $\geq 15$  mm) is based on the presence of otherwise unexplained increased LV wall thickness  $\geq 13$  mm in one or more LV myocardial segments, as measured using any cardiac imaging technique [echocardiography, cardiac magnetic resonance (CMR) or CT].

In families with genetic forms of HCM, mutation carriers can have non-diagnostic morphological abnormalities that are sometimes associated with abnormal ECG findings. While the specificity of such abnormalities is low, in the context of familial disease they can represent early or mild expression of the disease, and the presence of multiple features increases the accuracy for predicting disease in genotyped populations.<sup>59–61</sup> In general, the presence of any abnormality [for example, abnormal Doppler myocardial imaging and strain,<sup>62–64</sup> incomplete systolic anterior motion (SAM) or elongation of the mitral valve leaflet(s) and abnormal papillary muscles], particularly in the presence of an abnormal ECG, increases the probability of disease in relatives.<sup>59,65,66</sup>

## 5.2 History and physical examination

Age is one of the most important factors to take into account when considering the possible causes for HCM. For example, inherited metabolic disorders and congenital dysmorphic syndromes are much more common in neonates and infants than in older children

or adults, whereas wild-type TTR-related amyloidosis is a disease mostly of men over the age of 65 years.

Construction of a three- to four-generation family pedigree helps to confirm a genetic origin of disease and identifies other family members that are at risk of disease development. Specific features to note in the family history include sudden cardiac deaths, unexplained heart failure, cardiac transplantation, pacemaker and defibrillator implants, and evidence for systemic disease (stroke at a young age, skeletal muscle weakness, renal dysfunction, diabetes, deafness, etc.). Pedigree analysis can also determine the likely mode of inheritance. Most genetic forms of HCM are autosomal-dominant (Web Table 2) and are therefore characterized by the presence of affected individuals in every generation, with transmission from parents of either sex (including male to male) and a 50% risk to offspring. X-linked inheritance should be suspected if males are the only or most severely affected individuals and there is no male-to-male transmission. Autosomal recessive inheritance, the least common pattern, is likely when both parents of the proband are unaffected and consanguineous. When women—but not men—transmit the disease to children of either sex, mitochondrial DNA mutations should be considered.

Many individuals with HCM complain of few, if any, symptoms. In such cases the diagnosis can be incidental or the result of screening. Some patients experience angina, dyspnoea, palpitations and



syncope (see section 8: Assessment of symptoms). A number of non-cardiac symptoms act as pointers for specific diagnoses (Table 3).<sup>67</sup> Similarly, general physical examination can provide diagnostic clues in patients with syndromic or metabolic causes of HCM. Paradoxically, cardiovascular examination is often normal but, in patients with LV outflow tract obstruction (LVOTO), a number of typical features may be identified including a rapid up-and-down stroke to the arterial pulse and an ejection systolic murmur at the left sternal edge that radiates to the right upper sternal edge and apex. The intensity of the murmur is increased by manoeuvres that reduce ventricular preload or afterload, such as standing up from the squatting position and forceful attempted exhalation against a closed airway (Valsalva manoeuvre). Most patients with LVOTO also have signs of mitral regurgitation.

**Table 3** Examples of signs and symptoms suggestive of specific diagnoses (modified from Rapezzi et al.<sup>67</sup>)

Symptom/sign	Diagnosis
Learning difficulties, mental retardation	<ul style="list-style-type: none"> <li>• Mitochondrial diseases</li> <li>• Noonan/LEOPARD/Costello syndrome</li> <li>• Danon disease</li> </ul>
Sensorineural deafness	<ul style="list-style-type: none"> <li>• Mitochondrial diseases (particularly with diabetes)</li> <li>• Anderson-Fabry disease</li> <li>• LEOPARD syndrome</li> </ul>
Visual impairment	<ul style="list-style-type: none"> <li>• Mitochondrial diseases (retinal disease, optic nerve atrophy)</li> <li>• TTR-related amyloidosis (cotton wool type vitreous opacities)</li> <li>• Danon disease (retinitis pigmentosa)</li> <li>• Anderson-Fabry disease (cataracts, corneal opacities)</li> </ul>
Gait disturbance	<ul style="list-style-type: none"> <li>• Friedreich's ataxia</li> </ul>
Paraesthesia/sensory abnormalities/neuropathic pain	<ul style="list-style-type: none"> <li>• Amyloidosis</li> <li>• Anderson-Fabry disease</li> </ul>
Carpal tunnel syndrome	<ul style="list-style-type: none"> <li>• TTR-related amyloidosis (especially when bilateral and in male patients)</li> </ul>
Muscle weakness	<ul style="list-style-type: none"> <li>• Mitochondrial diseases</li> <li>• Glycogen storage disorders</li> <li>• FHL1 mutations</li> <li>• Friedreich's ataxia</li> </ul>
Palpebral ptosis	<ul style="list-style-type: none"> <li>• Mitochondrial diseases</li> <li>• Noonan/LEOPARD syndrome</li> <li>• Myotonic dystrophy</li> </ul>
Lentigines/café au lait spots	<ul style="list-style-type: none"> <li>• LEOPARD/Noonan syndrome</li> </ul>
Angiokeratomata, hypohidrosis	<ul style="list-style-type: none"> <li>• Anderson-Fabry disease</li> </ul>

FHL1 = four and a half LIM domains 1; LEOPARD = lentigines, ECG abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth and sensorineural deafness; TTR = transthyretin

**Table 4** Electrocardiographic abnormalities suggesting specific diagnoses or morphological variants<sup>67</sup>

Finding	Comment
Short PR interval/pre-excitation	Pre-excitation is a common feature of storage diseases (Pompe, PRKAG2, and Danon) and mitochondrial disorders (MELAS, MERFF). A short PR interval without pre-excitation is seen in Anderson-Fabry disease.
AV block	Progressive atrioventricular conduction delay is common in mitochondrial disorders, some storage diseases (including Anderson-Fabry disease), amyloidosis, desminopathies and in patients with PRKAG2 mutations.
Extreme LVH (Sokolow score $\geq 50$ )	Extremely large QRS voltage is typical of storage diseases such as Pompe and Danon disease, but can be caused by pre-excitation alone.
Low QRS voltage (or normal voltages despite increased LV wall thickness)	Low QRS voltage in the absence of pericardial effusion, obesity and lung disease is rare in HCM (limited to cases with end-stage evolution) but is found in up to 50% of patients with AL amyloidosis and 20% with TTR amyloidosis. Differential diagnosis between HCM and cardiac amyloidosis is aided by measuring the ratio between QRS voltages and LV wall thickness.
Extreme superior ("North West") QRS axis deviation	Seen in patients with Noonan syndrome who have severe basal hypertrophy extending into the RV outflow tract.
Giant negative T wave inversion ( $>10$ mm)	Giant negative T wave inversion in the precordial and/or inferolateral leads suggests involvement of the LV apex.
Abnormal Q waves $\geq 40$ ms in duration and/or $\geq 25\%$ of the R wave in depth and/or $\geq 3$ mm in depth in at least two contiguous leads except aVR	Abnormally deep Q waves in the inferolateral leads, usually with a positive T wave, are associated with an asymmetrical distribution of LVH. Q waves of abnormal duration ( $\geq 40$ ms) are associated with areas of replacement fibrosis.
Coved ST segment elevation in lateral chest leads	Some patients with apical or distal hypertrophy develop small apical aneurysms, sometimes associated with myocardial scarring. These may only be detectable on CMR, ventriculography or contrast echo, and are occasionally associated with ST elevation in the lateral chest leads.

AV = atrioventricular; AL = amyloid light chain; CMR = cardiac magnetic resonance; HCM = hypertrophic cardiomyopathy; LV = left ventricular; LVH = left ventricular hypertrophy; MELAS = mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERFF = myoclonic epilepsy with ragged red fibres; PRKAG2 = gamma-2 subunit of the adenosine monophosphate-activated protein kinase; RV = right ventricular; TTR = transthyretin.

### 5.3 Resting and ambulatory electrocardiography

The standard 12-lead ECG can be normal at presentation (6% of patients in referral cohort studies) but generally shows a variable combination of LVH, ST- and T-wave abnormalities, and pathological Q-waves.<sup>68</sup> When interpreted in conjunction with findings on echocardiography and CMR imaging, features that would normally indicate other conditions, such as myocardial ischaemia or infarction, can—with age at diagnosis, inheritance pattern and associated clinical features—suggest an underlying diagnosis or provide clues to the distribution of hypertrophy and myocardial scar (Table 4). For this reason, the ECG is recommended at the first clinic visit in all individuals with known or suspected HCM and should be repeated whenever there is a change in symptoms in patients with an established diagnosis. The ECG is also a sensitive—though non-specific—early marker of disease in relatives.<sup>61</sup>

The frequency of arrhythmias detected during ambulatory electrocardiographic monitoring is age-related. Asymptomatic non-sustained ventricular tachycardia (NSVT), at a rate between 120 and 200 beats per minute (BPM), occurs in 25% of adults with HCM.<sup>69,70</sup> Paroxysmal supraventricular arrhythmias occur during ambulatory electrocardiographic monitoring in up to 38% of patients.<sup>70</sup> Ambulatory ECG monitoring is recommended at the initial clinical assessment to assess the risk of sudden cardiac death (section 9.5: Sudden cardiac death) and stroke (section 9.4: Atrial tachyarrhythmia).

#### Recommendations on electrocardiography

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Standard 12-lead electrocardiography is recommended in patients with suspected hypertrophic cardiomyopathy to aid diagnosis and provide clues to underlying aetiology.	I	B	61,67,68
48-hour ambulatory ECG monitoring is recommended in patients at their initial clinical assessment, to detect atrial and ventricular arrhythmia.	I	B	69–73

ECG = electrocardiogram.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

### 5.4 Echocardiography

Echocardiography is central to the diagnosis and monitoring of HCM. In most patients, hypertrophy preferentially involves the interventricular septum in the basal LV segments but often extends into the lateral wall, the posterior septum and LV apex.<sup>74</sup> As increased ventricular wall thickness can be found at any location (including the right ventricle), the presence, distribution and severity of hypertrophy should be documented using a standardized protocol

for cross-sectional imaging from several projections. Correct orientation and beam alignment along orthogonal planes are essential to avoid oblique sections and over-estimation of wall thickness. Measurements of LV wall thickness should be performed at end-diastole, preferably in short-axis views. M-mode measurements in the parasternal long axis projection should be avoided if possible, to prevent over-estimation of septal thickness by oblique cuts. A standardized approach to myocardial segmentation and nomenclature should be followed for all imaging modalities.<sup>75</sup>

#### 5.4.1 Assessment of left ventricular wall thickness

There are a number of echocardiographic indices that provide a semi-quantitative score of LVH, but for diagnostic purposes the single most relevant parameter is the maximum LV wall thickness at any level.

*In patients with known or suspected HCM it is essential that all LV segments from base to apex be examined, ensuring that the wall thickness is recorded at mitral, mid-LV and apical levels.*

Accurate assessment of LV wall thickness can be challenging when hypertrophy is confined to one or two segments, particularly in the anterolateral wall or the LV apex.<sup>74,76–80</sup> In such cases, extra care is needed during imaging (e.g. transducer angulation to avoid problems related to lateral resolution and foreshortening). Similarly, meticulous imaging of the apex by parasternal and multiple apical views is required to detect apical HCM. If a segment is not visualized adequately, LV opacification—using ultrasound contrast agents and/or CMR—should be considered.<sup>81</sup>

#### 5.4.2 Associated abnormalities of the mitral valve and left ventricular outflow tract

Approximately one-third of patients have resting SAM of the mitral valve leaflets that results in obstruction to the LV outflow tract, while another third have latent obstruction only during manoeuvres that change loading conditions and LV contractility (see 5.4.3: Assessment of latent obstruction).<sup>82–85</sup> Other morphological features that contribute to LVOTO include papillary muscle abnormalities (hypertrophy, anterior and internal displacement, direct insertion into the anterior mitral valve leaflet) and mitral leaflet abnormalities such as elongation or accessory tissue.<sup>78,86–90</sup> Although dynamic LVOTO is common in patients with HCM, it also occurs in other circumstances, such as calcification of the posterior mitral annulus, hypertension, hypovolaemia and hypercontractile states.

By convention, LVOTO is defined as an instantaneous peak Doppler LV outflow tract pressure gradient  $\geq 30$  mm Hg at rest or during physiological provocation such as Valsalva manoeuvre, standing and exercise. A gradient of  $\geq 50$  mm Hg is usually considered to be the threshold at which LVOTO becomes haemodynamically important. This concept comes from studies that demonstrate progressive impedance to flow above this value.<sup>78</sup>

*When a gradient is detected in the LV cavity, it is important to systematically exclude obstruction that is unrelated to SAM, including sub-aortic membranes, mitral valve leaflet abnormalities and mid-cavity obstruction, particularly when interventions to relieve LV outflow obstruction are contemplated.*

Systematic two-dimensional (2D) and Doppler echocardiography is usually sufficient to determine the mechanism and severity of

LVOTO but, when non-invasive images are poor, transoesophageal echocardiography (TOE) or invasive pressure measurements combined with CMR may be considered in selected patients.

Systolic anterior motion of the mitral valve nearly always results in failure of normal leaflet coaptation and mitral regurgitation, which is typically mid-to-late systolic and inferolaterally oriented; measurement of the velocity and timing of the mitral jet helps to differentiate it from LV outflow tract turbulence. SAM-related mitral regurgitation is inherently dynamic in nature and its severity varies with the degree of LVOTO.<sup>78,91,92</sup>

*The presence of a central- or anteriorly directed jet of mitral regurgitation should raise suspicion of an intrinsic mitral valve abnormality and prompt further assessment with TOE if necessary.*

### 5.4.3 Assessment of latent obstruction


Identification of LVOTO is important in the management of symptoms and assessment of sudden cardiac death risk (see section 9.5: Sudden cardiac death). 2D and Doppler echocardiography during a Valsalva manoeuvre in the sitting and semi-supine position—and then on standing if no gradient is provoked—is recommended in all patients (Figure 3).<sup>78,93</sup> Exercise stress echocardiography is recommended in symptomatic patients if bedside manoeuvres fail to induce LVOTO  $\geq 50$  mm Hg. Pharmacological provocation with

dobutamine is not recommended, as it is not physiological and can be poorly tolerated. Similarly, nitrates do not reproduce exercise-induced gradients and should be reserved for patients who cannot perform physiologically stressful procedures.<sup>94</sup> There is some evidence that post-prandial gradients are higher than those performed in the fasting state and pre-treatment with  $\beta$ -blockers often reduces the incidence and severity of exercise-induced LV outflow tract gradients.<sup>95</sup> Since there are relatively few data comparing stress echocardiography protocols,<sup>93,95–98</sup> laboratories should develop and validate their own and ensure that staff are properly trained in the procedure.

In asymptomatic patients, bedside provocation manoeuvres are useful in risk stratification (see section 9.5: Sudden cardiac death) but routine exercise stress echocardiography in this situation has not been prospectively evaluated and should only be considered in selected patients when the presence of a LVOT gradient is relevant to lifestyle advice and decisions on medical treatment.

### 5.4.4 Left atrial enlargement

The left atrium (LA) is often enlarged, and its size provides important prognostic information.<sup>72,73,99</sup> Although most published studies use anteroposterior LA diameter,<sup>100</sup> comparable findings using LA volume indexed to body surface area are reported.<sup>101,102</sup> The



**Figure 3** Protocol for the assessment and treatment of left ventricular outflow tract obstruction.

cause of LA enlargement is multifactorial, but the most common mechanisms are SAM-related mitral regurgitation and elevated LV filling pressures.

#### 5.4.5 Assessment of diastolic function

Patients with HCM often have diastolic dysfunction and the assessment of LV filling pressures is helpful in the evaluation of symptoms and disease staging. Doppler echocardiographic parameters are sensitive measures of diastolic function, but are influenced by loading conditions, heart rate and age, and there is no single echocardiographic parameter that can be used as a diagnostic hallmark of LV diastolic dysfunction.<sup>103</sup> Therefore, a comprehensive evaluation of diastolic function—including Doppler myocardial imaging, pulmonary vein flow velocities, pulmonary artery systolic pressure and LA size—is recommended as part of the routine assessment of HCM.<sup>103</sup> Patients with a restrictive LV filling pattern [ratio of mitral peak velocity of early filling (E) to mitral peak velocity of late filling (A)  $\geq 2$ ; E-wave deceleration time  $\leq 150$  ms] may be at higher risk for adverse outcome, even with a preserved ejection fraction (EF).<sup>104,105</sup> Data on the relationship between non-invasive Doppler myocardial imaging-derived estimates of LV filling pressure and invasive pressure studies are contradictory,<sup>106</sup> but some studies show correlation between an elevated ratio of early transmitral flow velocity (E) to early mitral annulus velocity ( $e'$ )  $> 12$ – $15$  and raised LV end-diastolic pressure, exercise capacity and prognosis.<sup>107,108</sup>

#### 5.4.6 Systolic function

Radial contractile function (EF or fractional shortening) is typically normal or increased in patients with HCM. However, EF is a poor measure of LV systolic performance when hypertrophy is present.<sup>109</sup> Myocardial longitudinal velocities and deformation parameters (strain and strain rate), derived from Doppler myocardial imaging or speckle tracking techniques, are often reduced despite a normal EF and may be abnormal before the development of increased wall thickness in genetically affected relatives. Myocardial longitudinal deformation is typically reduced at the site of hypertrophy.<sup>110</sup>

#### 5.4.7 Value of echocardiography in differential diagnosis

A number of echocardiographic features can point to a specific diagnosis (Table 5).<sup>67</sup> Concentric hypertrophy is more common in metabolic and infiltrative disorders and biventricular hypertrophy and obstruction to the outflow of both ventricles is frequent in Noonan syndrome and associated disorders. Clues that suggest myocardial storage disease or infiltration include sparkling or granular myocardial texture, small pericardial effusion, thickening of the interatrial septum, nodular thickening of the aortic valve, and mildly reduced EF with restrictive physiology.

#### 5.4.8 Contrast echocardiography

Apical hypertrophy may be overlooked due to near-field artefacts. Poor visualization of the lateral LV wall may also obscure localized

**Table 5** Echocardiographic features that suggest specific aetiologies (modified from Rapezzi et al.<sup>67</sup>)

Finding	Specific diseases to be considered
Increased interatrial septum thickness	Amyloidosis
Increased AV valve thickness	Amyloidosis; Anderson-Fabry disease
Increased RV free wall thickness	Amyloidosis, myocarditis, Anderson-Fabry disease, Noonan syndrome and related disorders
Mild to moderate pericardial effusion	Amyloidosis, myocarditis
Ground-glass appearance of ventricular myocardium on 2D echocardiography	Amyloidosis
Concentric LVH	Glycogen storage disease, Anderson-Fabry disease, PRKAG2 mutations
Extreme concentric LVH (wall thickness $\geq 30$ mm)	Danon disease, Pompe disease
Global LV hypokinesia (with or without LV dilatation)	Mitochondrial disease, TTR-related amyloidosis, PRKAG2 mutations, Danon disease, myocarditis, advanced sarcomeric HCM, Anderson-Fabry disease
Right ventricular outflow tract obstruction	Noonan syndrome and associated disorders

2D = two-dimensional; AV = atrioventricular; HCM = hypertrophic cardiomyopathy; LV = left ventricular; LVH = left ventricular hypertrophy; PRKAG2 = gamma-2 subunit of the adenosine monophosphate-activated protein kinase; RV = right ventricle; TTR = transthyretin.

hypertrophy. In cases of doubt, intravenous ultrasound contrast agents should be used to outline the endocardium.<sup>81</sup>

*In all patients undergoing septal alcohol ablation (SAA), intracoronary contrast echocardiography is recommended to ensure correct localization of alcohol (see section 9.1.3.2: Septal alcohol ablation).*<sup>111–113</sup>

#### 5.4.9 Transoesophageal echocardiography

Transoesophageal echocardiography should be considered in patients with poor transthoracic echo windows, as an alternative or complementary investigation to CMR. It is particularly useful in patients with LVOTO if the mechanism is unclear, when assessing the mitral valve apparatus before a septal reduction procedure, and when severe mitral regurgitation caused by intrinsic valve abnormalities is suspected.<sup>114–117</sup> In patients undergoing septal myectomy, perioperative TOE should be used to guide the surgical strategy and to detect surgical complications (ventricular septal defect and aortic regurgitation (AR)) and residual LVOTO.<sup>116–118</sup> Rarely, TOE with intracoronary contrast injection of the candidate septal perforator arteries is necessary to guide septal alcohol ablation when transthoracic windows are insufficient to visualize contrast within the myocardium.

**Recommendations for transthoracic echocardiographic evaluation in hypertrophic cardiomyopathy**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
In all patients with HCM at initial evaluation, transthoracic 2D and Doppler echocardiography are recommended, at rest and during Valsalva manoeuvre in the sitting and semi-supine positions—and then on standing if no gradient is provoked.	I	B	72–74,76, 78,82,83, 99,119–121
Measurement of maximum diastolic wall thickness is recommended, using 2D short-axis views in all LV segments, from base to apex.	I	C	74–80
A comprehensive evaluation of LV diastolic function is recommended, including pulsed Doppler of mitral valve inflow, tissue Doppler velocities at the mitral annulus, pulmonary vein flow velocities, pulmonary artery systolic pressure, and measurement of LA size and volume.	I	C	103–105
In <i>symptomatic</i> patients with a resting or provoked <sup>d</sup> peak instantaneous LV outflow tract gradient <50 mm Hg, 2D and Doppler echocardiography <i>during exercise</i> in the standing, sitting or semi-supine position is recommended to detect provokable LVOTO and exercise-induced mitral regurgitation.	I	B	84,85,93,94
In <i>asymptomatic</i> patients with a resting or provoked <sup>d</sup> peak instantaneous LV outflow tract gradient <50 mm Hg, 2D and Doppler echocardiography <i>during exercise</i> —in the standing, sitting or semi-supine positions—may be considered when the presence of an LVOT gradient is relevant to lifestyle advice and decisions on medical treatment.	IIb	C	84,85,93,94
In patients with sub-optimal images or with suspected LV apical hypertrophy or aneurysm, TTE with LV cavity opacification—using intravenous echocardiographic contrast agents—should be considered as an alternative to CMR imaging.	IIa	C	81

Intracoronary contrast echocardiography is recommended in all patients undergoing SAA, to ensure correct localization of alcohol.	I	B	111–113
---	---	---	---------

2D = two-dimensional; CMR = cardiac magnetic resonance; LA = left atrium; LV = left ventricle; LVOTO = left ventricular outflow tract obstruction; SAA = septal alcohol ablation; TTE = transthoracic  
<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.  
<sup>d</sup>Provocation with Valsalva, standing or oral nitrate.

**Recommendations on transoesophageal echocardiography**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Perioperative TOE is recommended in patients undergoing septal myectomy, to confirm the mechanism of LVOTO, to guide the surgical strategy, to assess post-surgical complications and to detect residual LV outflow tract obstruction.	I	C	114–118
TOE should be considered in patients with LVOTO if the mechanism is unclear, or when assessing the mitral valve apparatus before a septal reduction procedure, or when severe mitral regurgitation, caused by intrinsic valve abnormalities, is suspected.	IIa	C	114–117
TOE with intracoronary contrast injection of the candidate septal perforator artery should be considered to guide septal alcohol ablation when transthoracic windows are insufficient for proper visualization of echo-contrast within the myocardium.	IIa	C	122

LVOTO = left ventricular outflow tract obstruction; TOE = transoesophageal echocardiography.  
<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.

**5.5 Cardiovascular magnetic resonance imaging**

Cardiovascular magnetic resonance imaging embraces several modalities that provide detailed information on cardiac morphology, ventricular function and myocardial tissue characteristics<sup>123</sup>. Cardiovascular magnetic resonance evaluation of patients with known or suspected HCM should be in line with current ESC recommendations (<http://www.escardio.org/communities/EACVI>) and should be performed and interpreted by teams experienced in cardiac imaging and in the evaluation of heart muscle disease.

**5.5.1 Assessment of ventricular morphology and function**

CMR should be considered in patients with HCM at their baseline assessment if local resources and expertise permit.

In patients with good echocardiographic images, CMR provides similar information on ventricular function and morphology,<sup>124,125</sup> but it is helpful in establishing the diagnosis of HCM in patients with poor acoustic windows or when some LV regions are poorly visualized—such as the anterolateral wall, the LV apex and the right ventricle.<sup>126,127</sup> As in 2D echocardiography, over-estimation of wall thickness can result from oblique sections (particularly at the LV apex) or from inclusion of paraseptal structures such as the moderator band or false tendons. Over-estimation of wall thickness is also possible in spoiled gradient echo images and so steady-state free precession (SSFP) cine sequences are preferred. Cardiovascular magnetic resonance imaging is superior to transthoracic echocardiography (TTE) in the measurement of LV mass, but LV mass itself correlates weakly with maximal wall thickness and can be normal in patients with asymmetric HCM, especially when it involves less than two LV segments.<sup>124,128</sup> Cardiovascular magnetic resonance imaging is superior to standard 2D echocardiography in the detection of LV apical and anterolateral hypertrophy, aneurysms<sup>129</sup> and thrombi,<sup>130</sup> and is more sensitive in the detection of subtle markers of disease, such as myocardial crypts and papillary muscle abnormalities in patients with sarcomeric protein gene mutations.<sup>131–133</sup>

Phase velocity flow mapping sequences can be used to determine the peak velocity of blood flow through the LV outflow tract in patients with LVOTO, but proper alignment of the imaging plane, to obtain the highest flow velocities is time-consuming and prone to error. Intravoxel dephasing and signal loss due to phase offset errors, also make the accurate quantification of turbulent flow difficult and LV outflow gradients can only be measured at rest. For these reasons, Doppler echocardiography is the modality of choice for quantification of LVOTO. Similarly, while mitral inflow velocities and pulmonary vein flow derived from phase contrast CMR (PC-CMR) provide highly reproducible and accurate data in experienced hands, echocardiography is the preferred method for assessment of diastolic function in routine practice.<sup>103</sup>

In selected cases where echocardiographic images are suboptimal, CMR is helpful in pre-operative planning for surgical myectomy, particularly in patients with multi-level LV obstruction (LV outflow tract and mid-cavity) and in patients with right ventricular (RV) outflow tract abnormalities. CMR can also quantify the amount of tissue necrosis induced by septal alcohol ablation, as well as the location of scarring and the regression of LV mass following the procedure.<sup>134,135</sup>

### 5.5.2 Myocardial fibrosis

By using the intrinsic magnetic properties of different tissues and the distribution of gadolinium-based contrast agents, CMR can be used to detect expansion of the myocardial interstitium caused by fibrosis. Late gadolinium enhancement (LGE) is present in 65% of patients (range 33–84%), typically in a patchy mid-wall pattern in areas of hypertrophy and at the anterior and posterior RV insertion points.<sup>136</sup> Late gadolinium enhancement is unusual in non-hypertrophied segments except in advanced stages of disease, when full-thickness LGE in association with wall thinning is common.<sup>136</sup> Late gadolinium enhancement may be associated with increased myocardial stiffness and adverse LV remodelling and the extent of LGE is associated with a higher incidence of regional wall motion abnormalities. Late gadolinium enhancement varies substantially with the quantification method used and the 2-standard deviation technique is the only one validated against necropsy.<sup>137</sup>

Assessment of LGE before invasive treatment of LVOTO may be useful in selecting the most appropriate therapy by assessing the degree of septal fibrosis (see section 9.1).

### 5.5.3 Late Gadolinium Enhancement and Prognosis

The association between LGE and long-term outcomes has been examined in six studies,<sup>138–143</sup> four of which are included in a meta-analysis (*Web Table 4*).<sup>144</sup> All published studies are limited by selection and referral bias, incomplete risk assessment and differences in scanning protocols and LGE quantification. The pooled data support a relationship between LGE and cardiovascular mortality, heart failure death and all-cause death, but show only a trend towards an increased risk of SCD.<sup>144</sup> Late gadolinium enhancement is associated with NSVT on Holter monitoring.<sup>140,142</sup>

*On balance, the extent of LGE on CMR has some utility in predicting cardiovascular mortality, but current data do not support the use of LGE in prediction of SCD risk.*

### 5.5.4 Differential diagnosis

Cardiac magnetic resonance imaging rarely distinguishes the causes of HCM by their magnetic properties alone, but the distribution and severity of interstitial expansion can, in context, suggest specific diagnoses. Anderson-Fabry disease is characterized by a reduction in non-contrast T1 signal and the presence of posterolateral LGE.<sup>145,146</sup> In cardiac amyloidosis, there is often global, sub-endocardial or segmental LGE and a highly specific pattern of myocardial and blood-pool gadolinium kinetics caused by similar myocardial and blood T1 signals.<sup>22,147</sup> The absence of fibrosis may be helpful in differentiating HCM from physiological adaptation in athletes, but LGE may be absent in people with HCM, particularly the young and those with mild disease.

### Recommendations for cardiovascular magnetic resonance evaluation in hypertrophic cardiomyopathy

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
It is recommended that CMR studies be performed and interpreted by teams experienced in cardiac imaging and in the evaluation of heart muscle disease.	I	C	148,149
In the absence of contraindications, CMR with LGE is recommended in patients with suspected HCM who have inadequate echocardiographic windows, in order to confirm the diagnosis.	I	B	126,127
In the absence of contraindications, CMR with LGE should be considered in patients fulfilling diagnostic criteria for HCM, to assess cardiac anatomy, ventricular function, and the presence and extent of myocardial fibrosis.	IIa	B	124,126,127,130,136,138–143
CMR with LGE imaging should be considered in patients with suspected apical hypertrophy or aneurysm.	IIa	C	127,129
CMR with LGE imaging should be considered in patients with suspected cardiac amyloidosis.	IIa	C	22,147
CMR with LGE may be considered before septal alcohol ablation or myectomy, to assess the extent and distribution of hypertrophy and myocardial fibrosis.	IIb	C	150,151

CMR = cardiac magnetic resonance; HCM = hypertrophic cardiomyopathy; LGE = late gadolinium enhancement.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 5.6 Nuclear imaging and computerized tomography

Nuclear imaging, including positron emission tomography (PET) has been used to measure myocardial blood flow and to detect myocardial perfusion defects in patients with HCM, but its value in the diagnosis of HCM is limited.<sup>152–155</sup> The major clinical contribution of nuclear imaging is the detection of TTR-related cardiac amyloidosis. Transthyretin is a tetrameric plasma transport protein synthesized in the liver and is the precursor protein in senile systemic amyloidosis and familial TTR-related amyloidosis.<sup>156,157</sup> Several studies have suggested that TTR-derived fibrils show avidity for bone tracers, in particular 99mTechnetium-3,3-diphosphono-1,2-propano-di-carboxylic acid (99mTc-DPD), whereas there is no uptake of tracer in the hearts of patients with HCM caused by sarcomeric protein gene mutations. For this reason, bone scintigraphy (ideally with 99mTc-DPD) should be considered in patients in whom TTR amyloidosis is a possibility (age > 65 years, history of bilateral carpal tunnel syndrome, absent family history of HCM, and features consistent with cardiac amyloidosis on ECG and cardiac imaging).<sup>156–158</sup>

The high contrast resolution of CT provides clear delineation of the myocardium and accurate measurement of wall thickness, ventricular volumes, ejection fraction and LV mass, which correlate well with magnetic resonance imaging, echocardiography and gated SPECT.<sup>159</sup> Cardiovascular CT permits the simultaneous imaging of the coronary arteries and valves and can be used to guide catheter ablation of supraventricular arrhythmia.<sup>159</sup> Data on myocardial tissue characterization in small cohorts suggest that contrast CT may be useful in the detection of replacement myocardial fibrosis but this requires further study.<sup>160,161</sup> Cardiac CT should be considered in patients for whom there are inadequate echocardiographic imaging and contraindications for CMR.<sup>159</sup>

### Recommendations for nuclear scintigraphy

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Bone scintigraphy (particularly with 99mTc-DPD) should be considered in patients with symptoms, signs and non-invasive tests consistent with TTR-related amyloidosis.	IIa	B	156–158
Cardiac CT should be considered in patients who have inadequate echocardiographic imaging and contraindications for CMR.	IIa	C	159

CT = computerized tomography; 99mTc-DPD = 99mTechnetium-3,3-diphosphono-1,2-propano-di-carboxylic acid; TTR = transthyretin.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 5.7 Endomyocardial biopsy

Many of the genetic and non-genetic causes of HCM have characteristic histological appearances, but the diagnosis of HCM is clinical and relies on non-invasive testing in the first instance. As the underlying

aetiology can usually be determined using clinical assessment, pedigree analysis, non-invasive imaging, laboratory testing and molecular genetic analysis, endomyocardial biopsy is not part of the routine diagnostic work-up, but it may be considered in clinical scenarios where myocardial infiltration or storage is suspected following specialized tests (including biopsy of other more accessible tissues).<sup>162,163</sup>

### Recommendations for endomyocardial biopsy

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Endomyocardial biopsy may be considered when the results of other clinical assessments suggest myocardial infiltration, inflammation or storage that cannot be confirmed by other means.	IIb	C	162,163

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 5.8 Laboratory tests

Routine laboratory testing aids the detection of extra-cardiac conditions that cause or exacerbate ventricular dysfunction (for example, thyroid disease, renal dysfunction and diabetes mellitus) and secondary organ dysfunction in patients with severe heart failure. High levels of brain natriuretic peptide (BNP),<sup>164</sup> N-terminal pro-brain natriuretic peptide (NT-proBNP)<sup>165</sup> and high sensitivity cardiac troponin T (hs-cTnT) are associated with cardiovascular events, heart failure and death. Despite comparable values of ventricular wall thickness, plasma BNP values are three to five times as high in patients with cardiac amyloidosis as those in other causes of HCM. A list of recommended laboratory tests is shown in Table 6.

First-line laboratory screening in children is similar to that for adults and should include haematology, glucose, cardiac enzymes (creatinine kinase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase), renal and liver function tests, pH, electrolytes and uric acid. Following specialist evaluation, additional tests are often required, including measurement of lactate, pyruvate, ammonia, ketones, free fatty acids, carnitine profile, urine organic acids and amino acids.

## 6. Genetic testing and family screening

In the majority of cases, HCM is inherited as an autosomal dominant genetic trait with a 50% risk of transmission to offspring.<sup>34</sup> Some cases are explained by *de novo* mutations, but apparently sporadic cases can arise because of incomplete penetrance in a parent and, less commonly, autosomal recessive inheritance. In patients fulfilling HCM diagnostic criteria, sequencing of sarcomere protein genes identifies a disease-causing mutation in up to 60% of cases.<sup>34,167</sup> The likelihood of finding a causal mutation is highest in patients with familial disease and lowest in older patients and individuals with non-classical features.

**Table 6 Recommended laboratory tests in adult patients with hypertrophic cardiomyopathy**

Test	Comment
Haemoglobin	<ul style="list-style-type: none"> <li>Anaemia exacerbates chest pain and dyspnoea and should be excluded whenever there is a change in symptoms.</li> </ul>
Renal function	<ul style="list-style-type: none"> <li>Renal function may be impaired in patients with severe left ventricular impairment.</li> <li>Impaired GFR and proteinuria may be seen in amyloidosis, Anderson-Fabry disease and mitochondrial DNA disorders.</li> </ul>
Liver transaminases	<ul style="list-style-type: none"> <li>Liver tests may be abnormal in mitochondrial disorders, Danon disease and <math>\beta</math>-oxidation defects.</li> </ul>
Creatine phosphokinase	<ul style="list-style-type: none"> <li>Serum creatine phosphokinase is raised in metabolic disorders such as Danon and mitochondrial disease.</li> </ul>
Plasma/leucocyte alpha galactosidase A (in men aged >30 years)	<ul style="list-style-type: none"> <li>Low (&lt;10% normal values) or undetectable plasma and leucocyte alpha galactosidase A is present in male patients with Anderson-Fabry disease.<sup>a</sup></li> <li>Plasma and leucocyte enzyme levels are often within the normal range in affected females and so genetic testing may be considered if clinically suspected.</li> </ul>
Serum immunoglobulin free light chain assay, serum and urine immunofixation, and urine electrophoresis	<ul style="list-style-type: none"> <li>Should be considered if amyloidosis is suspected from history and non-invasive tests. Confirmation of the diagnosis usually requires histological analysis.</li> </ul>
Fasting glucose	<ul style="list-style-type: none"> <li>May be elevated in some mitochondrial DNA disorders</li> <li>May be low in fatty acid and carnitine disorders.</li> </ul>
Brain natriuretic peptide and troponin T	<ul style="list-style-type: none"> <li>Elevated plasma levels of BNP, NT-proBNP and troponin T are associated with higher risk of cardiovascular events, heart failure and death.</li> </ul>
Thyroid function tests	<ul style="list-style-type: none"> <li>Should be measured at diagnosis and monitored every 6 months in patients treated with amiodarone.</li> </ul>
Plasma Lactate	<ul style="list-style-type: none"> <li>Elevated in some patients with mitochondrial disorders.</li> </ul>

BNP = brain natriuretic peptide; DNA = deoxyribonucleic acid; GFR = glomerular filtration rate; NT-proBNP = N-terminal pro brain natriuretic peptide.  
<sup>a</sup>Pseudo-deficiency may be seen in some genetic variants such as D313Y.<sup>166</sup>

## 6.1 Counselling in probands

Genetic counselling is recommended in all patients when HCM cannot be explained solely by a non-genetic cause.<sup>168</sup>

Counselling should be performed by trained healthcare professionals, working within multidisciplinary teams, to help patients understand and manage the psychological, social, professional, ethical and legal implications of a genetic disease.<sup>169–173</sup> Counselling also facilitates the gathering of information from other family members, including cardiac and non-cardiac symptoms and autopsy

reports that can be used to construct a detailed family pedigree. Pedigree analysis helps to determine the probability of familial disease and the likely mode of inheritance, and provides clues to the underlying aetiology.<sup>67</sup> The consequences of a positive test for the patient and their relatives should be explained, and patients should be provided with information on patient support groups and other sources of information including approved websites.

### Recommendations on genetic counselling

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Genetic counselling is recommended for all patients with HCM when their disease cannot be explained solely by a non-genetic cause, whether or not clinical or genetic testing will be used to screen family members.	I	B	169–173
Genetic counselling should be performed by professionals trained for this specific task working within a multidisciplinary specialist team.	IIa	C	168–173

HCM = hypertrophic cardiomyopathy.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 6.2 Methods for molecular genetic screening in probands

Conventional genetic practice uses pedigree analysis and clinical evaluation to target molecular testing to the most likely diagnosis. New, high-throughput sequencing (HTS) technologies, capable of analysing entire exomes at similar cost and accuracy to conventional sequencing methods, offer an alternative approach in which no *a priori* assumptions are made about the cause of disease.<sup>174,175</sup> However, screening large numbers of genes results in the identification of many rare non-synonymous genetic variants of unknown significance.<sup>175–177</sup> An intermediate approach is the analysis of a pre-defined panel of HCM-related genes using HTS, but the benefit compared with other strategies remains to be determined.<sup>19</sup>

Irrespective of the sequencing methodology employed, genetic analysis should include the most commonly implicated sarcomere protein genes (Figure 1; Web Table 2). In patients who have features suggestive of specific rare genetic diseases (see section 5) there should be a rational search for pathogenic mutations in other genes. All mutation analyses should comply with the general principles of genetic testing and diagnostic tests should be conducted by certified laboratories using validated methods of genetic analysis and reporting.<sup>169–173</sup>

## 6.3 Indications for genetic testing in probands

The task force acknowledge that limited resources make implementation of genetic testing challenging in some healthcare systems. Nevertheless, identification of causative mutations facilitates pre-symptomatic diagnosis of family members, clinical surveillance and reproductive advice.



For this reason, genetic testing is recommended in patients fulfilling diagnostic criteria for HCM to enable cascade genetic screening of their relatives.<sup>24,175,178–180</sup>

The lack of robust data on specific genotype–phenotype associations means that the impact of genetic testing on clinical management is limited mostly to some of the rare genetic causes of HCM. Genetic testing may be of limited clinical value when first-degree relatives are unavailable or unwilling to consider screening for the disease.

Genetic testing in individuals with an equivocal clinical diagnosis (e.g. athletes and hypertensives), should only be performed after detailed clinical and family assessment by teams experienced in the diagnosis and management of cardiomyopathies as the absence of a sarcomere mutation does not exclude familial HCM and variants of uncertain significance are difficult to interpret.<sup>168</sup>

Genetic analysis of post-mortem tissue or DNA samples can be valuable in the assessment of surviving relatives, but must be interpreted in the light of detailed post-mortem examination of the heart and in accordance with conventional rules for assigning pathogenicity to genetic variants.<sup>181,182</sup>

#### Recommendations on genetic testing in probands

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Genetic testing is recommended in patients fulfilling diagnostic criteria for HCM, when it enables cascade genetic screening of their relatives.	I	B	24,175,178–180
It is recommended that genetic testing be performed in certified diagnostic laboratories with expertise in the interpretation of cardiomyopathy-related mutations.	I	C	168,172,183
In the presence of symptoms and signs of disease suggestive of specific causes of HCM, genetic testing is recommended to confirm the diagnosis.	I	B	36–40,43–46,67
Genetic testing in patients with a borderline <sup>d</sup> diagnosis of HCM should be performed only after detailed assessment by specialist teams.	IIa	C	168
Post-mortem genetic analysis of stored tissue or DNA should be considered in deceased patients with pathologically confirmed HCM, to enable cascade genetic screening of their relatives.	IIa	C	181,182

DNA = deoxyribonucleic acid; HCM = hypertrophic cardiomyopathy.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

<sup>d</sup>Borderline: left ventricular wall thickness 12–13 mm in adults; left ventricular hypertrophy in the presence of hypertension, athletic training, valve disease.

## 6.4 Genetic and clinical screening of relatives

The legal framework for informing relatives about the presence of a potentially inheritable condition in their family varies considerably

around the world. In most countries it is the proband (usually the first person in the family to be diagnosed) and not the clinician, who must inform relatives and invite them for screening on behalf of the healthcare system.<sup>184</sup> An information letter is sometimes provided to the patient to help this process.<sup>184</sup> Since most relatives have no symptoms at initial clinical screening, it is important that they are provided with information about the consequences of a diagnosis for life insurance, pension, occupation, sporting activities, and eligibility for fostering and adoption *before* they are tested.

### 6.4.1 Families with definite disease causing genetic mutations

When a definite causative genetic mutation is identified in a patient, his or her relatives should first be genetically tested, and then clinically evaluated if they are found to carry the same mutation (Figure 4).

Economic decision models have compared the cost-effectiveness of molecular screening to clinical screening alone and have shown that the combination of genetic testing and clinical screening identifies more individuals at risk of developing the disease and allows a greater number to be discharged from follow-up.<sup>185,186</sup> For this reason, cascade genetic testing can be offered to all relatives when a definite mutation is identified in the proband. When the mutation is absent, relatives should be discharged from clinic but advised to seek re-assessment if they develop symptoms or if new clinically relevant data emerge in the family. A different approach may be considered in children, to take into account issues of consent and the long-term implications of a positive genetic test. If requested by the parents or legal guardian, clinical evaluation may precede or be substituted for genetic evaluation when this has been agreed to be in the best interests of the child.

### 6.4.2 Families without definite disease causing genetic mutations

First-degree adult relatives should be offered clinical screening with an ECG and echocardiogram when genetic testing is not performed in the proband, or when genetic analysis fails to identify a definite mutation or reveals one or more genetic variants of unknown significance (Figure 4).<sup>168,185,187,188</sup>

*Importantly, the phenomenon of age-related penetrance means that a normal clinical evaluation does not exclude the possibility of disease development in the future; first-degree relatives should therefore be offered repeat assessment.*<sup>168</sup>

The frequency of clinical screening in the absence of a genetic diagnosis should be guided by the age of onset and severity of cardiomyopathy within the family (e.g. the occurrence of multiple and early sudden deaths) and active participation in competitive sport. Individuals who have non-diagnostic clinical features consistent with early disease should be seen initially at intervals of 6–12 months and then less frequently if there is no progression. All relatives who complain of new cardiovascular symptoms should be re-evaluated promptly.

**Recommendations for genetic and clinical testing of adult relatives**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Cascade genetic screening, after pre-test counselling, is recommended in first-degree adult relatives of patients with a definite disease-causing mutation.	I	B	24,175,178–180
Clinical evaluation, employing ECG and echocardiography and long-term follow-up, is recommended in first-degree relatives who have the same definite disease-causing mutation as the proband. <sup>d</sup>	I	C	168
First-degree relatives who do not have the same definite disease-causing mutation as the proband <sup>d</sup> should be discharged from further follow-up but advised to seek re-assessment if they develop symptoms or when new clinically relevant data emerge in the family.	IIa	B	34,185,186,189
When no definite genetic mutation is identified in the proband <sup>d</sup> or genetic testing is not performed, clinical evaluation with ECG and echocardiography should be considered in first-degree adult relatives and repeated every 2–5 years (or 6–12 monthly if non-diagnostic abnormalities are present).	IIa	C	168,185,187,188

ECG = electrocardiogram.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.


<sup>d</sup>Proband = usually the first family member to be diagnosed with the condition.

**6.5 Clinical and genetic screening of children**

Clinical and genetic testing of children should be guided by the best interests of each child in accordance with international standards for good practice.<sup>190–192</sup> Potential benefits of screening in childhood include reduction of uncertainty and anxiety, psychological adjustment, the opportunity to make realistic life plans, and targeted clinical surveillance. Potential harm includes increased ambiguity if a specific phenotype cannot be predicted, alteration of self-image, distortion of perception of the child by parents and other responsible adults such as teachers, increased anxiety and guilt, and compromised life insurance prospects.

*The guiding principle is that a genetic or a clinical test in a child should have an impact on management, lifestyle and further clinical screening.*

Prospective clinical data on children with disease causing sarcomere protein gene mutations are limited, but best evidence suggests that clinically important events in asymptomatic children are rare before puberty.<sup>189</sup> The consensus view of the committee preparing these Guidelines is that clinical and/or genetic screening should be considered from the age of 10 years onwards. Clinical or genetic testing at a younger age may be appropriate in families with early-onset disorders (for example, disorders of the MAPK pathway, inherited errors of metabolism or multiple sarcomere mutations), when there is a malignant family history in childhood and when children have cardiac symptoms or are involved in particularly demanding physical activity.



**Figure 4** Flow chart for the genetic and clinical screening of probands and relatives.

### Recommendations for genetic and clinical screening in children

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
The children of patients with a definite disease-causing mutation should be considered for predictive genetic testing—following pre-test family counselling—when they are aged 10 or more years and this should be carried out in accordance with international guidelines for genetic testing in children.	IIa	C	168,190,192
In first-degree child relatives aged 10 or more years, in whom the genetic status is unknown, clinical assessment with ECG and echocardiography should be considered every 1–2 years between 10 and 20 years of age, and then every 2–5 years thereafter.	IIa	C	168
If requested by the parent(s) or legal representative(s), clinical assessment with ECG and echocardiography may precede or be substituted for genetic evaluation after counselling by experienced physicians and when it is agreed to be in the best interests of the child.	IIb	C	
When there is a malignant family history in childhood or early-onset disease or when children have cardiac symptoms or are involved in particularly demanding physical activity, clinical or genetic testing of first-degree child relatives before the age of 10 years may be considered.	IIb	C	168

ECG = electrocardiogram.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

### 6.6 Follow-up of mutation carriers without a phenotype

Preliminary studies suggest that there are no major adverse psychological consequences associated with long-term clinical and genetic screening in children and adults at risk of disease development when they are managed in expert centres.<sup>189</sup> There are very few data on the natural histories of individuals who carry a disease-causing mutation and have no phenotype, but recent studies suggest a benign clinical course for most clinically unaffected mutation carriers.<sup>189,193</sup> The clinical significance of mild morphological and functional abnormalities is uncertain but probably minor in most cases.<sup>194–196</sup> Sudden cardiac death is rare in the absence of cardiac hypertrophy and is confined mostly to isolated reports of patients with troponin T gene mutations.<sup>27,28,197,198</sup> Cross-sectional studies suggest age-related

increases in penetrance,<sup>30,189,199–201</sup> implying that a proportion of clinically unaffected mutation carriers will develop overt cardiomyopathy later in life. Thus, precautionary long-term evaluation of normal healthy mutation carriers is recommended. Mutation carriers without disease expression on ECG or echocardiography, who wish to participate in competitive sports, should be advised on an individual basis, taking into account the local legal framework, the underlying mutation and the type of sporting activity.<sup>202</sup>

### Recommendations for follow-up of mutation carriers without a phenotype

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
In definite mutation carriers who have no evidence of disease expression, sports activity may be allowed after taking into account the underlying mutation and the type of sport activity, and the results of regular and repeated cardiac examinations.	IIb	C	202

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 6.7 Pre-implantation and pre-natal genetic testing

(See also section 11.4)

Pre-natal genetic diagnosis can be performed at the beginning of pregnancy using chorionic villus sampling or amniocentesis, but the procedure is not legal in some European countries and is restricted to severe and untreatable diseases in others. Given the considerable variability in the phenotypic expression of HCM and its often benign natural history, pre-natal genetic diagnosis of HCM will rarely be appropriate.<sup>168,203</sup> Alternative options to pre-natal diagnosis can be discussed, such as adoption, artificial insemination using donated gametes, and pre-implantation genetic diagnosis.<sup>168</sup> Use of foetal echocardiography to detect early disease is not recommended since the probability of cardiac expression in the foetus is extremely low, with the exception of some syndromic and metabolic disorders.

## 7. Delivery of care

Hypertrophic cardiomyopathy is an 'umbrella' term that encompasses a diverse and complex spectrum of genetic and acquired diseases. As a consequence, the diagnosis and management of patients with HCM requires a range of skills and competencies. In some healthcare systems, a 'hub and spoke' model—in which specialist services are concentrated in a small number of central facilities, with less specialist aspects of care provided by district cardiology services—may be the most effective way of providing the necessary range of skills.<sup>148,204</sup> In other systems, a less centralized approach may be more practical. Whatever the model used, all patients and families should be managed in accordance with the same internationally agreed standards.

Whilst it is not the remit of this task force to describe in detail systems of care for patients with HCM, adherence to a standard of

care is essential if the recommendations of these Guidelines are to be implemented effectively.

**Recommendations on delivery of care**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
It is recommended that individuals who have an uncertain diagnosis, severe symptoms or increased risk for disease-related complications, be referred to specialist teams for further investigation and management.	I	C	148,149
Irrespective of symptom status, regular clinical surveillance of patients—and, when appropriate, their first-degree relatives—is recommended.	I	C	168
In all cases of HCM, clinicians should consider evaluation of patients in centres with multidisciplinary teams, with expertise in the diagnosis, genetics, risk stratification and management of heart muscle disease.	Ila	C	148,149

HCM = hypertrophic cardiomyopathy.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

**7.1 Education and training**

With advancing knowledge and greater public awareness of inherited cardiac conditions, the demand for specialist cardiomyopathy services will grow. National societies and healthcare providers should ensure that there is a workforce with the necessary skills to fulfil this need, and provide sufficient educational resources to improve and maintain competencies for all professional groups involved in the care of patients with HCM. National and international societies should also develop registries and care networks for patients with cardiomyopathies.

**8. Assessment of symptoms**

Most people with HCM are asymptomatic and have a normal lifespan but some develop symptoms, often many years after the appearance of ECG or echocardiographic evidence of LVH. In infants, symptoms and signs of heart failure include tachypnoea, poor feeding, excessive sweating and failure to thrive. Older children, adolescents and adults complain of fatigue and dyspnoea as well as chest pain, palpitations and syncope. Systematic 2D and Doppler echocardiography and ambulatory ECG monitoring are usually sufficient to determine the most likely cause of symptoms. Assessment of LVOTO as outlined in section 5.4 should be part of the routine evaluation of all symptomatic patients.

**8.1 Chest pain**

Many patients complain of chest pain at rest or on exertion. Pain may also be precipitated by large meals or alcohol.<sup>205–207</sup> The causes of chest pain include myocardial ischaemia due to microvascular dysfunction, increased LV wall stress and LVOTO. Congenital coronary

artery anomalies, including tunnelled left anterior descending artery or atherosclerotic coronary artery disease, may also be responsible.<sup>208</sup> Systolic compression of epicardial and intramural vessels is very common but is not usually of clinical importance.<sup>209–211</sup>

Resting ECG abnormalities and a high prevalence of perfusion abnormalities on nuclear imaging and CMR mean that these techniques are of limited use in differentiating obstructive coronary disease from other causes of chest pain and in determining pre-test probability of coronary disease in patients with HCM.<sup>212–217</sup> Patients with typical angina on exertion should be considered for invasive or CT coronary angiography on the basis of their symptoms, age, gender and atherosclerosis risk factors, as outlined in existing ESC Guidelines.<sup>159,218</sup> Coronary angiography is recommended in adult survivors of cardiac arrest, in patients with sustained ventricular arrhythmia and in symptomatic patients with previous coronary revascularization procedures.<sup>219</sup> Invasive or CT coronary angiography should be considered before septal reduction therapy in all patients aged 40 years or more, irrespective of the presence of typical angina.

**Recommendations on coronary angiography**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Invasive coronary angiography is recommended in adult survivors of cardiac arrest, in patients with sustained ventricular tachyarrhythmia and in patients with severe stable angina (Canadian Cardiovascular Society (CCS) Class ≥3).	I	C	219
Invasive or CT coronary angiography should be considered in patients with typical exertional chest pain (CCS Class <3) who have an intermediate pre-test probability of atherosclerotic coronary artery disease based on age, gender and risk factors for atherosclerosis, or a history of coronary revascularization.	Ila	C	159,218
In all patients aged 40 years or more, invasive or CT coronary angiography should be considered before septal reduction therapy, irrespective of the presence of typical exertional chest pain.	Ila	C	220,221

CT = computed tomography; CCS = Canadian Cardiovascular Society

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

**8.2 Heart failure**

Symptoms of chronic heart failure are frequent, but the clinical profile of advanced heart failure varies between patients. In some, heart failure is associated with diastolic dysfunction with preserved EF and small LV size; in others, symptoms are caused by systolic left ventricular dysfunction or LVOTO (with or without mitral insufficiency).<sup>222</sup> Atrial fibrillation can complicate any of these scenarios and exacerbate symptoms.<sup>223</sup> Recognition of the heterogeneous pathophysiology of heart failure in HCM is important because it influences management.

In most patients, there is a life-long process of progressive and adverse cardiac remodelling, characterized by myocardial fibrosis and wall thinning.<sup>222,224,225</sup> In the early stages of this process, patients are often asymptomatic, and conventional non-invasive indices of cardiac performance are within the normal range. As the disease progresses, there is a decline in LV diastolic and systolic function, associated with either mild-to-moderate LV dilation, decreased LV wall thickness, and a fall in LV EF (sometimes referred to as the 'burnt-out' or hypokinetic dilated phase) or severe LV diastolic dysfunction, accompanied by marked atrial dilation with little or no LV dilation (the 'restrictive' phenotype).<sup>222</sup> Mitral and tricuspid regurgitation and moderate-to-severe pulmonary hypertension are often present in these advanced stages.<sup>226</sup>

Presentation with acute heart failure is uncommon, but this can be precipitated by arrhythmias [AF, supraventricular tachycardia (SVT) or sustained ventricular tachycardia (VT)], acute mitral regurgitation (e.g. chordal rupture or infective endocarditis), myocardial ischaemia and infarction, and comorbidity (e.g. anaemia or hyperthyroidism).

### 8.2.1 Invasive pressure studies

Non-invasive cardiac imaging has largely replaced cardiac catheterization in the routine assessment of cardiac function. Invasive measurement of intra-cardiac pressures may be appropriate when non-invasive cardiac imaging is insufficient to assess the severity of LVOTO and when planning invasive therapy (e.g. treatment of valve disease) and cardiac transplantation.<sup>227</sup>

#### Recommendations on invasive haemodynamic studies

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Cardiac catheterization—to evaluate right and left heart function and pulmonary arterial resistance—is recommended in patients being considered for heart transplantation or mechanical circulatory support.	I	B	227–229
In symptomatic patients with inconclusive, non-invasive cardiac imaging, left and right heart catheterization may be considered, to assess the severity of LVOTO and to measure LV filling pressures.	IIb	C	230

LV = left ventricular; LVOTO = left ventricular outflow tract obstruction.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

### 8.2.2 Cardiopulmonary exercise testing

When performed in experienced laboratories, cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases, provides objective information about the severity of functional limitation and its mechanisms. It may be helpful in differentiating HCM from physiological ventricular hypertrophy in athletes and can provide diagnostic clues, such as a disproportionate reduction in peak oxygen consumption and low anaerobic threshold in

patients with metabolic disorders.<sup>231,232</sup> When facilities are available, cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases, should be considered at the initial clinical evaluation, when patients report a change in symptoms, and when considering invasive LV outflow tract gradient reduction.<sup>233–235</sup> Cardiopulmonary exercise testing is recommended in all patients being considered for cardiac transplantation.<sup>227</sup>

When cardiopulmonary exercise testing is unavailable, conventional treadmill- or bicycle ergometry, with simultaneous electrocardiography, can be used as an alternative. Irrespective of the method of exercise testing, measurement of blood pressure during exercise is recommended, using a standard sphygmomanometer, in order to determine the change in systolic blood pressure that may provide prognostic information (See 9.5: Sudden cardiac death).<sup>236,237</sup>

#### Recommendations on cardiopulmonary exercise testing

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases, is recommended in severely symptomatic patients with systolic and/or diastolic LV dysfunction being evaluated for heart transplantation or mechanical support.	I	B	233,238
Irrespective of symptoms, cardiopulmonary exercise testing with simultaneous measurement of respiratory gases (or standard treadmill or bicycle ergometry when unavailable) should be considered to assess the severity and mechanism of exercise intolerance and change in systolic blood pressure.	IIa	B	233,235–237
Cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases (or standard treadmill or bicycle ergometry when unavailable), should be considered in symptomatic patients undergoing septal alcohol ablation and septal myectomy to determine the severity of exercise limitation.	IIa	C	233–235

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

LV = left ventricular

## 8.3 Syncope

Causes of syncope in HCM include hypovolaemia, complete heart block,<sup>239</sup> sinus node dysfunction,<sup>239</sup> sustained ventricular tachycardia, LVOTO,<sup>240</sup> and abnormal vascular reflexes.<sup>237,241,242</sup> Occasionally atrial arrhythmias with fast ventricular response can precipitate syncope, particularly in individuals with preserved atrial function and high filling pressures.<sup>223</sup> There can be more than one reason why patients with HCM lose consciousness, including co-morbidities such as epilepsy and diabetes.<sup>243</sup>

Syncope after prolonged standing in a hot environment, or during the postprandial absorptive state, is suggestive of neurally mediated (reflex) syncope, particularly when it is associated with nausea and vomiting. Syncope during exertion, or immediately following palpitation or chest pain, suggests a cardiac mechanism.<sup>243</sup> Provocable

obstruction<sup>85</sup> should be excluded when patients experience recurrent effort syncope in similar circumstances—for example, when hurrying upstairs or straining. Ventricular arrhythmias are an uncommon cause of syncope, but should be suspected after an unheralded episode, particularly when it occurs at rest or on minimal exertion.

As unexplained non-vasovagal syncope is a risk factor for sudden cardiac death,<sup>99,244–248</sup> particularly when it occurs in young patients in close temporal proximity to their first evaluation,<sup>99</sup> treatment with a prophylactic implantable cardioverter defibrillator (ICD) may be appropriate in individuals with other features indicative of high sudden death risk, even if the mechanism of syncope is undetermined at the end of a complete work-up. The fact that syncope may be caused by mechanisms other than ventricular arrhythmia means that patients may remain at risk of recurrent syncope after ICD implantation.

Patients with syncope should undergo 12-lead ECG, standard upright exercise test and 48-hour ambulatory ECG monitoring and, if a bradyarrhythmia is identified, it should be treated in accordance with current ESC Guidelines on cardiac pacing.<sup>249</sup> Exercise stress echocardiography should be considered, particularly in patients with exertional or postural syncope, to detect provokable LVOTO.<sup>85</sup> In patients with recurrent episodes of unexplained syncope, who are at low risk of SCD, an implantable loop recorder (ILR) should be considered.<sup>249,250</sup> There are few data on tilt testing in patients with HCM, but a high rate of positive tests in patients without a history of syncope suggests that it is not useful in routine assessment unless there are other features to suggest an autonomic mechanism.<sup>243,251,252</sup>

### Recommendations on investigation of syncope

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
12-lead ECG, upright exercise test, resting and exercise 2D and Doppler echocardiography, and 48-hour ambulatory ECG monitoring are recommended in patients with unexplained syncope, to identify the cause of their symptoms.	I	C	243
An ILR should be considered in patients with recurrent episodes of unexplained syncope, who are at low risk of SCD.	IIa	C	243,250

2D = two-dimensional; ECG = electrocardiogram; ILR = implantable loop recorder; SCD = sudden cardiac death.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 8.4 Palpitations

Many patients complain of palpitations,<sup>165,246</sup> caused by symptomatic cardiac contractions and ventricular ectopy. A sustained episode of palpitation lasting for more than a few minutes is often caused by supraventricular arrhythmia. In patients with frequent palpitations, 48-hour ambulatory electrocardiography should be performed.<sup>250,253</sup> If a cause is not identified, an ILR may be considered.

### Recommendations on palpitations

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
For patients with frequent or sustained palpitations, 48-hour ambulatory ECG monitoring is recommended, to identify the likely cause.	I	C	250,253
An ILR may be considered for patients with frequent palpitations, in whom no cause is identified following prolonged ECG monitoring.	IIb	C	250

ECG = electrocardiogram; ILR = implantable loop recorder.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 8.5 Role of electrophysiological testing

The routine use of electrophysiological studies (EPS) in patients with syncope or symptoms suggestive of arrhythmia is not recommended. EPS are indicated in patients with persistent or recurrent supraventricular tachycardia (atrial flutter, atrial tachycardia, atrioventricular nodal re-entry tachycardia, accessory atrioventricular pathway mediated tachycardias) and in patients who have evidence from other non-invasive tests, suggestive of either sino-atrial disease or AV block.<sup>249,254</sup> Electrophysiological studies are also indicated when patients have ventricular pre-excitation, to identify and treat an ablatable substrate.<sup>255</sup> Invasive EPS may be considered in selected patients with documented, symptomatic, monomorphic, sustained (> 30 s) ventricular tachycardia, to identify and treat an ablatable arrhythmia substrate.<sup>256,257</sup>

### Recommendations on electrophysiological testing

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Invasive electrophysiological study is recommended in patients with documented persistent or recurrent supraventricular tachycardia (atrial flutter, atrial tachycardia, atrioventricular nodal re-entry tachycardia, accessory atrioventricular pathway mediated tachycardias) and in patients with ventricular pre-excitation, in order to identify and treat an ablatable substrate.	I	C	249,254 255
Invasive electrophysiological study may be considered in selected patients with documented, symptomatic, monomorphic, sustained (>30 s) ventricular tachycardia in order to identify and treat an ablatable arrhythmia substrate.	IIb	C	256,257
Invasive electrophysiological study with programmed ventricular stimulation is not recommended for sudden cardiac death risk stratification.	III	C	

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 9. Management of symptoms and complications

In the absence of large randomized trials,<sup>2</sup> pharmacological therapy is administered on an empirical basis to improve functional capacity, reduce symptoms and prevent disease progression. In symptomatic patients with LVOTO, the aim is to improve symptoms by using drugs, surgery, alcohol ablation or pacing. Therapy in symptomatic patients without LVOTO focuses on management of arrhythmia, reduction of LV filling pressures, and treatment of angina. Patients with progressive LV systolic or diastolic dysfunction refractory to medical therapy may be candidates for cardiac transplantation.

### 9.1 Left ventricular outflow tract obstruction

By convention, LVOTO is defined as a peak instantaneous Doppler LV outflow tract gradient of  $\geq 30$  mm Hg, but the threshold for invasive treatment is usually considered to be  $\geq 50$  mm Hg.

Most patients with a maximum resting or provoked LV outflow tract gradient  $< 50$  mm Hg should be managed in accordance with the recommendations for non-obstructive HCM but, in a very small number of selected cases with LV outflow tract gradients between 30 and 50 mm Hg and no other obvious cause of symptoms, invasive gradient reduction may be considered, acknowledging that data covering this group are lacking.

#### 9.1.1 General measures

All patients with LVOTO should avoid dehydration and excess alcohol consumption, and weight loss should be encouraged. Arterial and venous dilators, including nitrates and phosphodiesterase type 5 inhibitors, can exacerbate LVOTO and should be avoided if possible (see also management of hypertension, section 12.2).<sup>258</sup> New-onset or poorly controlled AF can exacerbate symptoms caused by LVOTO and should be managed by prompt restoration of sinus rhythm or ventricular rate control.<sup>223</sup> Digoxin should be avoided in patients with LVOTO because of its positive inotropic effects.<sup>259</sup>

#### Recommendations for treatment of left ventricular outflow tract obstruction: general measures

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Arterial and venous dilators, including nitrates and phosphodiesterase inhibitors, should be avoided if possible in patients with resting or provokable LVOTO.	<b>IIa</b>	<b>C</b>	258,260
Restoration of sinus rhythm or appropriate rate control should be considered before considering invasive therapies in patients with new-onset or poorly controlled atrial fibrillation.	<b>IIa</b>	<b>C</b>	261,262
Digoxin is not recommended in patients with resting or provokable LVOTO.	<b>III</b>	<b>C</b>	259

LVOTO = left ventricular outflow tract obstruction.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

#### 9.1.2 Drug therapy

By consensus, patients with symptomatic LVOTO are treated initially with non-vasodilating  $\beta$ -blockers titrated to maximum tolerated dose, but there are very few studies comparing individual  $\beta$ -blockers. Small and mostly retrospective studies suggest that oral propranolol can abolish or reduce resting and provokable LVOTO and provide symptomatic benefit.<sup>263–265</sup> One study has shown improved exercise tolerance and suppression of supraventricular and ventricular arrhythmias in patients treated with sotalol.<sup>266</sup>

If  $\beta$ -blockers alone are ineffective, disopyramide (when available), titrated up to a maximum tolerated dose (usually 400–600 mg/day), may be added.<sup>267,268</sup> This Class IA anti-arrhythmic drug can abolish basal LV outflow pressure gradients and improve exercise tolerance and functional capacity without proarrhythmic effects or an increased risk of sudden cardiac death.<sup>267,268</sup> Dose-limiting anticholinergic side-effects include dry eyes and mouth, urinary hesitancy or retention, and constipation.<sup>267,268</sup> The QTc interval should be monitored during dose up-titration and the dose reduced if it exceeds 480 ms. Disopyramide should be avoided in patients with glaucoma, in men with prostatism, and in patients taking other drugs that prolong the QT interval, such as amiodarone and sotalol. Disopyramide may be used in combination with verapamil.<sup>268</sup> Disopyramide should be used cautiously in patients with—or prone to—AF in whom drug-induced enhancement of AV conduction can increase the ventricular rate.

Verapamil (starting dose 40 mg three times daily to maximum 480 mg daily) can be used when  $\beta$ -blockers are contraindicated or ineffective, but close monitoring is required in patients with severe obstruction ( $\geq 100$  mm Hg) or elevated pulmonary artery systolic pressures, as it can provoke pulmonary oedema.<sup>269</sup> Short-term oral administration may increase exercise capacity, improve symptoms and normalize or improve LV diastolic filling without altering systolic function.<sup>270–273</sup> Similar findings have been demonstrated for diltiazem (starting dose 60 mg three times daily to maximum 360 mg daily)<sup>274</sup> and it should be considered in patients who are intolerant- or have contraindications to  $\beta$ -blockers and verapamil. Nifedipine and other dihydropyridine calcium antagonists are *not* recommended for the treatment of LVOTO.<sup>275,276</sup>

Low-dose loop or thiazide diuretics may be used cautiously to improve dyspnoea associated with LVOTO, but it is important to avoid hypovolaemia.

Beta-blockers should be considered in neonates and children with LVOTO and limited data on verapamil suggest that it can also be used safely in children.<sup>272</sup> There are no data on which to make specific recommendations for disopyramide therapy in children. Medical therapy may be considered in asymptomatic or mildly symptomatic adolescents and adults who have a resting or provoked LVOTO and left atrial enlargement.

*Rarely, patients with severe provokable LVOTO can present with hypotension and pulmonary oedema that mimics acute myocardial ischaemia. Recognition of this scenario is important, as the use of vasodilators and positive inotropes in this setting can be life-threatening. Treatment should instead consist of oral or i.v.  $\beta$ -blockers and vasoconstrictors (e.g. phenylephrine, metaraminol and norepinephrine).*

### Recommendations on medical treatment of LVOTO

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Non-vasodilating $\beta$ -blockers, titrated to maximum tolerated dose, are recommended as first-line therapy to improve symptoms in patients with resting or provoked <sup>d</sup> LVOTO.	I	B	263,265, 267,268
Verapamil, titrated to maximum tolerated dose, is recommended to improve symptoms in patients with resting or provoked <sup>d</sup> LVOTO, who are intolerant or have contraindications to $\beta$ -blockers.	I	B	268,270–274
Disopyramide, titrated to maximum tolerated dose, <sup>e</sup> is recommended in addition to a $\beta$ -blocker (or, if this is not possible, with verapamil) to improve symptoms in patients with resting or provoked <sup>d</sup> LVOTO.	I	B	267,268
Disopyramide, titrated to maximum tolerated dose, <sup>e</sup> may be considered as monotherapy to improve symptoms in patients with resting or provoked <sup>d</sup> LVOTO (exercise or Valsalva manoeuvre) taking caution in patients with—or prone to—AF, in whom it can increase ventricular rate response.	IIb	C	267
$\beta$ -Blockers or verapamil may be considered in children and asymptomatic adults with resting or provoked <sup>d</sup> LVOTO, to reduce left ventricular pressures.	IIb	C	272
Low-dose loop- or thiazide diuretics may be used with caution in symptomatic LVOTO, to improve exertional dyspnoea.	IIb	C	
Diltiazem, titrated to maximum tolerated dose, should be considered in symptomatic patients with resting or provoked <sup>d</sup> LVOTO, who are intolerant or have contraindications to $\beta$ -blockers and verapamil, to improve symptoms.	IIa	C	274
Oral or i.v. $\beta$ -blockers and vasoconstrictors should be considered in patients with severe provokable LVOTO presenting with hypotension and pulmonary oedema.	IIa	C	260

LVOTO = left ventricular outflow tract obstruction.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

<sup>d</sup>Provocation with Valsalva manoeuvre, upright exercise or oral nitrates if unable to exercise.

<sup>e</sup>QTc interval should be monitored during up-titration of disopyramide and the dose reduced if it exceeds 480 ms.

### 9.1.3 Invasive treatment of left ventricular outflow tract obstruction

There are no data to support the use of invasive procedures to reduce LV outflow obstruction in asymptomatic patients, regardless of its severity.

Invasive treatment to reduce LVOTO should be considered in patients with an LVOTO gradient  $\geq 50$  mm Hg, moderate-to-severe symptoms (New York Heart Association (NYHA) functional Class III–IV) and/or recurrent exertional syncope in spite of maximally tolerated drug therapy. In some centres, invasive therapy is also considered in patients with mild symptoms (NYHA Class II) who have a resting or maximum provoked gradient of  $\geq 50$  mm Hg (exercise or Valsalva) and moderate-to-severe SAM related mitral regurgitation, AF, or moderate-to-severe left atrial dilation but there are few data supporting this practice.<sup>277</sup>

#### 9.1.3.1 Surgery

The most commonly performed surgical procedure used to treat LVOTO is ventricular septal myectomy (Morrow procedure), in which a rectangular trough that extends distally to beyond the point of the mitral leaflet–septal contact is created in the basal septum below the aortic valve.<sup>278</sup> This abolishes or substantially reduces LV outflow tract gradients in over 90% of cases, reduces SAM-related mitral regurgitation, and improves exercise capacity and symptoms. Long-term symptomatic benefit is achieved in 70–80% of patients with a long-term survival comparable to that of the general population.<sup>279–287</sup> Pre-operative determinants of a good long-term outcome are age  $< 50$  years, left atrial size  $< 46$  mm, absence of atrial fibrillation and male gender.<sup>287</sup>

The main surgical complications are AV nodal block, ventricular septal defect and aortic regurgitation (AR), but these are uncommon in experienced centres using intraoperative TOE guidance.<sup>286,288,289</sup> When there is co-existing mid-cavity obstruction, the standard myectomy can be extended distally into the mid-ventricle around the base of the papillary muscles, but data on the efficacy and long-term outcomes of this approach are limited.<sup>290</sup>

Concomitant mitral valve surgery is required in 11–20% of patients undergoing myectomy.<sup>114</sup> In patients with marked mitral leaflet elongation and/or moderate-to-severe mitral regurgitation, septal myectomy can be combined with one of several adjunctive procedures, including mitral valve replacement, posterior-superior realignment of the papillary muscles, partial excision and mobilization of papillary muscles, anterior mitral leaflet plication, and anterior leaflet extension using a glutaraldehyde-treated pericardial patch that stiffens the mid-portion of the leaflet.<sup>291–294</sup> An elongated anterior mitral leaflet favours mitral valve repair instead of replacement.<sup>295</sup> Surgical mortality for myectomy with mitral intervention is around 3–4%.<sup>294,296,297</sup>

#### 9.1.3.2 Septal alcohol ablation

In experienced centres, selective injection of alcohol into a septal perforator artery (or sometimes other branches of the left anterior descending coronary artery) to create a localized septal scar has outcomes similar to surgery in terms of gradient reduction, symptom improvement and exercise capacity.<sup>298–302</sup> The main non-fatal complication is AV block in 7–20% of patients and the procedural mortality is similar to isolated myectomy.<sup>299–303</sup>



Due to the variability of the septal blood supply, myocardial contrast echocardiography is essential prior to alcohol injection. If the contrast agent cannot be localized exclusively to the basal septum at and adjacent to the point of mitral-septal contact, the procedure should be abandoned.<sup>111–113</sup>

Injection of large volumes of alcohol in multiple septal branches—with the aim of gradient reduction in the catheter laboratory—is not recommended, as it is associated with a high risk of complications and arrhythmic events.<sup>304</sup>

Alternative methods have been reported in small numbers of patients, including non-alcohol septal embolisation techniques (coils,<sup>305,306</sup> polyvinyl alcohol foam particles,<sup>307</sup> cyanoacrylate<sup>308</sup>) and direct endocavitary ablation (radiofrequency, cryotherapy).<sup>309,310</sup> These alternative methods have not been directly compared with other septal reduction therapies and long-term outcome/safety data are not available.

### 9.1.3.3 Surgery vs. alcohol ablation

Experienced multidisciplinary teams should assess all patients before intervention.

The choice of therapy should be based on a systematic assessment of the mitral valve and septal anatomy that includes deliberate exclusion of other LV outflow tract and mitral valve abnormalities requiring surgical treatment. A summary of the key points in pre-operative assessment is shown in Figure 5. Septal ablation may be less effective in patients with extensive septal scarring on CMR and in patients with very severe hypertrophy ( $\geq 30$  mm), but systematic data are lacking. In general, the risk of ventriculoseptal defect following septal alcohol ablation and septal myectomy is higher in patients with mild hypertrophy ( $\leq 16$  mm) at the point of the mitral leaflet–septal contact. In such cases, alternatives such as dual chamber pacing (see 9.1.3.5: Dual chamber pacing) or mitral valve repair/replacement may be considered.

There are no randomized trials comparing surgery and septal alcohol ablation (SAA), but several meta-analyses have shown that both procedures improve functional status with a similar procedural mortality.<sup>311–314</sup> Septal alcohol ablation is associated with a higher risk of AV block, requiring permanent pacemaker implantation and larger residual LV outflow tract gradients.<sup>311–314</sup> In contrast to myectomy, most patients develop right-, rather than left bundle branch block after SAA. The risk of AV block following surgery and alcohol ablation is highest in patients with pre-existing conduction disease, and prophylactic permanent pacing before intervention has been advocated.<sup>315</sup>

The operative mortality of septal myectomy in children is  $< 2\%$  in experienced centres.<sup>288</sup> Recurrence of LVOTO requiring reoperation is rare, except in infants and neonates, due to technical limitations of resection and progression of myocardial hypertrophy. Septal alcohol ablation is controversial in children, adolescents and young adults because there are no long-term data on the late effects of a myocardial scar in these groups, and because the technical difficulties and potential hazards of the procedure in smaller children and infants are greater.

## Recommendations on septal reduction therapy

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
It is recommended that septal reduction therapies be performed by experienced operators, working as part of a multidisciplinary team expert in the management of HCM.	I	C	148,149
Septal reduction therapy to improve symptoms is recommended in patients with a resting or maximum provoked LVOT gradient of $\geq 50$ mm Hg, who are in NYHA functional Class III–IV, despite maximum tolerated medical therapy.	I	B	311–314
Septal reduction therapy should be considered in patients with recurrent exertional syncope caused by a resting or maximum provoked LVOTO gradient $\geq 50$ mm Hg despite optimal medical therapy.	IIa	C	240,316
Septal myectomy, rather than SAA, is recommended in patients with an indication for septal reduction therapy and other lesions requiring surgical intervention (e.g. mitral valve repair/replacement, papillary muscle intervention).	I	C	295
Mitral valve repair or replacement should be considered in symptomatic patients with a resting or maximum provoked LVOTO gradient $\geq 50$ mm Hg and moderate-to-severe mitral regurgitation not caused by SAM of the mitral valve alone.	IIa	C	291–294
Mitral valve repair or replacement may be considered in patients with a resting or maximum provoked LVOTO gradient $\geq 50$ mm Hg and a maximum septal thickness $\leq 16$ mm at the point of the mitral leaflet–septal contact or when there is moderate-to-severe mitral regurgitation following isolated myectomy.	IIb	C	296,317

AF = atrial fibrillation; HCM = hypertrophic cardiomyopathy; LA = left atrium; LVOTO = left ventricular outflow tract obstruction; NYHA = New York Heart Association; SAA = septal alcohol ablation; SAM = systolic anterior motion.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

### 9.1.3.4 Minimum activity requirements

As with other invasive procedures, the results of surgery and alcohol ablation are likely to be better in centres that perform large numbers of procedures. In the absence of specific data, recommendations for the number of interventions per centre and operator are extrapolated from other scenarios. A minimum caseload of 10 SAA and 10 septal myectomies per operator per year is reasonable. More than

one trained operator should be available for both procedures, to ensure the safety and sustainability of interventional programmes. National data collection and prospective registries are encouraged to monitor safety and outcomes.

*Surgeons and cardiologists who perform invasive gradient reduction therapies should be trained in experienced centres and should work as part of a multidisciplinary team experienced in the management of HCM.*

9.1.3.5 Dual chamber pacing


Three small, randomized, placebo-controlled studies of dual chamber pacing and several long-term observational studies have reported reductions in LV outflow tract gradients and variable improvement in symptoms and quality of life.<sup>318–322</sup> In one trial, a retrospective subgroup analysis suggested that older patients (> 65 years) are more likely to benefit.<sup>321</sup> One study has directly compared SAA with pacing and demonstrated superior gradient reduction with ablation.<sup>323</sup> A recent Cochrane review concluded that the data on the benefits of pacing are based on physiological measures and lack information on clinically relevant end-points.<sup>324</sup>

Permanent AV sequential pacing with short AV interval may be considered in symptomatic adult patients who are unsuitable for—or unwilling to consider—other invasive septal reduction therapies, and in patients who have other pacing indications. Pacing parameters should be optimized to achieve maximum pre-excitation of the RV apex with minimal compromise of LV filling (typically achieved with a resting sensed AV interval of 100 ± 30 ms).<sup>325</sup> To ensure complete ventricular capture during exercise, a dynamic paced AV interval should be enabled and the programmed upper rate limit should be higher than the fastest sinus rate achieved during exercise.<sup>249</sup> Atrio-ventricular nodal ablation or modification has been advocated as a method for achieving optimal AV programming in some patients with a very short P-R interval, but this is not recommended.<sup>326</sup>

**Recommendations on indications for cardiac pacing in patients with obstruction**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Sequential AV pacing, with optimal AV interval to reduce the LV outflow tract gradient or to facilitate medical treatment with β-blockers and/or verapamil, may be considered in selected patients with resting or provokable LVOTO ≥50 mm Hg, sinus rhythm and drug-refractory symptoms, who have contraindications for septal alcohol ablation or septal myectomy or are at high risk of developing heart block following septal alcohol ablation or septal myectomy.	IIb	C	268,318–322
In patients with resting or provokable LVOTO ≥50 mm Hg, sinus rhythm and drug-refractory symptoms, in whom there is an indication for an ICD, a dual-chamber ICD (instead of a single-lead device) may be considered, to reduce the LV outflow tract gradient or to facilitate medical treatment with β-blockers and/or verapamil.	IIb	C	268,318–322,327

AV = atrioventricular; ICD = implantable cardioverter defibrillator; LVOTO = left ventricular outflow tract obstruction.  
<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.



**Figure 5** Pre-assessment check list for patients being considered for invasive septal reduction therapies. AF = atrial fibrillation; MV = mitral valve; RVOT = right ventricular outflow tract; SAM = systolic anterior motion.

## 9.2 Left ventricular mid-cavity obstruction and apical aneurysms

LV mid-cavity obstruction occurs in approximately 10% of patients with HCM.<sup>328,329</sup> Patients with mid-cavity obstruction tend to be very symptomatic and, in a number of studies, have shown an increased risk of progressive heart failure and SCD.<sup>328–330</sup> Approximately 25% of patients also have an LV apical aneurysm which, in some series, is associated with higher cardiovascular mortality.<sup>129,328,329,331</sup> Patients with LV mid-cavity obstruction should be treated with high dose  $\beta$ -blockers, verapamil or diltiazem, but the response is often sub-optimal. Small experience, mostly from single centres, suggests that mid-ventricular obstruction can be relieved by transaortic myectomy, a transapical approach or combined transaortic and transapical incisions, with good short-term outcomes.<sup>332,333</sup>

LV apical aneurysms by themselves rarely need treatment. A few patients develop monomorphic ventricular tachycardia related to adjacent apical scarring, which may be amenable to mapping and ablation.<sup>331,334</sup> Rarely, thrombi are present within the aneurysm and should be treated with long-term oral anticoagulation.<sup>335,336</sup> The evidence linking aneurysms to an increased risk of sudden death is confined to small series of selected patients.<sup>129</sup> Prophylactic ICD implantation is not recommended in the absence of other clinical features that suggest an increased risk of SCD (see section 9.5).

## 9.3 Management of symptoms in patients without left ventricular outflow tract obstruction

### 9.3.1 Heart failure

#### 9.3.1.1 Drug therapy

A general approach to the management of heart failure symptoms is shown in Figure 6. In breathless patients with a normal EF and no evidence of resting or provokable LVOTO, the aim of drug therapy is to reduce LV diastolic pressures and improve LV filling by slowing the heart rate with  $\beta$ -blockers, verapamil or diltiazem (ideally monitored by ambulatory ECG recording) and cautious use of loop diuretics. Restoration of sinus rhythm or ventricular rate control is essential in patients who have permanent or frequent paroxysms of AF (see Atrial tachyarrhythmia, section 9.4) but digoxin is not recommended in patients with preserved EF because of the potentially adverse effects of positive inotropic stimulation.<sup>259</sup>

Very few studies have examined the effect of renin-angiotensin-aldosterone system (RAAS) inhibition in patients with HCM.<sup>2</sup> In the absence of randomized trials, the benefit of RAAS inhibition on hospitalization, symptoms and mortality is assumed, and it is recommended that patients with reduced EF and heart failure symptoms should be treated with diuretics,  $\beta$ -blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB) and mineralocorticoid receptor antagonists (MRA) in line with the ESC Guidelines for the management of chronic heart failure.<sup>337</sup> An EF of <50% is recommended as the threshold for considering therapy with RAAS inhibitors because of the preservation of cavity size in patients with HCM and advanced systolic failure.<sup>337</sup> Relatively small LV volumes also mean that some patients may be unable to tolerate high doses of vasodilators and diuretics. In the absence of significant LVOTO, digoxin (0.125 mg–0.5 mg o.d.), alone or in combination with  $\beta$ -blocker, may be used to control heart rate response in patients with AF and an EF <50%.

### Recommendations for patients with heart failure and preserved LV ejection fraction ( $\geq 50\%$ )

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
In patients in NYHA functional Class II–IV with an EF $\geq 50\%$ and no evidence for resting or provokable LVOTO, $\beta$ -blockers, verapamil or diltiazem should be considered, to improve heart failure symptoms.	IIa	C	274,338
Low-dose loop and thiazide diuretics should be considered in patients in NYHA functional Class II–IV with an EF $\geq 50\%$ and no evidence for resting or provokable LVOTO, to improve heart failure symptoms.	IIa	C	

EF = ejection fraction; LVOTO = left ventricular outflow tract obstruction; NYHA = New York Heart Association.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

### Recommendations for patients with heart failure and reduced LV ejection fraction (<50%)

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
An ACE inhibitor (or ARB if ACE inhibitor not tolerated) should be considered, in addition to a $\beta$ -blocker, for patients without LVOTO who have an LVEF <50%, to reduce the risks of HF hospitalization and premature death. <sup>d</sup>	IIa	C	337
A $\beta$ -blocker should be considered, in addition to an ACE inhibitor (or ARB if ACE inhibitor not tolerated), for patients without LVOTO who have an LVEF <50% to improve symptoms and reduce the risks of HF hospitalization and premature death. <sup>d</sup>	IIa	C	337
Low-dose loop diuretics should be considered for symptomatic patients in NYHA functional Class II–IV with an LVEF <50%, to improve symptoms and reduce the risk of HF hospitalization. <sup>d</sup>	IIa	C	337
For all patients with persisting symptoms (NYHA functional Class II–IV) and an LVEF <50%—despite treatment with an ACE inhibitor (or an ARB if an ACE inhibitor is not tolerated) and a $\beta$ -blocker—a mineralocorticoid receptor antagonist (MRA) should be considered, to reduce the risks of HF hospitalization and premature death. <sup>d</sup>	IIa	C	337
Low-dose digoxin may be considered for patients without LVOTO who are in NYHA functional Class II–IV and have an EF <50% and permanent atrial fibrillation to control heart rate response.	IIb	C	337

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; EF = ejection fraction; HF = heart failure; MRA = mineralocorticoid receptor antagonist; LV = left ventricular; NYHA = New York Heart Association.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

<sup>d</sup>In the absence of randomized trials in HCM, the benefit on hospitalization, symptoms and mortality is assumed but unproven.

9.3.1.2 Cardiac resynchronization therapy

Regional heterogeneity of LV contraction and relaxation is common in patients with HCM and LV dyssynchrony may be a marker of poor prognosis. Case reports and one cohort study have shown that cardiac resynchronization therapy (CRT) can improve heart failure symptoms in patients with left bundle branch block (LBBB) (> 120 ms) and is associated with reverse remodelling of the left atrium and LV in patients with impaired LV systolic function.<sup>339</sup> In the absence of randomized trials, CRT may be considered in individual patients with refractory symptoms, LV EF <50% and LBBB (QRS duration > 120 ms). For patients who have progressed to severe LV dysfunction (EF ≤35%), CRT should be in accordance with current ESC Guidelines.<sup>249</sup>

**Recommendations on cardiac resynchronization therapy**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Cardiac resynchronization therapy to improve symptoms may be considered in patients with HCM, maximum LVOTG <30 mm Hg, drug refractory symptoms, NYHA functional Class II–IV, LVEF <50% and LBBB with a QRS duration >120 ms.	IIb	C	339

EF = ejection fraction; HCM, hypertrophic cardiomyopathy; LBBB = left bundle branch block; LV = left ventricular; LVOTG = left ventricular outflow tract gradient; NYHA = New York Heart Association.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

9.3.1.3 Cardiac transplantation

Orthotopic cardiac transplantation should be considered in patients with moderate-to-severe drug refractory symptoms (NYHA functional Class III–IV) and no LVOTO who meet standard eligibility criteria (see the ESC Guidelines on acute and chronic heart failure).<sup>337</sup> HCM accounts for 1–5% of all cardiac transplants performed in the USA

**Recommendations on cardiac transplantation**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Orthotopic cardiac transplantation should be considered in eligible patients who have an LVEF <50% and NYHA functional Class III–IV symptoms despite optimal medical therapy or intractable ventricular arrhythmia.	IIa	B	340,341,343,344
Orthotopic cardiac transplantation may be considered in eligible patients with normal LVEF (≥50%) and severe drug refractory symptoms (NYHA functional Class III–IV) caused by diastolic dysfunction.	IIb	B	340,341,343,344

HF = heart failure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

and up to 7% of patients on the heart transplantation waiting list in European centres.<sup>340</sup> In adolescents and adults, end-stage HCM

with LV dilation and systolic dysfunction is the most common clinical profile, with progression to intractable heart failure being more rapid in young patients.<sup>341</sup> In infants, massive cardiac hypertrophy with small ventricular cavities and refractory diastolic heart failure is more typical.<sup>342</sup> Around 5% of patients referred for cardiac transplantation have refractory ventricular arrhythmia, with or without heart failure symptoms.<sup>340</sup> Post-transplant survival is similar to that of other non-HCM indications and superior to that of patients with ischaemic heart disease, with a lower rate of acute rejection.<sup>340,341,343,344</sup>

9.3.1.4 Left ventricular assist devices

As there are increasing numbers of patients with end-stage heart failure and the organ donor pool remains limited, mechanical circulatory support with an LV assist device (LVAD) or biventricular assist device (BiVAD) is increasingly used as a short-term bridge to transplant, or destination therapy in individuals who are not eligible for transplantation. Left ventricular assist devices are rarely used as a bridge to orthotopic heart transplantation in patients with HCM, because their small LV cavities and restrictive LV physiology are thought to preclude device placement.<sup>345</sup> However, preliminary data show that patients with HCM and end-stage heart failure may benefit from continuous axial flow LVAD therapy. In one study, right heart failure, prolonged inotropic support, and central venous catheter infections were more common in patients with HCM who were treated with LVADs, but the procedural mortality was comparable to patients with dilated cardiomyopathy and ischaemic heart disease.<sup>346</sup> Further research is required in this area but continuous axial flow LVAD therapy may be an option for bridging to therapy in selected patients who are transplant candidates. There are no data on bridge-to-recovery or destination therapy in patients with HCM.

**Recommendations on left ventricular assist devices**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Continuous axial flow LVAD therapy may be considered in selected patients with end-stage HF despite optimal pharmacological and device treatment, who are otherwise suitable for heart transplantation, to improve symptoms, and reduce the risk of HF hospitalization from worsening HF and premature death while awaiting a transplant.	IIb	C	346

HF = heart failure; LVAD = left ventricular assist device.


<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

9.3.2 Angina

β-Blockers or calcium antagonists should be considered in patients with exertional or prolonged episodes of angina-like pain in the absence of resting or provokable LVOTO or obstructive coronary artery disease. Both classes of drug improve diastolic function and reduce myocardial oxygen demand and, in the case of verapamil, may improve stress-induced sub-endocardial perfusion defects.<sup>347–351</sup> In the absence of LVOTO, cautious use of oral nitrates may be considered.



**Figure 6** Algorithm for the treatment of heart failure in hypertrophic cardiomyopathy. ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; LVEF = left ventricular ejection fraction; LVOTO = left ventricular outflow tract obstruction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.

**Recommendations for chest pain on exertion in patients without left ventricular outflow tract obstruction**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
β-Blockers and calcium antagonists should be considered, to improve symptoms in patients with angina-like chest pain and no evidence for LVOTO or obstructive coronary artery disease.	IIa	C	347–351
Oral nitrates may be considered, to improve symptoms in patients with angina-like chest pain and no evidence for LVOTO or obstructive coronary artery disease.	IIb	C	

LVOTO = left ventricular outflow tract obstruction.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

**9.4 Atrial tachyarrhythmia**

Atrial fibrillation is the most common arrhythmia in patients with HCM. Predisposing factors include increased left atrial pressure and size, caused by diastolic dysfunction, LVOTO and mitral regurgitation. In a recent systematic review, the prevalence and annual incidence of AF were 22.5% and 3.1%, respectively; the prevalence and annual incidence of thromboembolism (stroke and peripheral embolism) in patients with AF were 27.1% and 3.8%.<sup>72</sup> Clinical features most closely associated with paroxysmal or permanent AF include age and left atrial enlargement.<sup>72</sup> Other possible predictors include LVOTO, P-wave duration >140 ms on signal-averaged ECG, paroxysmal SVT, ST-T changes on baseline electrocardiography, premature ventricular contractions, LGE on CMR, and abnormal coronary flow reserve.<sup>72</sup> Reported predictors of thromboembolic events include paroxysmal or chronic AF, severe symptoms (NYHA functional Classes III and IV), older age, increased left atrial volume index, male sex and a history of heart failure admissions.<sup>72</sup>

*As left atrial size is a consistent predictor for AF and stroke in patients with HCM, patients in sinus rhythm with LA diameter ≥45 mm should undergo 6–12 monthly 48-hour ambulatory ECG monitoring to detect AF.*

There are fewer data on the prevalence and characteristics of atrial flutter and other atrial arrhythmias but, in general, atrial flutter should be managed conventionally and the risk of thromboembolism considered the same as for AF.

#### 9.4.1 Acute treatment

New-onset AF is frequently associated with heart failure symptoms and so should be treated promptly in accordance with ESC guidelines.<sup>261,262</sup> Immediate direct current (DC) cardioversion is recommended in haemodynamically unstable patients.<sup>261,262</sup> If patients have severe symptoms of angina or heart failure, intravenous  $\beta$ -blockers or amiodarone are recommended.

In haemodynamically stable patients, oral  $\beta$ -blockers or non-dihydropyridine calcium channel antagonists are recommended to slow the ventricular response to AF.<sup>261,262</sup> If pre-excitation is present, non-dihydropyridine calcium channel antagonists and adenosine are contraindicated.<sup>261,262</sup> Digoxin should be avoided in patients with LVOTO and normal EF. Similarly, Class IC anti-arrhythmics, such as flecainide and propafenone, should be avoided as they may prolong QRS duration and the QT interval, and increase the ventricular rate due to conversion to atrial flutter and 1:1 ventricular conduction.<sup>261,262</sup>

When rate control is achieved, elective DC cardioversion should be considered after a minimum of 3 weeks effective [international normalized ratio (INR) between 2.0 and 3.0] anticoagulation with a vitamin K antagonist (VKA). If earlier DC cardioversion is contemplated, a TOE-based strategy should be followed in accordance with ESC guidelines.<sup>261,262</sup>

#### 9.4.2 Thromboembolism prophylaxis

The ESC Guidelines on stroke prophylaxis in patients with AF recommend a risk factor-based approach in which the risk for patients with non-valvular AF is calculated from a scoring system known as 'congestive heart failure, hypertension, age  $\geq 75$  (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, and female sex' (CHA<sub>2</sub>DS<sub>2</sub>-VASc).<sup>261,262</sup>

*As patients with HCM tend to be younger than other high risk groups and have not been included in clinical trials of thromboprophylaxis, use of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score to calculate stroke risk is not recommended.*

*Given the high incidence of stroke in patients with HCM and paroxysmal, persistent or permanent AF, it is recommended that all patients with AF should receive treatment with VKA. In general, lifelong therapy with oral anticoagulants is recommended, even when sinus rhythm is restored.*

Two observational studies have reported lower rates of stroke in patients treated with warfarin than in those on antiplatelets or no therapy.<sup>223,352</sup> Thus, therapy with a combination of aspirin 75–100 mg and clopidogrel 75 mg daily should be considered only in patients who are unable or unwilling to take oral anticoagulants (OAC). Assessment of the risk of bleeding is recommended when prescribing antithrombotic therapy (whether with VKA, or aspirin in combination with clopidogrel). Even though the 'hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly'

(HAS-BLED) score was not evaluated in patients with HCM, it would seem to be a reasonable tool to assess the risk of bleeding.<sup>353</sup> A HAS-BLED score of  $\geq 3$  indicates high bleeding risk and caution should be exercised, with regular clinical reviews.<sup>261,262</sup>

There are no data on the use of new oral anticoagulants (NOAC) in patients with HCM, but they are recommended when adjusted-dose VKA (INR 2.0–3.0) cannot be used due to a failure to maintain therapeutic anticoagulation or when patients experience side-effects of VKAs or are unable to attend- or undertake INR monitoring. A direct thrombin inhibitor (dabigatran) or an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) is recommended in this situation. Recommendations for anticoagulation before and after cardioversion are the same as in current ESC guidelines.<sup>261,262</sup>

#### 9.4.3 Ventricular rate control

Ventricular rate control using  $\beta$ -blockers and non-dihydropyridine calcium channel antagonists—alone or in combination—is recommended in patients with paroxysmal, persistent or permanent AF.<sup>261,262</sup> The choice of medication should be individually determined according to age, lifestyle and heart failure symptoms, and the dose modulated to avoid symptomatic bradycardia but to achieve a resting heart rate <100 BPM. The adequacy of rate control should be assessed during exercise. When adequate rate control cannot be achieved, AV node ablation and permanent pacing may be considered. In the absence of data on the long-term effects of RV pacing on LV function in HCM, the choice of pacing after AV node ablation in patients with persistent or permanent AF should be in line with ESC guidelines, with the exception that CRT-P (CRT with a pacemaker) may be considered in patients with impaired LV function (EF <50%).<sup>261,262</sup> In the absence of significant LVOTO, digoxin (0.125 mg–0.5 mg o.d.), alone or in combination with  $\beta$ -blockers, may be used to control heart rate response in patients with AF and an EF <50%, although data on its efficacy in this context are lacking.

#### 9.4.4 Rhythm control

There are no randomized, controlled trials examining the effect of anti-arrhythmic drugs or radiofrequency ablation on long-term prevention of AF in patients with HCM. One observational study demonstrated that amiodarone therapy was associated with maintenance of sinus rhythm and fewer alterations in drug therapy, embolic episodes and attempted DC cardioversion.<sup>354</sup> Others have shown that, in patients variously treated with amiodarone,  $\beta$ -blockers or calcium channel blockers,<sup>223,355</sup> there was no significant difference in the duration of sinus rhythm and survival after the first episode of AF. One short-term, double-blind, cross-over study ( $n = 30$ ) demonstrated suppression of supraventricular arrhythmia with sotalol.<sup>266</sup> Disopyramide is used to treat LVOTO,<sup>267</sup> but its effect on AF suppression in HCM is unknown. There are also no systematic data on the use of dronedarone in patients with HCM but, in view of recent studies showing an increase in cardiovascular events including cardiovascular mortality, it is not recommended in HCM.<sup>261,356</sup>

There are few data on catheter ablation for AF in patients with HCM,<sup>357–361</sup> but the technique should be considered in patients without severe left atrial enlargement, who have drug refractory

symptoms or who are unable to take anti-arrhythmic drugs.<sup>357</sup> Medium-term maintenance of sinus rhythm is achieved in up to 67% of patients;<sup>357–361</sup> failure to suppress AF is associated with left atrial size and older age.<sup>357,358</sup>

**Recommendations on atrial fibrillation/atrial flutter**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Unless contraindicated, oral anticoagulation with VKA (target INR 2.0–3.0) is recommended in patients who develop persistent, permanent or paroxysmal AF, to prevent thromboembolism.	I	B	223,352
Antithrombotic therapy is recommended for patients with atrial flutter, as for those with AF.	I	C	261,262
Assessment of the risk of bleeding with the HAS-BLED score should be considered when prescribing antithrombotic therapy (whether with VKA or antiplatelet therapy).	IIa	B	353
Restoration of sinus rhythm, by DC or pharmacological cardioversion with intravenous amiodarone, should be considered in patients presenting with recent-onset AF.	IIa	C	261,262
Amiodarone should be considered for achieving rhythm control and to maintain sinus rhythm after DC cardioversion.	IIa	B	354
β-Blockers, verapamil and diltiazem are recommended for controlling ventricular rate in patients with permanent or persistent AF.	I	C	261,262
Catheter ablation for atrial fibrillation should be considered in patients without severe left atrial enlargement, who have drug refractory symptoms or are unable to take anti-arrhythmic drugs.	IIa	B	357–361
Ablation of the AV node to control heart rate may be considered when the ventricular rate cannot be controlled with drugs and when AF cannot be prevented by anti-arrhythmic therapy or is associated with intolerable side-effects.	IIb	C	261,262
Following AV node ablation in patients with an LVEF ≥50%, implantation of a dual-chamber (DDD) pacemaker with mode-switch function is recommended for patients with paroxysmal AF and a single-chamber (VVIR) pacemaker for those in persistent or permanent AF.	I	C	261,262
In patients with any type of AF and LVEF <50%, implantation of a CRT pacemaker may be considered after AV node ablation.	IIb	C	261,262

48-Hour ambulatory ECG monitoring every 6–12 months to detect AF should be considered in patients who are in sinus rhythm and have an LA diameter of ≥45 mm	IIa	C	72
Ablation procedures during septal myectomy may be considered in patients with HCM and symptomatic AF.	IIb	C	362
Antiplatelet therapy using aspirin 75–100 mg plus clopidogrel 75 mg daily (where there is a low risk of bleeding) should be considered when patients refuse the use of any OAC (whether VKAs or NOACs).	IIa	B	363
When adjusted-dose VKA (INR 2–3) cannot be used in a patient with AF—due to failure to maintain therapeutic anticoagulation, side-effects of VKAs, or inability to attend or undertake INR monitoring—a direct thrombin inhibitor (dabigatran) or an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) is recommended.	I	B	364,365
Unless there is a reversible cause of AF, lifelong OAC therapy with a VKA (INR 2.0–3.0) is recommended, even if sinus rhythm is restored.	I	C	261,262

AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; DC = direct current; ECG = electrocardiogram; HAS-BLED = (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly); HCM = hypertrophic cardiomyopathy; INR = international normalized ratio; LA = left atrium; NOAC = new oral oral anticoagulant; LVEF = left ventricular ejection fraction; OAC = oral anticoagulant; VKA = vitamin K antagonist;  
<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.

**9.5 Sudden cardiac death**

Most contemporary series of adult patients with HCM report an annual incidence for cardiovascular death of 1–2%, with SCD, heart failure and thromboembolism being the main causes of death.<sup>366</sup> The most commonly recorded fatal arrhythmic event is spontaneous ventricular fibrillation (VF), but asystole, AV block and pulseless electrical activity are described.<sup>239,367–371</sup>

**9.5.1 Clinical risk assessment**

Estimation of SCD risk is an integral part of clinical management. A large body of evidence suggests that, in adolescents and adults, the risk assessment should comprise of clinical and family history, 48-hour ambulatory ECG, TTE (or CMR in the case of poor echo windows) and a symptom-limited exercise test. Clinical features that are associated with an increased SCD risk and that

**Table 7** Major clinical features associated with an increased risk of sudden cardiac death in adults

Risk Factor	Comment
Age	<ul style="list-style-type: none"> <li>The effect of age on SCD has been examined in a number of studies<sup>73,82,99,208,244,372–374</sup> and two have shown a significant association, with an increased risk of SCD in younger patients.<sup>73,99</sup></li> <li>Some risk factors appear to be more important in younger patients, most notably, NSVT,<sup>69</sup> severe LVH<sup>375</sup> and unexplained syncope.<sup>99</sup></li> </ul>
Non-sustained ventricular tachycardia	<ul style="list-style-type: none"> <li>NSVT (defined as <math>\geq 3</math> consecutive ventricular beats at <math>\geq 120</math> BPM lasting <math>&lt; 30</math> seconds) occurs in 20–30% of patients during ambulatory ECG monitoring and is an independent predictor of SCD.<sup>69,73,83,246,248,374</sup></li> <li>There is no evidence that the frequency, duration or rate of NSVT influences the risk of SCD.<sup>69,376</sup></li> </ul>
Maximum left ventricular wall thickness	<ul style="list-style-type: none"> <li>The severity and extent of LVH measured by TTE are associated with the risk of SCD.<sup>69,120,121,373</sup></li> <li>Several studies have shown the greatest risk of SCD in patients with a maximum wall thickness of <math>\geq 30</math> mm but there are few data in patients with extreme hypertrophy (<math>\geq 35</math> mm).<sup>69,73,120,247,248,373,377,378</sup></li> </ul>
Family history of sudden cardiac death at a young age	<ul style="list-style-type: none"> <li>While definitions vary,<sup>73,120,372,377</sup> a family history of SCD is usually considered clinically significant when one or more first-degree relatives have died suddenly aged <math>&lt; 40</math> years with or without a diagnosis of HCM, or when SCD has occurred in a first-degree relative at any age with an established diagnosis of HCM.</li> </ul>
Syncope	<ul style="list-style-type: none"> <li>Syncope is common in patients with HCM but is challenging to assess as it has multiple causes.<sup>379</sup></li> <li>Non-neurocardiogenic syncope for which there is no explanation after investigation is associated with increased risk of SCD.<sup>73,83,99,244,246–248</sup></li> <li>Episodes within 6 months of evaluation may be more predictive of SCD.<sup>99</sup></li> </ul>
Left atrial diameter	<ul style="list-style-type: none"> <li>Two studies have reported a positive association between LA size and SCD.<sup>73,99</sup> There are no data on the association between SCD and LA area and volume. Measurement of LA size is also important in assessing the risk of AF (see section 9.4).</li> </ul>
Left ventricular outflow tract obstruction	<ul style="list-style-type: none"> <li>A number of studies have reported a significant association with LVOTO and SCD.<sup>73,82,83,246,372,380</sup> Several unanswered questions remain, including the prognostic importance of provokable LVOTO and the impact of treatment (medical or invasive) on SCD.</li> </ul>
Exercise blood pressure response	<ul style="list-style-type: none"> <li>Approximately one third of adult patients with HCM have an abnormal systolic blood pressure response to exercise characterised by progressive hypotension or a failure to augment the systolic blood pressure that is caused by an inappropriate drop in systemic vascular resistance and a low cardiac output reserve.<sup>241,381</sup></li> <li>Various definitions for abnormal blood pressure response in patients with HCM have been reported<sup>69,83,246,377</sup>; for the purposes of this guideline an abnormal blood pressure response is defined as a failure to increase systolic pressure by at least 20 mm Hg from rest to peak exercise or a fall of <math>&gt; 20</math> mm Hg from peak pressure.<sup>237</sup></li> <li>Abnormal exercise blood pressure response is associated with a higher risk of SCD in patients aged <math>\leq 40</math> years,<sup>237</sup> but its prognostic significance in patients <math>&gt; 40</math> years of age is unknown.</li> </ul>

HCM = hypertrophic cardiomyopathy; LA = left atrium; LVH = left ventricular hypertrophy; LVOTO = left ventricular outflow tract obstruction; NSVT = non-sustained ventricular tachycardia; SCD = sudden cardiac death; TTE = transthoracic echocardiography.

have been used in previous guidelines to estimate risk are shown in Table 7.

### 9.5.2 Models for estimating sudden cardiac death risk

Trials in other cardiovascular diseases have shown that implantation of an ICD for primary and secondary prophylaxis can reduce mortality;<sup>382,383</sup> however, the threshold of risk that justifies device implantation is usually defined by the clinical characteristics of the populations enrolled in such studies, rather than an *a priori* definition of acceptable risk. This gives rise to a number of inconsistencies as the characteristics of trial populations vary. It is also likely that societal, economic and cultural factors influence the recommendations made by guideline committees.

*There are no randomized trials or statistically validated prospective prediction models that can be used to guide ICD implantation in patients with HCM. Recommendations are instead based on observational, retrospective cohort studies that have determined the relationship between clinical characteristics and prognosis.*

In the previous version of these Guidelines<sup>384</sup> and a more recent guideline from the American College of Cardiology Foundation/American Heart Association,<sup>385</sup> a small number of clinical characteristics (NSVT, maximal LV wall thickness  $\geq 30$ mm, family history of

SCD, unexplained syncope, and abnormal blood pressure response to exercise) were used to estimate risk and to guide ICD therapy. This approach has a number of limitations: specifically, it estimates relative—and not absolute—risk; it does not account for the different effect size of individual risk factors;<sup>386</sup> and some risk factors such as LV wall thickness are treated as binary variables when they are associated with a continuous increase in risk.<sup>121</sup> Consequently, current risk algorithms discriminate modestly between high- and low-risk patients.<sup>386</sup>

Other clinical features, such as myocardial fibrosis (determined by contrast enhanced CMR), LV apical aneurysms and the inheritance of multiple sarcomere protein gene mutations, have been suggested as arbiters that can be used to guide ICD therapy in individuals who are at an intermediate risk, but there are few data to support this approach.<sup>33,129,144</sup>

Recently, a multicentre, retrospective, longitudinal cohort study of 3675 patients—known as HCM Risk-SCD—developed and validated a new SCD risk prediction model.<sup>73</sup> HCM Risk-SCD uses predictor variables that have been associated with an increased risk of sudden death in at least one published multivariable analysis (Web Table 5).<sup>73</sup> This excludes abnormal blood pressure response as a risk marker. The model provides individualized 5-year risk estimates



and, in a head to head comparison with a model using four major risk factors, the performance of the prediction model improved substantially (C-index from 0.54 to 0.7) and compared favourably with other similar prediction algorithms such as CHA<sub>2</sub>DS<sub>2</sub>-VASc.<sup>73</sup>

The HCM Risk-SCD formula is as follows:

$$\text{Probability}_{\text{SCD at 5 years}} = 1 - 0.998^{\text{exp(Prognostic index)}}$$

where Prognostic index = [0.15939858 × maximal wall thickness (mm)] − [0.00294271 × maximal wall thickness<sup>2</sup> (mm<sup>2</sup>)] + [0.0259082 × left atrial diameter (mm)] + [0.00446131 × maximal (rest/Valsalva) left ventricular outflow tract gradient (mm Hg)] + [0.4583082 × family history SCD] + [0.82639195 × NSVT] + [0.71650361 × unexplained syncope] − [0.01799934 × age at clinical evaluation (years)].

N.B. In HCM Risk-SCD there was a non-linear relationship between the risk of SCD and maximum left ventricular wall thickness.<sup>73</sup> This is accounted for in the risk prediction model by the inclusion of a quadratic term for maximum left ventricular wall thickness.

### 9.5.3 Prevention of sudden cardiac death

#### 9.5.3.1 Exercise restriction

Although documented exercise-induced, sustained, ventricular arrhythmias are rare<sup>246</sup>—and most ICD therapies for ventricular arrhythmias occur in the absence of tachycardia or physical exertion<sup>387,388</sup>—patients with HCM should be advised against participation in competitive sports and discouraged from intense physical activity, especially when they have risk factors for SCD and/or LVOTO.

#### 9.5.3.2 Anti-arrhythmic drugs

There are no randomized, controlled data to support the use of anti-arrhythmics for the prevention of SCD in HCM. Amiodarone was associated with a lower incidence of SCD in one small observational study of patients with NSVT on Holter monitoring and in others, increased the threshold for VF, but observational data suggest that amiodarone often fails to prevent SCD.<sup>389,390</sup> Disopyramide does not appear to have a significant impact on the risk of SCD.<sup>267</sup>

#### 9.5.3.3 Implantable cardioverter defibrillators

**9.5.3.3.1 Secondary prophylaxis.** Patients with HCM who survive VF or sustained ventricular tachycardia are at very high risk of subsequent lethal cardiac arrhythmias and should receive an ICD.<sup>327,367,391–393</sup> In clinical practice, this population is very small and ICD therapy rarely poses a clinical dilemma.<sup>327</sup> There are few data on exercise-induced ventricular arrhythmias but data from one study suggests that it is associated with a high risk of sudden cardiac death.<sup>246</sup>

**9.5.3.3.2 Primary prophylaxis.** Identification of individuals without a history of VF, who are at high risk of SCD, remains a challenge and only a small subgroup of individuals currently treated with an ICD receives potentially lifesaving shocks.<sup>394</sup> At the same time, a large number of ICD recipients experience inappropriate shocks and implant complications.<sup>327</sup>

In these Guidelines, it is recommended that patients undergo a standardized clinical evaluation (see Web Table 5 and Figure 7) that records a pre-defined set of prognostic variables, which are then used to estimate the 5-year risk of SCD using the HCM Risk-SCD model [a Web-based calculator is provided with these Guidelines ([www.escardio.org/guidelines-surveys/esc-guidelines/Pages/hypertrophic-cardiomyopathy.aspx](http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/hypertrophic-cardiomyopathy.aspx))].

### Recommendations on prevention of sudden cardiac death

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Avoidance of competitive sports <sup>d</sup> is recommended in patients with HCM	I	C	395
ICD implantation is recommended in patients who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained VT causing syncope or haemodynamic compromise, and have a life expectancy of >1 year.	I	B	327,367, 391–393
HCM Risk-SCD is recommended as a method of estimating risk of sudden death at 5 years in patients aged ≥16 years without a history of resuscitated VT/VF or spontaneous sustained VT causing syncope or haemodynamic compromise.	I	B	73
It is recommended that the 5-year risk of SCD be assessed at first evaluation and re-evaluated at 1–2 year intervals or whenever there is a change in clinical status.	I	B	73
ICD implantation should be considered in patients with an estimated 5-year risk of sudden death of ≥6% and a life expectancy of >1 year, following detailed clinical assessment that takes into account the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health.	IIa	B	73,327, 393,396
ICD implantation may be considered in individual patients with an estimated 5-year risk of SCD of between ≥4% and <6% and a life expectancy of >1 year, following detailed clinical assessment that takes into account the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health.	IIb	B	73,327, 393,396
ICD implantation may be considered in individual patients with an estimated 5-year risk of SCD of <4% only when they have clinical features that are of proven prognostic importance, and when an assessment of the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health suggests a net benefit from ICD therapy.	IIb	B	73,327, 393,396
ICD implantation is not recommended in patients with an estimated 5-year risk of SCD of <4% and no other clinical features that are of proven prognostic importance.	III	B	73,327, 393,396

ICD = implantable cardioverter defibrillator; VF = ventricular fibrillation; VT = ventricular tachycardia.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

<sup>d</sup>ESC Guidelines define competitive sport as amateur or professional engagement in exercise training on a regular basis and participation in official competitions (see relevant ESC Guidelines for more detail).<sup>395</sup>


The published HCM Risk-SCD dataset has been used to construct three categories of risk (high, intermediate and low) that were determined by consensus (Figure 7). The recommendations for

ICD therapy in each risk category take into account not only the absolute statistical risk, but also the age and general health of the patient, socio-economic factors and the psychological impact of therapy. The recommendations are meant to be sufficiently flexible to account for scenarios that are not encompassed by the HCM Risk-SCD model.

*HCM Risk-SCD should not be used in patients <16 years of age, elite athletes or in individuals with metabolic/infiltrative diseases*

(e.g. Anderson-Fabry disease) and syndromes (e.g. Noonan syndrome). The model does not use exercise-induced LV outflow tract gradients and has not been validated before and after myectomy or alcohol septal ablation.

As the relationship between maximum LV wall thickness and risk is non-linear, the calculated risk for SCD falls in patients with severe LVH ( $\geq 35$  mm). This may reflect small numbers in this category but, as shown in the source paper, the rate of sudden deaths was



**Figure 7** Flow chart for ICD implantation.

very low in this group. This phenomenon has been seen in at least one previous study.<sup>99</sup>

Pending further studies, HCM-RISK should be used cautiously in patients with a maximum left ventricular wall thickness  $\geq 35$  mm.

Implantable cardioverter defibrillators are not recommended when the estimated 5-year risk of SCD is  $<4\%$  and there are no other clinical features that are of potential prognostic importance (for example multiple young sudden deaths in a family or an abnormal exercise blood pressure response). When such features are present, decisions on ICDs must be made on an individual basis and must balance the likely benefit against the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health.

**9.5.3.3.3 Practical aspects of ICD therapy.** Prior to ICD implantation, patients should be counselled on the risk of inappropriate shocks, implant complications, and the social and occupational implications (including driving restrictions) of an ICD. Studies examining the role of defibrillation testing at the time of implantation are continuing, but high defibrillation thresholds are reported in patients with severe LVH and in those on amiodarone treatment.<sup>397–400</sup> Until data specific to HCM are available, defibrillation testing may be considered at the physician's discretion. For patients who have a high defibrillation threshold or who fail to cardiovert on defibrillation testing, options include sub-pectoral implantation and standard manoeuvres such as reversal of shocking vector polarity, changing the shock tilt, including/excluding a superior vena cava coil followed by re-testing and, if necessary, implantation of a subcutaneous array.

The VF zone of the device should be programmed at  $>220$ /min to minimize shocks from rapidly conducted AF. An SVT discrimination zone, tailored to individual patient characteristics, may also be considered. Observational data show that anti-tachycardia pacing is effective in terminating ventricular arrhythmias in HCM but does not reduce the incidence of appropriate shocks.<sup>387,401</sup> As atrial leads do not reduce the incidence of inappropriate shocks,<sup>327,393,396</sup> most patients require only a single ventricular lead. Exceptions include patients with LVOTO, in whom an atrial lead provides the option for a short AV delay pacing, and patients in sinus rhythm with impaired LV systolic function, in whom CRT might be preferable (see section 9.3.1.2). In the light of results from the Multicenter Automatic Defibrillator Implantation Trial—Reduce Inappropriate Therapy (MADIT-RIT), shock-only programming can be considered in primary prevention, although this trial was conducted in patients with low EF.<sup>402</sup>

$\beta$ -Blockers and/or amiodarone are recommended in patients with an ICD, who continue to have symptomatic ventricular arrhythmias or recurrent shocks despite optimal treatment and device re-programming.<sup>219</sup> Electrophysiological study is recommended in patients with ICDs and inappropriate shocks due to regular supraventricular tachycardias, in order to identify and treat any ablatable arrhythmia substrate.<sup>403</sup>

The newly developed subcutaneous ICD lead system (S-ICD<sup>TM</sup>, Boston Scientific) has FDA approval and may be considered in HCM patients who have no indication for pacing.<sup>404</sup> Particular attention should be paid to ensuring optimal R-wave sensing at rest and on exercise, in order to avoid inappropriate shocks from

T-wave oversensing. Each patient should have more than one ECG vector that passes screening, to allow alternative programming if oversensing does occur.<sup>405,406</sup> Data from a multicentre registry that included 58 HCM patients provided preliminary efficacy and safety data.<sup>407</sup>

### Recommendations on practical aspects of implantable cardioverter defibrillator therapy

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Prior to ICD implantation, patients should be counselled on the risk of inappropriate shocks, implant complications and the social, occupational, and driving implications of the device.	I	C	219,327
$\beta$ -Blockers and/or amiodarone are recommended in patients with an ICD, who have symptomatic ventricular arrhythmias or recurrent shocks despite optimal treatment and device re-programming.	I	C	219,403
Electrophysiological study is recommended in patients with ICDs and inappropriate shocks due to regular supraventricular tachycardias, to identify and treat any ablatable arrhythmia substrate.	I	C	403
A subcutaneous ICD lead system (S-ICD <sup>TM</sup> ) may be considered in HCM patients who do not have an indication for pacing.	IIb	C	407

HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; S-ICD<sup>TM</sup> = subcutaneous ICD lead system

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

### 9.5.4 Risk of sudden death in children

Implantation of an ICD (epicardial if necessary) is indicated after a life-threatening ventricular arrhythmia in children. In very young children ( $<8$  years old), clinical risk stratification to determine the need for primary prophylaxis with an ICD is hampered by a lack of data. The risk of death or heart transplantation is greatest in infants or in patients with inherited metabolic disorders and malformation syndromes.<sup>408</sup> There is general agreement that, as in adults, severe LVH, unexplained syncope, NSVT and a family history of sudden death represent major risk factors for sudden cardiac death.<sup>409</sup> The definition of severe hypertrophy in infants, children and pre-adolescents has been assessed using different approaches and measurements.<sup>410,411</sup> The consensus view for these Guidelines is that a maximum left ventricular wall thickness  $\geq 30$  mm or a Z-score  $\geq 6$  is considered to be a major risk factor in children.<sup>410</sup>

Implantation of an ICD should be considered in children who have two or more major risk factors. Single-chamber defibrillators suffice in the majority of cases and reduce the likelihood of complications.<sup>412</sup> In individual patients with a single risk factor, ICD implantation may be considered after careful consideration of the risks and benefits to the child and family.

### Recommendations on implantation of cardioverter defibrillators in children

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
ICD implantation is recommended in children who have survived a cardiac arrest or experienced documented sustained ventricular tachycardia.	I	B	409,413,414
ICD implantation should be considered in children with two or more major paediatric risk factors <sup>d</sup> after appropriate counselling and when an assessment of the lifelong risk of complications and the impact of an ICD on lifestyle and psychological health suggests a net benefit from ICD therapy.	IIa	C	377,409,414
ICD implantation may be considered in children with a single major paediatric risk factor <sup>d</sup> after appropriate counselling and when an assessment of the lifelong risk of complications and the impact of an ICD on lifestyle and psychological health suggests a net benefit from ICD therapy.	IIb	C	409

ICD = implantable cardioverter defibrillator; HCM = hypertrophic cardiomyopathy; SCD = sudden cardiac death.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

<sup>d</sup>Major paediatric risk factors: Maximum left ventricular wall thickness  $\geq 30$  mm or a Z-score  $\geq 6$ , unexplained syncope, non-sustained ventricular tachycardia ( $\geq 3$  consecutive ventricular beats at  $\geq 120$  BPM lasting  $< 30$  seconds), family history of SCD (one or more first-degree relatives with SCD aged  $< 40$  years with or without the diagnosis of HCM, or SCD in a first-degree relative at any age with an established diagnosis of HCM).

## 9.6 Symptomatic bradycardia and atrioventricular block

Symptomatic bradycardia caused by sinus node dysfunction and AV block is relatively uncommon in HCM and should be treated in accordance with the current ESC Guidelines.<sup>249</sup> The presence of AV block should raise suspicion of particular genetic subtypes (desmin, FHL1, PRKAG2) in younger patients or amyloidosis and Anderson-Fabry disease in older patients (see section 5 on diagnosis). In contrast, chronotropic incompetence is quite common (particularly in Anderson-Fabry disease) and is an important cause of exercise limitation.<sup>415</sup> If AV block is caused by AV node blocking drugs, their dose should be adjusted and the need for pacing re-evaluated.

The benefit of rate-responsive pacing in treating exercise intolerance is uncertain. The risks of chronic RV pacing in HCM with respect to LV systolic function are unknown, but ventricular pacing should be minimized where possible unless treating LVOTO. CRT-P should be considered in patients with impaired systolic function (EF  $< 50\%$ ).<sup>339,416</sup>

## 9.7 Ventricular tachycardia

Non-sustained ventricular tachycardia (defined as three or more ventricular extrasystoles at a rate of  $\geq 120$  BPM, lasting  $< 30$  seconds) is a common finding on ambulatory ECG monitoring.<sup>69,70,417,418</sup> Its prevalence increases with age and correlates with LV wall thickness and the presence of late gadolinium enhancement on CMR.<sup>69,140</sup> Non-sustained ventricular tachycardia is a risk factor for SCD, but does not usually require anti-arrhythmic therapy. Its occurrence during or immediately following exercise is very rare, but may be associated with a high risk of SCD.<sup>246</sup>

Documented sustained monomorphic VT ( $\geq 30$  seconds) is uncommon but may be more frequent in patients with apical LV aneurysms.<sup>256,419</sup> Exclusion of coronary artery disease should be considered in patients with prolonged or symptomatic episodes and risk factors for coronary atherosclerosis. There is no evidence that haemodynamically tolerated, sustained VT carries a worse prognosis than NSVT but it should be considered as a risk factor for SCD. Patients with poorly tolerated VT should be considered for ICD therapy and treatment with  $\beta$ -blockers or amiodarone, to suppress further episodes. In patients with evidence for a focal origin, EPS and ablation may be considered.<sup>420–422</sup>

## 10. Recommendations for routine follow-up

*In general, patients with HCM require lifelong follow-up to detect changes in symptoms, risk of adverse events, LVOTO, LV function and cardiac rhythm.*

There are very few longitudinal data on the rates of change in symptoms or cardiac function, but cross-sectional studies show that the prevalence of LV systolic dysfunction and atrial arrhythmia increases with advancing age.<sup>222,224,225,423</sup> The frequency of monitoring is determined by the severity of disease, age and symptoms. A clinical examination, including 12-lead ECG and TTE, should be performed every 1–2 years, or sooner should patients complain of new heart failure symptoms. Ambulatory electrocardiography is recommended every year (or every 6 months in the presence of left atrial dilation  $\geq 45$  mm) to detect asymptomatic atrial and ventricular arrhythmia, and is indicated whenever patients experience syncope or palpitations.

When available, cardiopulmonary exercise testing can provide objective evidence for worsening disease but need only be performed every 2–3 years unless there is a change in symptoms. There are few data on changes in myocardial fibrosis on CMR during follow-up but, when available, CMR evaluation may be considered every five years or every 2–3 years in patients with progressive disease.<sup>424</sup>

A complete assessment, including ECG, TTE and ambulatory ECG monitoring should be performed within 1–3 months and at 6–12 months following invasive septal reduction therapies.

### Recommendations on routine follow-up

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
A clinical evaluation, including 12-lead ECG and TTE, is recommended every 12–24 months in clinically stable patients.	I	C	68,72,74,84,85
A clinical evaluation, including 12-lead ECG and TTE, is recommended whenever there is a change in symptoms.	I	C	68,72,74,84,85
48-Hour ambulatory ECG is recommended every 12–24 months in clinically stable patients, every 6–12 months in patients in sinus rhythm with left atrial dimension $\geq 45$ mm, and whenever patients complain of new palpitations.	I	C	69–73
CMR may be considered every 5 years in clinically stable patients, or every 2–3 years in patients with progressive disease.	IIb	C	424
Symptom-limited exercise testing should be considered every 2–3 years in clinically stable patients, or every year in patients with progressive symptoms.	IIa	C	425
Cardiopulmonary exercise testing (when available) may be considered every 2–3 years in clinically stable patients, or every year in patients with progressive symptoms.	IIb	C	233,426

CMR = cardiac magnetic resonance; ECG = electrocardiogram; TTE = transthoracic echocardiogram.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

## 11. Reproduction and contraception

### 11.1 Introduction

Pregnancy is associated with many physiological changes, including a 40–50% increase in plasma volume and cardiac output, a reduction in systemic vascular resistance and a hypercoagulable state. Whilst most women with HCM have uncomplicated pregnancies, these physiological changes are associated with increased risk for mother and foetus, as the volume load can be poorly tolerated in the setting of LVOTO and diastolic dysfunction. *Adequate and timely counselling on contraception, the risks associated with pregnancy, and the risk of disease transmission to the foetus is important in all women with HCM.*<sup>427,428</sup>

### 11.2 Contraception and termination of pregnancy

When a girl with HCM reaches fertility, she should be counselled to use safe and effective contraception, since unplanned pregnancy carries an increased risk.<sup>427</sup> Barrier methods (condoms, diaphragms, pelvic ring) are safe but not as effective as oral contraceptives, even when combined with spermicides (failure rate at 1 year 15–30%).

Low dose oral contraceptives with 20  $\mu\text{g}$  or 30  $\mu\text{g}$  ethinyl-oestradiol are effective (though less so in adolescents) and can be safely used in most women with HCM, except for those with increased thromboembolic risk (e.g. women with heart failure or AF), unless they are using adequate oral anticoagulation therapy. Oral contraceptives are *inadvisable* in any women who smoke and are older than 35 years or who have a history of venous thromboembolism. Emergency contraception is safe for women with HCM.<sup>427,429</sup> Progesterone-only contraceptives are a safe alternative but the effectiveness of the progesterone-only pill (desogestrel) depends on compliance (daily intake with  $< 12$  hours of variation). Other progesterone-only contraceptives can be used, including 3-monthly injections with medroxyprogesterone acetate or dermal progesterone implants, but should be used cautiously in women with diastolic or systolic heart failure because of the risk of fluid retention. The levonorgestrel-releasing intra-uterine device (IUD) is a safe and effective alternative. Progesterone-only methods are not always tolerated because of irregular blood loss. A copper IUD may be used but is less effective and is associated with an increase in monthly blood loss. Antibiotic prophylaxis at the time of IUD insertion is not necessary, but vaso-vagal reactions can occur during implantation and, in women with severe LVOTO, it should therefore be implanted after cardiology consultation and in a hospital setting.

Sterilization can be safely accomplished by tubal ligation, although the risks of anaesthesia and abdominal inflation should be considered. Hysteroscopic sterilization with an Essure<sup>TM</sup> device (Bayer) is an alternative but can also be associated with vasovagal reactions.<sup>427,429</sup>

Termination of pregnancy should be performed in-hospital after consultation with a cardiologist. Dilation and evacuation are usually safe; as prostaglandin E1 or E2 can lower systemic vascular resistance and increase heart rate, haemodynamic monitoring is indicated. Prostaglandin F increases pulmonary artery pressure and should be avoided.<sup>427</sup>

### 11.3 Infertility treatment

*In vitro* fertilization can be associated with fluid retention and with arterial and venous thromboembolism. It is probably safe in low-risk HCM patients, but should be avoided in patients with heart failure or AF and in women with severe hypertrophy and restrictive LV filling pattern.<sup>427</sup> When pre-implantation genetic diagnosis (see section 6) is an issue, the risk of *in vitro* fertilization should be taken into account.

### 11.4 Pre-conception counselling

Most women with HCM tolerate pregnancy well. The hypertrophied small left ventricle can, in most cases, accommodate the physiological increase in blood volume without undue rise in filling pressures. The few reported cases of maternal death have occurred mostly in women who were known to be at very high risk.<sup>430–432</sup> Deterioration during pregnancy most often occurs in women who are symptomatic before pregnancy.<sup>431,433,434</sup> The prevalence of heart failure during pregnancy differs between studies but it is probably more likely in women who had impaired LV function before pregnancy.<sup>431–433,435</sup> Left ventricular outflow tract gradients tend to increase slightly during pregnancy and high pre-pregnancy LVOT gradients have been reported to be associated with more pregnancy complications.<sup>430–432,434,436</sup> Women with arrhythmias

pre-pregnancy are more likely to experience recurrence in pregnancy,<sup>430,436</sup> but pregnancy *per se* does not seem to substantially increase the risk of arrhythmia.<sup>430,432,433,436</sup>

Ideally, risk assessment should be performed before conception, using the modified World Health Organization (WHO) classification.<sup>427</sup> Most HCM patients are WHO Class II or III (Table 8).<sup>427</sup> Justification for advising against pregnancy (WHO Class IV) is present in a small minority with significant LV dysfunction or severe symptomatic LVOTO. Pregnancy may be possible after relief of LVOTO.

Echocardiography should be performed to evaluate ventricular function, mitral regurgitation and LVOTO. Exercise testing (preferably pre-pregnancy or, in asymptomatic pregnant women, to 80% of predicted maximal heart rate) is an important tool to assess functional capacity, heart rate response and arrhythmias.<sup>427,437</sup> A plan for use of medication and follow-up during pregnancy should be made and discussed with the patient and her partner before conception.<sup>427</sup> Genetic counselling is recommended in all women with HCM (see section 6).

## 11.5 Management of pregnancy and delivery

Women in WHO Class II should be assessed each trimester. Women in WHO Class III should be followed monthly or bimonthly, in specialized centres, by a multidisciplinary team.<sup>427</sup> The focus should be on symptomatic status, LV outflow obstruction, arrhythmias and ventricular function. Echocardiography should be performed each trimester or when new symptoms occur.

Recommendations for drug use during pregnancy and breastfeeding are summarized in Web Table 6.<sup>427</sup> When medication is prescribed, possible harmful effects to the foetus need to be considered. However, both doctor and patient should realise that withholding medication from the mother may seriously threaten her health and therefore also the foetus (e.g. treatment of serious ventricular arrhythmias and anticoagulation therapy for AF). *Ultimately, the interests of the mother should prevail.*

$\beta$ -Blockers should be continued if already used before pregnancy (though re-evaluation of the need for their use is recommended) and side-effects such as growth retardation, neonatal bradycardia or hypoglycaemia are usually not severe and can be easily managed.

$\beta$ -Blockers should be started when new symptoms occur.<sup>427,434</sup> Metoprolol is the most widely used; atenolol is not advised because it has been associated with more growth retardation. *Whenever  $\beta$ -blockers are prescribed, monitoring of foetal growth and of the condition of the neonate is recommended.*

Verapamil and diltiazem are classified by the FDA as class C, meaning that their potential benefits may warrant their use in pregnant women despite potential risks.

*Disopyramide should only be used when potential benefits outweigh risks, since it can cause uterine contractions.*<sup>438</sup>

Amiodarone should only be used when absolutely necessary, because of risk of the foetal thyroid toxicity, growth retardation, and neurological adverse effects.<sup>427,439,440</sup>

Poorly tolerated AF can be safely cardioverted during pregnancy. Since a few cases of foetal distress immediately following electrical cardioversion have been described, this procedure should be carried out with facilities available for cardiac monitoring and emergency caesarean section.<sup>441</sup> Therapeutic anticoagulation with low molecular weight heparin with anti-factor-Xa monitoring (peak anti-Xa level 0.8–1.2 U/mL 4–6 hours post-dose) in the first trimester and from the 36<sup>th</sup> week onwards—or VKAs in the second and third trimester—is recommended for paroxysmal or persistent AF.<sup>427</sup> New oral anticoagulants (e.g. dabigatran, rivaroxaban) are not advised because of proven toxicity in animals and insufficient data in humans. When indicated, pacemaker or ICD implantation during pregnancy should be performed, if possible with echocardiographic guidance.

A delivery plan should be made at the end of the second trimester by the multidisciplinary team. Planned vaginal delivery is generally preferred although asymptomatic women with mild disease may go into spontaneous labour. Caesarean section is mainly performed for obstetric indications but should be considered in patients with severe LVOTO, pre-term labour while on OAC, or severe heart failure. Epidural and spinal anaesthesia are beneficial for reduction of pain and stress but must be applied judiciously to avoid vasodilation and hypotension, especially when LVOTO is severe. Single-shot spinal anaesthesia should be avoided.<sup>427,442</sup> During delivery, monitoring of heart rate and rhythm should be considered in patients with a high risk of developing arrhythmias.<sup>434</sup> Oxytocin should only be given as a slow infusion, to avoid hypotension and tachycardia.

**Table 8 Modified WHO classification of maternal cardiovascular risk: principles and application**

Risk class	Risk of pregnancy	Application to HCM
I	No detectable increased risk of maternal mortality and no/mild risk of morbidity	-
II	Small increased risk of maternal mortality or moderate increase in morbidity	Most women with HCM: mild to moderate LVOTO; asymptomatic with or without medication, well-controlled arrhythmia, normal systolic LV function or mild LV dysfunction
III	Significantly increased risk of maternal mortality or severe morbidity	Severe LVOTO, symptoms or arrhythmias despite optimal medication, moderate systolic LV dysfunction
IV	Extremely high risk of maternal mortality or severe morbidity; pregnancy contraindicated	Severe systolic LV dysfunction, severe symptomatic LVOTO

HCM = hypertrophic cardiomyopathy; LV = left ventricle; LVOTO = left ventricular outflow tract obstruction; WHO = World Health Organization.

Because of increased risk of pulmonary oedema due to fluid shifts post-delivery, clinical observation should be continued for 24–48 hours.<sup>427</sup> There is no need to deactivate an ICD during vaginal delivery.

### Recommendations on reproductive issues in women with hypertrophic cardiomyopathy

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
Pre-pregnancy risk assessment and counselling is indicated in all women.	I	C	427,428
Counselling on safe and effective contraception is indicated in all women of fertile age.	I	C	427,429
Counselling on the risk of disease transmission is recommended for all men and women before conception.	I	C	427
β-Blockers (preferably metoprolol) should be continued in women who used them before pregnancy.	IIa	C	427,434
β-Blockers (preferably metoprolol) should be started in women who develop symptoms during pregnancy.	I	C	427,434
Whenever β-blockers are prescribed, monitoring of foetal growth and of the condition of the neonate is recommended.	I	C	427,434
Scheduled (induced) vaginal delivery is recommended as first choice in most patients	I	C	427
Therapeutic anticoagulation with LMWH or vitamin K antagonists depending on the stage of pregnancy <sup>d</sup> is recommended for atrial fibrillation.	I	C	427
Cardioversion should be considered for persistent atrial fibrillation.	IIa	C	441

LMWH = low molecular weight heparin.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Reference(s) supporting recommendations.

<sup>d</sup>See text for details

## 12. Special issues

### 12.1 Diagnosis of hypertrophic cardiomyopathy in athletes

Physiological adaptation to regular intense physical training is associated with ECG manifestations that reflect increased vagal tone, enlarged cardiac chamber size and an increase in LV wall thickness and mass.<sup>443</sup> The ability to reliably differentiate between HCM and this normal training effect is important, as an incorrect diagnosis has far-reaching implications for individual athletes and their families,

as well as for sporting organizations and society as a whole. Several clinical features that distinguish physiological from pathological hypertrophy have been described,<sup>444,445</sup> but dilemmas can arise in individuals with borderline or mild LVH.<sup>446</sup> In the absence of a validated 'gold standard', the diagnosis of HCM in an athlete requires integration of a number of different parameters of varying sensitivity and specificity. *Web Table 7* summarizes the features that assist in differentiating between HCM and physiological LV hypertrophy caused by physical training, and that are best supported by published data.<sup>59,445–460</sup>

### 12.2 Hypertension

In clinical practice, it can be a challenge to make a differential diagnosis between hypertensive heart disease on the one hand and HCM associated with systemic hypertension on the other. Regression of LVH with treatment of hypertension argues against the diagnosis of HCM, but the reverse is not necessarily true.<sup>461–466</sup> Clinical features that suggest a diagnosis of HCM in a patient with hypertension are summarized in *Table 9*.

#### 12.2.1 Imaging

Increased LV mass, determined by echocardiography, is present in >30% of hypertensive patients.<sup>467</sup> The degree of hypertrophy is influenced by ethnicity, neurohumoral factors, and genetic variants.<sup>468–470</sup> In general, maximal LV wall thickness is greater in patients with unequivocal HCM, but there is overlap between the two conditions.<sup>471–473</sup> The majority of patients with hypertensive LVH have a maximal interventricular septal thickness <15mm,<sup>474–477</sup> but in black patients (particularly in the presence of chronic kidney disease) maximal interventricular septal thickness is not uncommonly between 15 and 20 mm.<sup>478</sup> Late gadolinium enhancement is reported in the mid-myocardium and epicardium in both hypertension and HCM,<sup>136</sup> but tends to be located in the segment with the greatest wall thickness and at the RV insertion points in HCM.<sup>136</sup> Similarly, while diastolic abnormalities and LA dilation are seen in HCM and hypertension, severe diastolic dysfunction is more typical of HCM. Doppler myocardial imaging and strain imaging may help to distinguish the two entities.<sup>479,480</sup> Resting or exercise-induced LVOTO can be observed in hypertension and does not constitute a diagnostic criterion.<sup>481,482</sup>

#### 12.2.2 Electrocardiogram

On the 12-lead ECG, LVH by voltage criteria is seen in 10–20% of hypertensive patients with LVH, but—at least in Caucasians—marked repolarisation abnormalities, conduction abnormalities and Q-waves are unusual.<sup>68,467,483,484</sup> Atrial fibrillation is common in both conditions, affecting approximately one-third of patients. Premature ventricular complexes and NSVT are reported in up to 30% of patients with hypertension complicated by LVH.<sup>485–487</sup>

### 12.3 Isolated basal septal hypertrophy (sigmoid septum) in elderly people

Some elderly people have mild basal septal hypertrophy (sometimes referred to as a sigmoid septum or septal bulge) associated with increased angulation between the aorta and LV cavity. Many have a history of hypertension and some have calcification of the mitral valve annulus. The limited data suggest that individuals with this

**Table 9 Clinical features that assist in the differential diagnosis of hypertensive heart disease and hypertrophic cardiomyopathy**

Clinical features favouring hypertension only
Normal 12 lead ECG or isolated increased voltage without repolarisation abnormality
Regression of LVH over 6–12 months tight systolic blood pressure control (<130 mm Hg) <sup>466</sup>
Clinical features favouring hypertrophic cardiomyopathy
Family history of HCM
Right ventricular hypertrophy
Late gadolinium enhancement at the RV insertion points or localized to segments of maximum LV thickening on CMR
Maximum LV wall thickness $\geq 15$ mm (Caucasian); $\geq 20$ mm (black)
Severe diastolic dysfunction
Marked repolarisation abnormalities, conduction disease or Q-waves on 12 lead ECG

ECG = electrocardiogram; CMR = cardiac magnetic resonance imaging; HCM = hypertrophic cardiomyopathy; LV = left ventricle; LVH = left ventricular hypertrophy; RV = right ventricle.

pattern of ventricular remodelling are less likely to have familial disease or a mutation in a cardiac sarcomeric protein gene.<sup>488</sup> *Importantly, due to provokable LVOTO, some patients with basal septal hypertrophy experience symptoms on exertion and should be assessed using physiological provocation and stress echocardiography in the same way as patients with unequivocal HCM.*<sup>489,490</sup> Advice on family screening in this group is challenging, but should be guided by the implications for family members and the presence of suspicious symptoms in relatives.

## 12.4 Diagnosis and management of valve disease in patients with hypertrophic cardiomyopathy

### 12.4.1 Aortic valve disease

In the absence of a family history of HCM or a known history of HCM before the development of significant aortic valve disease, the differential diagnosis between, on the one hand, valvular aortic stenosis with severe LVH and, on the other, HCM associated with degenerative aortic valve disease can be challenging, particularly in the elderly with hypertension. In general, the pattern and severity of LV remodelling in aortic stenosis correlates modestly with the severity of valve narrowing. Between 20% and 30% have an asymmetric pattern of wall thickening, although the severity of hypertrophy is usually relatively mild (wall thickness  $\leq 15$  mm).<sup>491,492</sup> Left ventricular wall thickness  $\geq 15$  mm has been reported in older hypertensive patients in small cohorts, who were examined using CMR.<sup>450</sup> Systolic anterior motion and dynamic LVOTO is reported in patients with aortic stenosis and complicates accurate measurement of the valve gradient. The treatment of aortic stenosis should be in line with current ESC Guidelines.<sup>493</sup> In patients with aortic stenosis and in whom dynamic obstruction is not demonstrated pre-operatively, septal myectomy is controversial and not recommended for routine use.<sup>494</sup>

Up to one-third of patients with HCM have mild AR, probably caused by sub-aortic obstruction and high-velocity flow in the LV outflow tract.<sup>495,496</sup> Moderate-to-severe AR is much less common and is usually caused by primary disease of the aortic valve leaflets

or aortic root and infective endocarditis;<sup>497</sup> when present in a patient with LVOTO, a non-SAM-related mechanism for obstruction, such as a sub-aortic membrane, should be excluded. Aortic regurgitation may also occur following septal myectomy, particularly in children and young adults.<sup>498,499</sup> The severity of AR should be assessed in accordance with ESC guidelines by evaluating the anatomy of the valve, the size of the aortic root and of the ascending aorta, and other qualitative, semi-quantitative and quantitative parameters.<sup>500</sup> The size of the LV cavity is an unreliable marker of the severity of AR in HCM.

### 12.4.2 Mitral valve disease

Mitral valve abnormalities secondary to LVOTO are discussed in section 9.1.3. The assessment of intrinsic mitral valve abnormalities can be challenging in the presence of LVOTO that, in itself, causes mitral regurgitation. The usual integrative approach to the assessment of mitral regurgitation, as recommended in the ESC/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines on the management of valvular heart disease,<sup>493</sup> has some limitations in HCM because the LV cavity is often small, even in the presence of severe mitral regurgitation, and conventional quantitative and semi-quantitative Doppler parameters are not validated in patients with LVOTO. In general, qualitative measures of valve anatomy—continuous wave and colour Doppler, combined with left atrial size and estimation of pulmonary artery pressure—are more helpful. In selected cases, TOE may be helpful in defining the mechanism and severity of mitral valve regurgitation.

### 12.4.3 Endocarditis prophylaxis

Infective endocarditis in HCM is virtually confined to patients with LV outflow obstruction, particularly in those with LA dilation.<sup>501</sup> The incidence of endocarditis in patients with LVOTO was 3.8 per 1000 person-years and the probability of endocarditis 4.3% at 10 years of follow-up in a large cohort study.<sup>501</sup> Endocardial lesions most commonly occur on the thickened anterior mitral leaflet or adjacent surface of the proximal ventricular septum.<sup>497,502</sup> As in patients



**Table 10** General lifestyle considerations for patients with hypertrophic cardiomyopathy

Topic	General guidance
Exercise	<ul style="list-style-type: none"> <li>Patients with HCM should avoid competitive sports activities, but should maintain a healthy lifestyle</li> <li>Advice on recreational activities should be tailored to symptoms and the risk of disease-related complications including sudden cardiac death</li> </ul>
Diet, alcohol and weight	<ul style="list-style-type: none"> <li>Patients should be encouraged to maintain a healthy body mass index</li> <li>Large meals can precipitate chest pain, particularly in patients with LVOTO. Smaller, more frequent meals may be helpful</li> <li>Avoid dehydration and excess alcohol, particularly in patients with LVOTO</li> <li>Constipation is a frequent side-effect of verapamil/disopyramide and should be managed with diet and if necessary aperients</li> </ul>
Smoking	<ul style="list-style-type: none"> <li>There are no data that show an interaction between tobacco smoking and HCM, but patients should be provided with general advice on the health risks associated with smoking and, when available, information on smoking cessation</li> </ul>
Sexual activity	<ul style="list-style-type: none"> <li>Patients should be given the opportunity to discuss their concerns about sexual activity. Anxiety and depression following a diagnosis are frequent and some patients may express guilt or fear about their genetic diagnosis and the risk of transmission to offspring</li> <li>Patients should be counselled on the potential effect of their medication on sexual performance</li> <li>In general, patients should avoid PDE<sub>5</sub> inhibitors, particularly when they have LVOTO</li> </ul>
Medication	<ul style="list-style-type: none"> <li>Patients should be provided with information about their medication, including potential side-effects and interactions with prescribed medications, over-the-counter remedies and other complementary therapies</li> <li>Where possible, peripheral vasodilators should be avoided in patients, particularly when they have LVOTO</li> </ul>
Vaccination	<ul style="list-style-type: none"> <li>In the absence of contraindications, symptomatic patients should be advised to have yearly influenza vaccination</li> </ul>
Driving	<ul style="list-style-type: none"> <li>Most patients should be eligible for an ordinary driving licence and can continue driving unless they experience distracting or disabling symptoms</li> <li>Advice on driving licences for heavy goods or passenger-carrying vehicles should be in line with local legislation</li> <li>For further advice on driving with ICD see EHRA guidance<sup>504</sup> and local rules</li> </ul>
Occupation	<ul style="list-style-type: none"> <li>Most people with HCM will be able to continue in their normal job. The implications of heavy manual jobs that involve strenuous activity should be discussed with the appropriate specialist</li> <li>For some occupations such as pilots, and military and emergency services, there are strict guidelines on eligibility</li> <li>The social and financial implications of a diagnosis of HCM should be included in the counselling of relatives before clinical or genetic screening</li> </ul>
Holidays and travel insurance	<ul style="list-style-type: none"> <li>Most asymptomatic or mildly symptomatic patients can fly safely. For further advice see <i>Fitness to fly for passengers with cardiovascular disease</i><sup>505</sup></li> <li>Insurance companies may charge more for travel insurance. In some countries, patient support organizations can provide further advice about obtaining reasonable insurance</li> </ul>
Life insurance	<ul style="list-style-type: none"> <li>The diagnosis of HCM will result in difficulty obtaining life insurance or mortgages. Advice on the rules that apply in different countries should be provided to patients at diagnosis</li> </ul>
Pregnancy and childbirth	<ul style="list-style-type: none"> <li>See Reproduction and contraception (section 11)</li> </ul>
Education/schooling	<ul style="list-style-type: none"> <li>Teachers and other carers should be provided with advice and written information relevant to the care of children with HCM</li> <li>In the absence of symptoms and risk factors, children should be allowed to perform low to moderate level aerobic physical activity, in accordance with advice from their cardiologist</li> <li>Provision should be made for children with learning difficulties and other special needs</li> </ul>

ICD = implantable cardioverter defibrillator; EHRA = European Heart Rhythm Association; HCM = hypertrophic cardiomyopathy; LVOTO = left ventricular outflow tract obstruction; PDE<sub>5</sub> = phosphodiesterase 5.

with valve disease, good oral hygiene should be encouraged, but routine antibiotic prophylaxis is not recommended in patients with LV outflow tract gradients.<sup>503</sup> Antibiotic prophylaxis should be considered for high-risk procedures in patients with prosthetic heart valves or prosthetic material used for valve repair, previous endocarditis or congenital heart disease, in accordance with the ESC/EACTS Guidelines on the management of valvular heart disease.<sup>493,503</sup>

### 13. Living with cardiomyopathy: advice to patients

Most people with HCM lead normal and productive lives, but a small number experience significant symptoms and are at risk of disease-related complications. Irrespective of the severity of their

disease, it is important that individuals receive support and accurate advice from family practitioners and other healthcare professionals, and that they are encouraged to understand and manage the disease themselves. *Table 10* summarizes some of the key issues that should be discussed with patients, relatives and carers. When appropriate (for example, when considering pregnancy), patients should be referred to other specialist services.

## 14. Appendix

ESC National Cardiac Societies actively involved in the review process of the 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy.

**Austria:** Austrian Society of Cardiology, Matthias Frick;  
**Azerbaijan:** Azerbaijan Society of Cardiology, Farid Aliyev;  
**Belarus:** Belorussian Scientific Society of Cardiologists, Svetlana

Komissarova; **Belgium:** Belgian Society of Cardiology, Georges Mairesse; **Bosnia and Herzegovina:** Association of Cardiologists of Bosnia & Herzegovina, Elnur Smajić; **Bulgaria:** Bulgarian Society of Cardiology, Vasil Velchev; **Cyprus:** Cyprus Society of Cardiology, Loizos Antoniadis; **Czech Republic:** Czech Society of Cardiology, Ales Linhart; **Denmark:** Danish Society of Cardiology, Henning Bundgaard; **Finland:** Finnish Cardiac Society, Tiina Heliö; **France:** French Society of Cardiology, Antoine Leenhardt; **Germany:** German Cardiac Society, Hugo A. Katus; **Greece:** Hellenic Cardiological Society, George Efthymiadis; **Hungary:** Hungarian Society of Cardiology, Róbert Sepp; **Iceland:** Icelandic Society of Cardiology, Gunnar Thor Gunnarsson; **Israel:** Israel Heart Society, Shemy Carasso; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Alina Kerimkulova; **Latvia:** Latvian Society of Cardiology, Ginta Kamzola; **Lebanon:** Lebanese Society of Cardiology, Hady Skouri; **Libya:** Libyan Cardiac Society, Ghada Eldirsi; **Lithuania:** Lithuanian

Society of Cardiology, Ausra Kavoliuniene; **Malta:** Maltese Cardiac Society, Tiziana Felice; **Netherlands:** Netherlands Society of Cardiology, Michelle Michels; **Norway:** Norwegian Society of Cardiology, Kristina Hermann Haugaa; **Poland:** Polish Cardiac Society, Radoslaw Lenarczyk; **Portugal:** Portuguese Society of Cardiology, Dulce Brito; **Romania:** Romanian Society of Cardiology, Eduard Apetrei; **Russia:** Russian Society of Cardiology, Leo Bokheria; **Serbia:** Cardiology Society of Serbia, Dragan Lovic; **Slovakia:** Slovak Society of Cardiology, Robert Hatala; **Spain:** Spanish Society of Cardiology, Pablo Garcia Pavia; **Sweden:** Swedish Society of Cardiology, Maria Eriksson; **Switzerland:** Swiss Society of Cardiology, Stéphane Noble; **The Former Yugoslav Republic of Macedonia:** Macedonian FYR Society of Cardiology, Elizabeta Srbinska; **Turkey:** Turkish Society of Cardiology, Murat Özdemir; **Ukraine:** Ukrainian Association of Cardiology, Elena Nesukay; **United Kingdom:** British Cardiovascular Society, Neha Sekhri.

The CME text '2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy' is accredited by the European Board for Accreditation in Cardiology (EBAC). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). In compliance with EBAC/EACCME Guidelines, all authors participating in this programme have disclosed any potential conflicts of interest that might cause a bias in the article. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the participants prior to the CME activities.

CME questions for this article are available at: European Heart Journal <http://www.oxforde-learning.com/eurheartj> and European Society of Cardiology <http://www.escardio.org/guidelines>.

## References

- Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2008;**29**:270–276.
- Spoladore R, Maron MS, D'Amato R, Camici PG, Olivetto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. *Eur Heart J* 2012;**33**:1724–1733.
- Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, Takikawa R, Hasegawa I, Takahashi T, Suzuki J. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. *Am J Cardiol* 1987;**59**:183–184.
- Codd MB, Sugrue DD, Gersh BJ, Melton LJ III. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. *Circulation* 1989;**80**:564–572.
- Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. *Circulation* 1995;**92**:785–789.
- Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. *N Engl J Med* 1998;**339**:364–369.
- Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. *J Am Coll Cardiol* 1999;**33**:1590–1595.
- Nistri S, Thiene G, Basso C, Corrado D, Vitolo A, Maron BJ. Screening for hypertrophic cardiomyopathy in a young male military population. *Am J Cardiol* 2003;**91**:1021–1023, A8.
- Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, Lu S, Wu P, Zhang Y, Shen L, Cai Y, Zhen Y, Liu Y, Hui R. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. *Am J Med* 2004;**116**:14–18.
- Maron BJ, Spirito P, Roman MJ, Paranicas M, Okin PM, Best LG, Lee ET, Devereux RB. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). *Am J Cardiol* 2004;**93**:1510–1514.
- Maro EE, Janabi M, Kaushik R. Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. *Trop Doct* 2006;**36**:225–227.
- Ng CT, Chee TS, Ling LF, Lee YP, Ching CK, Chua TS, Cheok C, Ong HY. Prevalence of hypertrophic cardiomyopathy on an electrocardiogram-based pre-participation screening programme in a young male South-East Asian population: results from the Singapore Armed Forces Electrocardiogram and Echocardiogram screening protocol. *Europace* 2011;**13**:883–888.
- Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. The incidence of pediatric cardiomyopathy in two regions of the United States. *N Engl J Med* 2003;**348**:1647–1655.
- Nugent AW, Daubeney PE, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. *Circulation* 2005;**112**:1332–1338.
- Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. *Mayo Clin Proc* 2005;**80**:739–744.
- Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, Towbin JA, Seidman JG, Seidman CE. Shared genetic causes of cardiac hypertrophy in children and adults. *N Engl J Med* 2008;**358**:1899–1908.
- Brito D, Miltenberger-Miltenyi G, Vale PS, Silva D, Diogo AN, Madeira H. Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population. *Rev Port Cardiol* 2012;**31**:577–587.
- Kassem HS, Azer RS, Saber-Ayad M, Moharem-Elgamel S, Magdy G, Elguindy A, Cecchi F, Olivetto I, Yacoub MH. Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. *J Cardiovasc Transl Res* 2013;**6**:65–80.
- Lopes LR, Zekavati A, Syrris P, Hubank M, Giambartolomei C, Dalageorgou C, Jenkins S, McKenna W, Plagnol V, Elliott PM. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. *J Med Genet* 2013;**50**:228–239.
- Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. *N Engl J Med* 2011;**364**:1643–1656.
- Coats CJ, Elliott PM. Genetic biomarkers in hypertrophic cardiomyopathy. *Biomark Med* 2013;**7**:505–516.
- Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. *JACC Cardiovasc Imaging* 2010;**3**:155–164.
- Rapezzi C, Quarta CC, Obici L, Peretto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. *Eur Heart J* 2013;**34**:520–528.
- Olivetto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, Ommen SR, Theis JL, Vaubel RA, Re F, Armentano C, Poggesi C, Torricelli F, Cecchi F. Myofibrillar protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo Clin Proc* 2008;**83**:630–638.
- Olivetto I, Girolami F, Sciaga R, Ackerman MJ, Sotgia B, Bos JM, Nistri S, Sgalambro A, Grifoni C, Torricelli F, Camici PG, Cecchi F. Microvascular function

- is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofibrillar gene mutations. *J Am Coll Cardiol* 2011;**58**:839–848.
26. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. *N Engl J Med* 1995;**332**:1058–1064.
  27. Pasquale F, Syrris P, Kaski JP, Mogensen J, McKenna WJ, Elliott P. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. *Circ Cardiovasc Genet* 2012;**5**:10–17.
  28. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, Watkins H. Sudden death due to troponin T mutations. *J Am Coll Cardiol* 1997;**29**:549–555.
  29. Anan R, Shono H, Kisanuki A, Arima S, Nakao S, Tanaka H. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. *Circulation* 1998;**98**:391–397.
  30. Torricelli F, Girolami F, Olivetto I, Passerini I, Frusconi S, Vargiu D, Richard P, Cecchi F. Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. *Am J Cardiol* 2003;**92**:1358–1362.
  31. Nakajima-Taniguchi C, Matsui H, Fujio Y, Nagata S, Kishimoto T, Yamauchi-Takahara K. Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy. *J Mol Cell Cardiol* 1997;**29**:839–843.
  32. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. *Heart* 2013;**99**:1800–1811.
  33. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. *J Med Genet* 2005;**42**:pe59.
  34. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. *Circulation* 2003;**107**:2227–2232.
  35. Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman MJ, Olivetto I. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. *J Am Coll Cardiol* 2010;**55**:1444–1453.
  36. Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, Hughes DA. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. *Heart* 2011;**97**:1957–1960.
  37. Murphy RT, Mogensen J, McGarry K, Bahl A, Evans A, Osman E, Syrris P, Gorman G, Farrell M, Holton JL, Hanna MG, Hughes S, Elliott PM, MacRae CA, McKenna WJ. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. *J Am Coll Cardiol* 2005;**45**:922–930.
  38. Charron P, Villard E, Sebillon P, Laforet P, Maisonobe T, Duboscq-Bidot L, Romero N, Drouin-Garraud V, Frebourg T, Richard P, Eymard B, Komajda M. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. *Heart* 2004;**90**:842–846.
  39. Limongelli G, Masarone D, D'Alessandro R, Elliott PM. Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course. *Future Cardiol* 2012;**8**:71–88.
  40. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, Coccozza S. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. *Am J Hum Genet* 1996;**59**:554–560.
  41. Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, Rummey C, Meier T, Lynch DR. Idebeneone in Friedreich ataxia cardiomyopathy—results from a 6-month phase III study (IONIA). *Am Heart J* 2011;**161**:639–645.
  42. Limongelli G, D'Alessandro R, Maddaloni V, Rea A, Sarkozy A, McKenna WJ. Skeletal muscle involvement in cardiomyopathies. *J Cardiovasc Med (Hagerstown)* 2013;**14**:837–861.
  43. Friedrich FW, Wilding BR, Reischmann S, Crocini C, Lang P, Charron P, Muller OJ, McGrath MJ, Vollert I, Hansen A, Linke WA, Hengstenberg C, Bonne G, Morner S, Wichter T, Madeira H, Arbustini E, Eschenhagen T, Mitchell CA, Isnard R, Carrier L. Evidence for FHL 1 as a novel disease gene for isolated hypertrophic cardiomyopathy. *Hum Mol Genet* 2012;**21**:3237–3254.
  44. Olive M, Goldfarb L, Moreno D, Laforet E, Dagvadorj A, Sambuughin N, Martinez-Matos JA, Martinez F, Aljo J, Farrero E, Vicart P, Ferrer I. Desmin-related myopathy: clinical, electrophysiological, radiological, neuropathological and genetic studies. *J Neurol Sci* 2004;**219**:125–137.
  45. Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, Towbin JA, Connuck DM, Messerer JE, Lipshultz SE. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. *Am Heart J* 2012;**164**:442–448.
  46. Limongelli G, Pacileo G, Marino B, Diglio MC, Sarkozy A, Elliott P, Versacci P, Calabro P, De Zorzi A, Di Salvo G, Syrris P, Patton M, McKenna WJ, Dallapiccola B, Calabro R. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. *Am J Cardiol* 2007;**100**:736–741.
  47. Sarkozy A, Diglio MC, Dallapiccola B. Leopard syndrome. *Orphanet J Rare Dis* 2008;**3**:13.
  48. Lin AE, Grossfeld PD, Hamilton RM, Smoot L, Gripp KW, Proud V, Weksberg R, Wheeler P, Picker J, Irons M, Zackai E, Marino B, Scott CI Jr., Nicholson L. Further delineation of cardiac abnormalities in Costello syndrome. *Am J Med Genet* 2002;**111**:115–129.
  49. Falk RH. Diagnosis and management of the cardiac amyloidoses. *Circulation* 2005;**112**:2047–2060.
  50. Hiramitsu S, Morimoto S, Kato S, Uemura A, Kubo N, Kimura K, Sugiura A, Itoh T, Hishida H. Transient ventricular wall thickening in acute myocarditis: a serial echocardiographic and histopathologic study. *Jpn Circ J* 2001;**65**:863–866.
  51. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. *J Am Coll Cardiol* 2009;**53**:1475–1487.
  52. Ullmo S, Vial Y, Di Bernardo S, Roth-Kleiner M, Mivelaz Y, Sekarski N, Ruiz J, Meijboom EJ. Pathologic ventricular hypertrophy in the offspring of diabetic mothers: a retrospective study. *Eur Heart J* 2007;**28**:1319–1325.
  53. Huddle KR, Kallitakis B, Skoularigis J. Pheochromocytoma associated with clinical and echocardiographic features simulating hypertrophic obstructive cardiomyopathy. *Chest* 1996;**109**:1394–1397.
  54. Hradec J, Marek J, Petrasek J. The nature of cardiac hypertrophy in acromegaly: an echocardiographic study. *Cor Vasa* 1988;**30**:186–199.
  55. Jarzembowski TM, John E, Panaro F, Manzelli A, Cabrera A, Greco A, Varga P, Sankary H, Testa G, Benedetti E. Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. *Pediatr Transplant* 2005;**9**:117–121.
  56. Sachtleben TR, Berg KE, Elias BA, Cheatham JP, Felix GL, Hofschire PJ. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. *Med Sci Sports Exerc* 1993;**25**:1240–1245.
  57. Sumpter MD, Tatro LS, Stoecker WV, Rader RK. Evidence for risk of cardiomyopathy with hydroxychloroquine. *Lupus* 2012;**21**:1594–1596.
  58. Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, Huth RG, Habermehl P, Knuf M, Emschermann T, Stopfkuchen H. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. *Heart* 2000;**83**:667–672.
  59. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. *Heart* 1997;**77**:130–132.
  60. Charron P, Dubourg O, Desnos M, Isnard R, Hagege A, Millaire A, Carrier L, Bonne G, Tesson F, Richard P, Bouhour JB, Schwartz K, Komajda M. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. *Circulation* 1997;**96**:214–219.
  61. Charron P, Forissier JF, Amara ME, Dubourg O, Desnos M, Bouhour JB, Isnard R, Hagege A, Benaiche A, Richard P, Schwartz K, Komajda M. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. *Int J Cardiol* 2003;**90**:33–38.
  62. Hagege AA, Dubourg O, Desnos M, Mirochnik R, Isnard G, Bonne G, Carrier L, Guicheney P, Bouhour JB, Schwartz K, Komajda M. Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. *Eur Heart J* 1998;**19**:490–499.
  63. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quinones MA, Roberts R, Marian AJ. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. *Circulation* 2001;**104**:128–130.
  64. Cardim N, Perrot A, Ferreira T, Pereira A, Osterziel KJ, Reis RP, Correia JF. Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. *Am J Cardiol* 2002;**90**:128–132.
  65. Kobashi A, Suwa M, Ito T, Otake Y, Hirota Y, Kawamura K. Solitary papillary muscle hypertrophy as a possible form of hypertrophic cardiomyopathy. *Jpn Circ J* 1998;**62**:811–816.
  66. Maron MS, Olivetto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. *Circulation* 2011;**124**:40–47.
  67. Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L, Elliott PM. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and

- final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013;**34**:1448–1458.
68. McLeod CJ, Ackerman MJ, Nishimura RA, Tajik AJ, Gersh BJ, Ommen SR. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. *J Am Coll Cardiol* 2009;**54**:229–233.
  69. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. *J Am Coll Cardiol* 2003;**42**:873–879.
  70. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2005;**45**:697–704.
  71. Mulrow JP, Healy MJ, McKenna WJ. Variability of ventricular arrhythmias in hypertrophic cardiomyopathy and implications for treatment. *Am J Cardiol* 1986;**58**:615–618.
  72. Guttman OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. *Heart* 2013;Sept 7 doi: 10.1136/heartjnl-2013-304276. [Epub ahead of print].
  73. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). *Eur Heart J* 2013;doi: 10.1093/eurheartj/ehd439.
  74. Klues HG, Schiffrers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. *J Am Coll Cardiol* 1995;**26**:1699–1708.
  75. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002;**105**:539–542.
  76. Maron BJ, Gottdiener JS, Bonow RO, Epstein SE. Hypertrophic cardiomyopathy with unusual locations of left ventricular hypertrophy undetectable by M-mode echocardiography. Identification by wide-angle two-dimensional echocardiography. *Circulation* 1981;**63**:409–418.
  77. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. *J Am Coll Cardiol* 1983;**2**:437–444.
  78. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. *Prog Cardiovasc Dis* 1985;**28**:1–83.
  79. Rakowski H, Sasson Z, Wigle ED. Echocardiographic and Doppler assessment of hypertrophic cardiomyopathy. *J Am Soc Echocardiogr* 1988;**1**:31–47.
  80. Losi MA, Nistri S, Galderisi M, Betocchi S, Cecchi F, Olivetto I, Agricola E, Ballo P, Buralli S, D'Andrea A, D'Errico A, Mele D, Sciomer S, Mondillo S. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. *Cardiovasc Ultrasound* 2010;**8**:7.
  81. Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, Nihoyannopoulos P. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. *Eur J Echocardiogr* 2009;**10**:194–212.
  82. Maron MS, Olivetto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med* 2003;**348**:295–303.
  83. Elliott P, Gimeno J, Tome M, McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. *Eur Heart J* 2006;**27**:3073–3074.
  84. Maron MS, Olivetto I, Zenovich AG, Link MS, Pandian NG, Kuvlin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. *Circulation* 2006;**114**:2232–2239.
  85. Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, Ward D, Kohli SK, Page SP, Demetrescu C, Sevdalis E, Keren A, Pellerin D, McKenna WJ, Elliott PM. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. *Heart* 2008;**94**:1288–1294.
  86. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. *Circulation* 1991;**84**:1188–1197.
  87. Klues HG, Proschan MA, Dollar AL, Spirito P, Roberts WC, Maron BJ. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen. *Circulation* 1993;**88**:548–555.
  88. Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, Udelson JE, Manning WJ, Maron MS. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *Am J Cardiol* 2008;**101**:668–673.
  89. Kwon DH, Setser RM, Thamilarasan M, Popovic ZV, Smedira NG, Schoenhagen P, Garcia MJ, Lever HM, Desai MY. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Heart* 2008;**94**:1295–1301.
  90. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. *Circulation* 1998;**98**:2505–2508.
  91. Wigle ED. Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy. *Heart* 2001;**86**:709–714.
  92. Sherrid MV, Wever-Pinzon O, Shah A, Chaudhry FA. Reflections of inflections in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2009;**54**:212–219.
  93. Dimitrow PP, Bober M, Michalowska J, Sorysz D. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest. *Echocardiography* 2009;**26**:513–520.
  94. Marwick TH, Nakatani S, Haluska B, Thomas JD, Lever HM. Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy. *Am J Cardiol* 1995;**75**:805–809.
  95. Nistri S, Olivetto I, Maron MS, Ferrantini C, Coppini R, Grifoni C, Baldini K, Sgalambro A, Cecchi F, Maron BJ.  $\beta$ -blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2012;**110**:715–719.
  96. Miranda R, Cotrim C, Cardim N, Almeida S, Lopes L, Loureiro MJ, Simoes O, Cordeiro P, Fazendas P, Joao I, Carrageta M. Evaluation of left ventricular outflow tract gradient during treadmill exercise and in recovery period in orthostatic position, in patients with hypertrophic cardiomyopathy. *Cardiovasc Ultrasound* 2008;**6**:19.
  97. Nistri S, Olivetto I, Maron MS, Grifoni C, Baldini K, Baldi M, Sgalambro A, Cecchi F, Maron BJ. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. *Am J Cardiol* 2010;**106**:1301–1306.
  98. Joshi S, Patel UK, Yao SS, Castenada V, Isambert A, Winson G, Chaudhry FA, Sherrid MV. Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity. *J Am Soc Echocardiogr* 2011;**24**:75–82.
  99. Spirito P, Autore C, Rapezzi C, Bernabo P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barilla CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardiomyopathy. *Circulation* 2009;**119**:1703–1710.
  100. Nistri S, Olivetto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, Conte MR, Casazza F, Galderisi M, Maron BJ, Cecchi F. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). *Am J Cardiol* 2006;**98**:960–965.
  101. Losi MA, Betocchi S, Barbatì G, Parisi V, Tocchetti CG, Pastore F, Migliore T, Contaldi C, Caputi A, Romano R, Chiariello M. Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy. *J Am Soc Echocardiogr* 2009;**22**:76–81.
  102. Tani T, Yagi T, Kitai T, Kim K, Nakamura H, Konda T, Fujii Y, Kawai J, Kobori A, Ehara N, Kinoshita M, Kaji S, Yamamuro A, Morioka S, Kita T, Furukawa Y. Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy. *Cardiovasc Ultrasound* 2011;**9**:34.
  103. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *Eur J Echocardiogr* 2009;**10**:165–193.
  104. Kubo T, Gimeno JR, Bahl A, Steffensen U, Steffensen M, Osman E, Thaman R, Mogensen J, Elliott PM, Doi Y, McKenna WJ. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. *J Am Coll Cardiol* 2007;**49**:2419–2426.
  105. Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, Lorenzini M, Terzi F, Bacchi-Reggiani L, Boriani G, Branzi A, Boni L, Rapezzi C. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. *Am J Cardiol* 2009;**104**:1727–1731.
  106. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. *Circulation* 2007;**116**:2702–2708.
  107. Kitaoka H, Kubo T, Okawa M, Takenaka N, Sakamoto C, Baba Y, Hayashi K, Yamasaki N, Matsumura Y, Doi YL. Tissue doppler imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic cardiomyopathy. *J Am Soc Echocardiogr* 2011;**24**:1020–1025.

108. Ha JW, Cho JR, Kim JM, Ahn JA, Choi EY, Kang SM, Rim SJ, Chung N. Tissue Doppler-derived indices predict exercise capacity in patients with apical hypertrophic cardiomyopathy. *Chest* 2005;**128**:3428–3433.
109. Maciver DH. A new method for quantification of left ventricular systolic function using a corrected ejection fraction. *Eur J Echocardiogr* 2011;**12**:228–234.
110. Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging* 2014;**7**:11–19.
111. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. *Circulation* 1998;**98**:2415–2421.
112. Nagueh SF, Lakkis NM, He ZX, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Roberts R, Verani MS, Kleiman NS, Spencer WH III. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1998;**32**:225–229.
113. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, Horstkotte D. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. *Eur J Echocardiogr* 2004;**5**:347–355.
114. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. *J Am Coll Cardiol* 2000;**36**:2219–2225.
115. Oki T, Fukuda N, Iuchi A, Tabata T, Tanimoto M, Manabe K, Kageji Y, Sasaki M, Hama M, Ito S. Transesophageal echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: contributions of eccentric left ventricular hypertrophy and related abnormalities of the mitral complex. *J Am Soc Echocardiogr* 1995;**8**:503–510.
116. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. *J Am Coll Cardiol* 1992;**20**:42–52.
117. Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, Salcedo EE. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1992;**20**:1066–1072.
118. Flachskampf FA, Badano L, Daniel WG, Feneck RO, Fox KF, Fraser AG, Pasquet A, Pepi M, Perez d I, Zamorano JL, Roelandt JR, Pierard L. Recommendations for transesophageal echocardiography: update 2010. *Eur J Echocardiogr* 2010;**11**:557–576.
119. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. *Circulation* 1995;**92**:1680–1692.
120. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. *N Engl J Med* 2000;**342**:1778–1785.
121. Elliott PM, Gimeno B Jr., Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. *Lancet* 2001;**357**:420–424.
122. Kim MS, Klein AJ, Groves BM, Quaife RA, Salcedo EE. Left ventricular outflow tract obstruction in the presence of asymmetric septal hypertrophy and accessory mitral valve tissue treated with alcohol septal ablation. *Eur J Echocardiogr* 2008;**9**:720–724.
123. O'Hanlon R, Assomull RG, Prasad SK. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. *Curr Cardiol Rep* 2007;**9**:51–56.
124. Olivetto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M, Quarta G, Nistri S, Cecchi F, Salton CJ, Udelson JE, Manning WJ, Maron BJ. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2008;**52**:559–566.
125. Puntmann VO, Gebker R, Duckett S, Mirelis J, Schnackenburg B, Graef M, Razavi R, Fleck E, Nagel E. Left ventricular chamber dimensions and wall thickness by cardiovascular magnetic resonance: comparison with transthoracic echocardiography. *Eur Heart J Cardiovasc Imaging* 2013;**14**:240–246.
126. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. *Circulation* 2005;**112**:855–861.
127. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. *Heart* 2004;**90**:645–649.
128. Spiewak M, Chojnowska L, Malek LA, Milosz B, Petryka J, Zabicka M, Klopotoski M, Dabrowski M, Misko J, Ruzyllo W. Comparison between maximal left ventricular wall thickness and left ventricular mass in patients with hypertrophic cardiomyopathy. *Kardiol Pol* 2010;**68**:763–768.
129. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. *Circulation* 2008;**118**:1541–1549.
130. Weinsaft JW, Kim HW, Crowley AL, Klem I, Shenoy C, Van Assche L, Brosnan R, Shah DJ, Velazquez EJ, Parker M, Judd RM, Kim RJ. LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR. *JACC Cardiovasc Imaging* 2011;**4**:702–712.
131. Brouwer WP, Germans T, Head MC, van d V, Heymans MW, Christiaans I, Houweling AC, Wilde AA, van Rossum AC. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. *Eur Heart J Cardiovasc Imaging* 2012;**13**:292–297.
132. Germans T, Wilde AA, Dijkmans PA, Chai W, Kamp O, Pinto YM, van Rossum AC. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. *J Am Coll Cardiol* 2006;**48**:2518–2523.
133. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, Lesser JR, Lindberg J, Haas TS, Udelson JE, Manning WJ, Maron BJ. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging* 2012;**5**:441–447.
134. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 2007;**49**:350–357.
135. Yuan J, Qiao S, Zhang Y, You S, Duan F, Hu F, Yang W. Follow-up by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy who underwent percutaneous ventricular septal ablation. *Am J Cardiol* 2010;**106**:1487–1491.
136. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, Schulz-Menger J. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. *J Am Coll Cardiol* 2009;**53**:284–291.
137. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2004;**43**:2260–2264.
138. Prinz C, Schwarz M, Ilic I, Laser KT, Lehmann R, Prinz EM, Bitter T, Vogt J, van Buuren F, Bogunovic N, Horstkotte D, Faber L. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. *Can J Cardiol* 2013;**29**:358–363.
139. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;**56**:875–887.
140. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaiibeek L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;**56**:867–874.
141. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. *Circ Heart Fail* 2010;**3**:51–58.
142. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. *J Am Coll Cardiol* 2008;**51**:1369–1374.
143. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. *Circ Heart Fail* 2008;**1**:184–191.
144. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. *JACC Cardiovasc Imaging* 2012;**5**:370–377.
145. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. *Eur Heart J* 2003;**24**:2151–2155.
146. Sado DM, White SK, Piechnik SK, Banyersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. *Circ Cardiovasc Imaging* 2013;**6**:392–398.
147. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. *J Am Coll Cardiol* 2008;**51**:1022–1030.
148. Burton H., Alberg C., Stewart A. *Heart to Heart: Inherited Cardiovascular Conditions Services – A Needs Assessment and Service Review*. PHG Foundation, UK, 2009.

149. Rare diseases task force. European Reference Networks in the Field of Rare Diseases: State of the Art and Future Directions (third report). [http://www.eucerd.eu/?post\\_type=document&p=1204](http://www.eucerd.eu/?post_type=document&p=1204) 2008.
150. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. *J Am Coll Cardiol* 2009;**54**:242–249.
151. White RD, Obuchowski NA, Gunawardena S, Lipchik EO, Lever HM, Van Dyke CW, Lytle BW. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: presurgical and postsurgical evaluation by computed tomography magnetic resonance imaging. *Am J Card Imaging* 1996;**10**:1–13.
152. Bravo PE, Zimmerman SL, Luo HC, Pozios I, Rajaram M, Pinheiro A, Steenbergen C, Kamel IR, Wah RL, Bluemke DA, Bengel FM, Abraham MR, Abraham TP. Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging* 2013;**6**:210–217.
153. Fowler SJ, Narula J, Gurudevan SV. Review of noninvasive imaging for hypertrophic cardiac syndromes and restrictive physiology. *Heart Fail Clin* 2006;**2**:215–230.
154. Knaepen P, van Dockum WG, Gotte MJ, Broeze KA, Kuijter JP, Zwanenburg JJ, Marcus JT, Kok WE, van Rossum AC, Lammertsma AA, Visser FC. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study. *J Nucl Cardiol* 2006;**13**:660–667.
155. Timmer SA, Knaepen P. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography. *Eur Heart J Cardiovasc Imaging* 2013;**14**:95–101.
156. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. *JACC Cardiovasc Imaging* 2011;**4**:659–670.
157. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. *Eur J Nucl Med Mol Imaging* 2011;**38**:470–478.
158. Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Biagini E, Grigioni F, Bacchi-Reggiani ML, Lorenzini M, Milandri A, Branzi A, Rapezzi C. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. *JACC Cardiovasc Imaging* 2012;**5**:755–758.
159. Schroeder S, Achenbach S, Bengel F, Burgstahler C, Cademartiri F, de Feyter P, George R, Kaufmann P, Kopp AF, Knuuti J, Ropers D, Schuijff J, Tops LF, Bax JJ. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. *Eur Heart J* 2008;**29**:531–556.
160. Shiozaki AA, Senra T, Arteaga E, Martinelli FM, Pita CG, Avila LF, Parga F Jr., Mady C, Kalil-Filho R, Bluemke DA, Rochitte CE. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. *J Cardiovasc Comput Tomogr* 2013;**7**:173–181.
161. Bertliner JJ, Kino A, Carr JC, Bonow RO, Choudhury L. Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. *Int J Cardiovasc Imaging* 2013;**29**:191–197.
162. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, Bruneval P, Burke M, Butany J, Calabrese F, d'Amati G, Edwards WD, Fallon JT, Fishbein MC, Gallagher PJ, Halushka MK, McManus B, Pucci A, Rodriguez ER, Saffitz JE, Sheppard MN, Steenbergen C, Stone JR, Tan C, Thiene G, van der Wal AC, Winters GL. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. *Cardiovasc Pathol* 2012;**21**:245–274.
163. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. *Eur Heart J* 2007;**28**:3076–3093.
164. Geske JB, McKie PM, Ommen SR, Sorajja P. B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2013;**61**:2456–2460.
165. Coats CJ, Gallagher MJ, Foley M, O'Mahony C, Critoph C, Gimeno J, Dawnay A, McKenna WJ, Elliott PM. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. *Eur Heart J* 2013;**34**:2529–2537.
166. Niemann M, Rolfs A, Giese A, Mascher H, Breunig F, Ertl G, Wanner C, Weidemann F. Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease. *JIMD Rep* 2013;**7**:99–102.
167. Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. *Circulation* 2003;**108**:445–451.
168. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, Helio T, Keren A, McKenna WJ, Monserrat L, Pankuweit S, Perrot A, Rapezzi C, Ristic A, Seggewiss H, van Li, Tavazzi L. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2010;**31**:2715–2726.
169. Godard B, Kaariainen H, Kristoffersson U, Tranebjær L, Coviello D, Ayme S. Provision of genetic services in Europe: current practices and issues. *Eur J Hum Genet* 2003;**11 Suppl 2**:S13–S48.
170. Godard B, ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. *Eur J Hum Genet* 2003;**11 Suppl 2**:S49–S87.
171. Godard B, Raeburn S, Pembrey M, Bobrow M, Farndon P, Ayme S. Genetic information and testing in insurance and employment: technical, social and ethical issues. *Eur J Hum Genet* 2003;**11 Suppl 2**:S123–S142.
172. Cassiman JJ. Research network: EuroGentest: a European Network of Excellence aimed at harmonizing genetic testing services. *Eur J Hum Genet* 2005;**13**:1103–1105.
173. American Society of Human Genetics Board of Directors ACoMGBOD. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. *Am J Hum Genet* 1995;**57**:1233–1241.
174. Bortot B, Athanasakis E, Brun F, Rizzotti D, Mestroni L, Sinagra G, Severini GM. High-throughput genotyping robot-assisted method for mutation detection in patients with hypertrophic cardiomyopathy. *Diagn Mol Pathol* 2011;**20**:175–179.
175. Fokstuen S, Munoz A, Melacini P, Iliceto S, Perrot A, Ozcelik C, Jeanrenaud X, Rieubland C, Farr M, Faber L, Sigwart U, Mach F, Lerch R, Antonarakis SE, Blouin JL. Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. *J Med Genet* 2011;**48**:572–576.
176. Fata F, Vecoli C, Foffa I, Andreassi MG. Next generation sequencing in cardiovascular diseases. *World J Cardiol* 2012;**4**:288–295.
177. Meder B, Haas J, Keller A, Heid C, Just S, Borries A, Boisguerin V, Scharfenberger-Schmeier M, Stahler P, Beier M, Weichenhan D, Strom TM, Pfeufer A, Korn B, Katus HA, Rottbauer W. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. *Circ Cardiovasc Genet* 2011;**4**:110–122.
178. Christiaans I, Birnie E, Bonseel GJ, Mannens MM, Michels M, Majoor-Krakauer D, Dooijes D, van Tintelen JP, van den Berg MP, Volders PG, Arens YH, van den WA, Atsma DE, Helderma-van den Enden AT, Houweling AC, de Boer K, van der Smagt JJ, Hauer RN, Marcellis CL, Timmermans J, van Langen IM, Wilde AA. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. *Eur Heart J* 2011;**32**:1161–1170.
179. Andersen PS, Havndrup O, Hougs L, Sorensen KM, Jensen M, Larsen LA, Hedley P, Thomsen AR, Moolman-Smook J, Christiansen M, Bundgaard H. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. *Hum Mutat* 2009;**30**:363–370.
180. Havndrup O, Bundgaard H, Andersen PS, Allan LL, Vuust J, Kjeldsen K, Christiansen M. Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations. *Cardiovasc Res* 2003;**57**:347–357.
181. Bagnall RD, JD K, Duflo J, Semsarian C. Exome analysis based molecular autopsy in cases of sudden unexplained death in the young. *Heart Rhythm* 2014.
182. Basso C, Burke M, Fornes P, Gallagher PJ, De Gouveia RH, Sheppard M, Thiene G, Van Der WA. Guidelines for autopsy investigation of sudden cardiac death. *Pathologica* 2010;**102**:391–404.
183. Organisation for Economic Co-operation and Development (OECD). Guidelines for quality assurance in molecular genetic testing. <http://www.oecd.org/dataoecd/43/6/38839788.pdf> 2007.
184. van der Roest WVP, Pennings JM, Bakker M, van den Berg MP, van Tintelen JP. Family letters are an effective way to inform relatives about inherited cardiac disease. *Am J Med Genet A* 2009;**149A**:357–363.
185. Ingles J, McLaughran J, Scuffham PA, Atherton J, Semsarian C. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. *Heart* 2012;**98**:625–630.
186. Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. *Eur Heart J* 2010;**31**:926–935.

187. Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circ Heart Fail* 2009;**2**: 253–261.
188. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm* 2011;**8**:1308–1339.
189. Jensen MK, Havndrup O, Christiansen M, Andersen PS, Diness B, Axelsson A, Skovby F, Kober L, Bundgaard H. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. *Circulation* 2013;**127**:48–54.
190. Borry P, Stultiens L, Nys H, Cassiman JJ, Dierickx K. Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. *Clin Genet* 2006;**70**:374–381.
191. Bratt EL, Ostman-Smith I, Axelsson A, Berntsson L. Quality of life in asymptomatic children and adolescents before and after diagnosis of hypertrophic cardiomyopathy through family screening. *J Clin Nurs* 2013;**22**:211–221.
192. Ross LF, Saal HM, David KL, Anderson RR. Technical report: Ethical and policy issues in genetic testing and screening of children. *Genet Med* 2013;**15**:234–245.
193. Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. *Int J Cardiol* 2011;**152**:258–259.
194. Poutanen T, Tikanoja T, Jaaskelainen P, Jokinen E, Silvast A, Laakso M, Kuusisto J. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes. *Am Heart J* 2006;**151**:725.
195. Charron P, Dubourg O, Desnos M, Bouhour JB, Isnard R, Hagege A, Carrier L, Bonne G, Tesson F, Richard P, Hainque B, Schwartz K, Komajda M. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. *Eur Heart J* 1998;**19**:1377–1382.
196. Gandjbakhch E, Gackowski A, Tezenas du MS, Isnard R, Hamroun A, Richard P, Komajda M, Charron P. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. *Eur Heart J* 2010;**31**:1599–1607.
197. Christiaans I, Lekanne dit Deprez RH, van Langen IM, Wilde AA. Ventricular fibrillation in MYH 7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. *Heart Rhythm* 2009;**6**:1366–1369.
198. Maron BJ, Kragel AH, Roberts WC. Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. *Br Heart J* 1990;**63**:308–310.
199. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. *N Engl J Med* 1998;**338**:1248–1257.
200. Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, Hermida-Prieto M, Sabater M, Garcia-Molina E, Ortiz M, Rodriguez-Garcia MI, Nunez L, Gimeno JR, Castro-Beiras A, Valdes M. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. *Heart* 2010;**96**:1980–1984.
201. Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS, Elliott PM, McKenna WJ. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. *Circ Cardiovasc Genet* 2012;**5**:156–166.
202. Pelliccia A, Corrado D, Bjornstad HH, Panhuyzen-Goedkoop N, Urhausen A, Carre F, Anastasakis A, Vanhees L, Arbustini E, Priori S. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. *Eur J Cardiovasc Prev Rehabil* 2006;**13**:876–885.
203. Charron P, Heron D, Gargiulo M, Feingold J, Oury JF, Richard P, Komajda M. Prenatal molecular diagnosis in hypertrophic cardiomyopathy: report of the first case. *Prenat Diagn* 2004;**24**:701–703.
204. Donnai D, Elles R. Integrated regional genetic services: current and future provision. *BMJ* 2001;**322**:1048–1052.
205. Gilligan DM, Nihoyannopoulos P, Fletcher A, Sbarouni E, Dritsas A, Oakley CM. Symptoms of hypertrophic cardiomyopathy, with special emphasis on syncope and postprandial exacerbation of symptoms. *Clin Cardiol* 1996;**19**:371–378.
206. Feiner E, Arabadjian M, Winson G, Kim B, Chaudhry F, Sherrid MV. Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2013;**61**:2487–2488.
207. Paz R, Jortner R, Tunick PA, Sclarovsky S, Eilat B, Perez JL, Kronzon I. The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy. *N Engl J Med* 1996;**335**:938–941.
208. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. *Circulation* 2003;**108**:2342–2348.
209. Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. *J Am Coll Cardiol* 2000;**36**:2270–2278.
210. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Tajik AJ, Holmes DR. Myocardial bridging in adult patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2003;**42**:889–894.
211. Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. *Eur Heart J* 2009;**30**:1627–1634.
212. Yamada M, Elliott PM, Kaski JC, Prasad K, Gane JN, Lowe CM, Doi Y, McKenna WJ. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. *Eur Heart J* 1998;**19**:500–507.
213. Elliott PM, Kaski JC, Prasad K, Seo H, Slade AK, Goldman JH, McKenna WJ. Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. *Eur Heart J* 1996;**17**:1056–1064.
214. Elliott PM, Rosano GM, Gill JS, Poole-Wilson PA, Kaski JC, McKenna WJ. Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy. *Heart* 1996;**75**:179–183.
215. Romero-Farina G, Candell-Riera J, Galve E, Armadans L, Ramos F, Castell J, Aguade S, Nogales JM, Soler-Soler J. Do myocardial perfusion SPECT and radionuclide angiography studies in adult patients with hypertrophic cardiomyopathy have prognostic implications? *J Nucl Cardiol* 2004;**11**:578–586.
216. Soler R, Rodriguez E, Monserrat L, Mendez C, Martinez C. Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: relationship with left ventricular perfusion and contractile function. *J Comput Assist Tomogr* 2006;**30**:412–420.
217. Barbosa CA, Castro CC, Avila LF, Parga F Jr., Hattem DM, Fernandez EA. Late enhancement and myocardial perfusion in hypertrophic cardiomyopathy (comparison between groups). *Arq Bras Cardiol* 2009;**93**:426–25.
218. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hämilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013;**34**:2949–3003.
219. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis G, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, Smith SC Jr., Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Europace* 2006;**8**:746–837.
220. Okayama S, Uemura S, Soeda T, Horii M, Saito Y. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. *J Cardiovasc Comput Tomogr* 2010;**4**:62–65.
221. Mitsutake R, Miura S, Sako H, Nishikawa H, Saku K. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy. *Int J Cardiol* 2008;**129**:e61–e63.
222. Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, Bellini N, Smaniotto G, Zucchetto M, Illiceto S, Thiene G, Maron BJ. Clinicopathological

- profiles of progressive heart failure in hypertrophic cardiomyopathy. *Eur Heart J* 2010;**31**:2111–2123.
223. Olivetto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation* 2001;**104**:2517–2524.
  224. Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, Elliott PM, McKenna WJ. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. *Heart* 2005;**91**:920–925.
  225. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. *Circulation* 2006;**114**:216–225.
  226. Olivetto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. *Circ Heart Fail* 2012;**5**:535–546.
  227. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacci P, Augustine S, Aaronson K, Barr M. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. *J Heart Lung Transplant* 2006;**25**:1024–1042.
  228. Lindelow B, Andersson B, Waagstein F, Bergh CH. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. *Eur Heart J* 1999;**20**:148–156.
  229. Chen JM, Levin HR, Michler RE, Prusmack CJ, Rose EA, Aaronson KD. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. *J Thorac Cardiovasc Surg* 1997;**114**:627–634.
  230. Geske JB, Cullen MW, Sorajja P, Ommen SR, Nishimura RA. Assessment of left ventricular outflow gradient: hypertrophic cardiomyopathy versus aortic valvular stenosis. *JACC Cardiovasc Interv* 2012;**5**:675–681.
  231. Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B, McKenna WJ. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. *J Am Coll Cardiol* 2000;**36**:864–870.
  232. Elliott PM, Hanna MG, Ward SA, Chinnery PF, Turnbull DM, Wood NW, McKenna WJ. Diagnostic utility of metabolic exercise testing in a patient with cardiovascular disease. *Heart* 1999;**81**:441–443.
  233. Sharma S, Elliott P, Whyte G, Jones S, Mahon N, Whipp B, McKenna WJ. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. *Am J Cardiol* 2000;**86**:162–168.
  234. Diodati JG, Schenke WH, Waclawiw MA, McIntosh CL, Cannon RO III. Predictors of exercise benefit after operative relief of left ventricular outflow obstruction by the myotomy-myectomy procedure in hypertrophic cardiomyopathy. *Am J Cardiol* 1992;**69**:1617–1622.
  235. Arena R, Owens DS, Arevalo J, Smith K, Mohiddin SA, McAreavey D, Ullisney KL, Tripodi D, Fananapazir L, Plehn JF. Ventilatory efficiency and resting hemodynamics in hypertrophic cardiomyopathy. *Med Sci Sports Exerc* 2008;**40**:799–805.
  236. Olivetto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1999;**33**:2044–2051.
  237. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. *Circulation* 1997;**96**:2987–2991.
  238. Mancini DM, Eisen H, Kusssmaul W, Mull R, Edmunds LH Jr., Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation* 1991;**83**:778–786.
  239. Barriales-Villa R, Centurion-Inda R, Fernandez-Fernandez X, Ortiz MF, Perez-Alvarez L, Rodriguez G I, Hermida-Prieto M, Monserrat L. Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy. *Rev Esp Cardiol* 2010;**63**:985–988.
  240. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. *Circulation* 1996;**94**:467–471.
  241. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. *Circulation* 1991;**84**:686–696.
  242. Prasad K, Williams L, Campbell R, Elliott PM, McKenna WJ, Frenneaux M. Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation. *Heart* 2008;**94**:1312–1317.
  243. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC, Gajek J, Gjesdal K, Krahn A, Massin M, Pepi M, Pezawas T, Granell RR, Sarasin F, Ungar A, van Dijk JG, Walma EP, Wieling W, Abe H, Benditt DG, Decker WW, Grubb BP, Kaufmann H, Morillo C, Olshansky B, Parry SW, Sheldon R, Shen WK, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popsescu BA, Reiner Z, Sechtem U, Sirnes PA, Tenders M, Vardas P, Widimsky P, Auricchio A, Acarturk E, Andreotti F, Asteggiano R, Bauersfeld U, Bellou A, Benetos A, Brandt J, Chung MK, Cortelli P, Da Costa A, Extramiana F, Ferro J, Gorenek B, Hedman A, Hirsch R, Kaliska G, Kenny RA, Kjeldsen KP, Lampert R, Molgard H, Paju R, Puodziukynas A, Ravele A, Roman P, Scherer M, Schondorf R, Sicari R, Vanbrabant P, Wolpert C, Zamorano JL. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). *Eur Heart J* 2009;**30**:2631–2671.
  244. Kofflard MJ, Ten Cate FJ, van der LC, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. *J Am Coll Cardiol* 2003;**41**:987–993.
  245. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. *Eur Heart J* 2006;**27**:1933–1941.
  246. Gimeno JR, Tome-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, Lambiasi P, McKenna WJ, Elliott PM. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. *Eur Heart J* 2009;**30**:2599–2605.
  247. Efthimiadis GK, Parcharidou DG, Giannakoulas G, Pagourelis ED, Charalampidis P, Savvopoulos G, Ziakas A, Karvounis H, Styliadis IH, Parcharidis GE. Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. *Am J Cardiol* 2009;**104**:695–699.
  248. Dimitrow PP, Chojnowska L, Rudzinski T, Piotrowski W, Ziolkowska L, Wojtarowicz A, Wycisk A, Dabrowska-Kugacka A, Nowalany-Kozielska E, Sobkowicz B, Wrobel W, Aleszewicz-Baranowska J, Rynkiewicz A, Lobo-Grudzien K, Marchel M, Wysokinski A. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. *Eur Heart J* 2010;**31**:3084–3093.
  249. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tenders M, Torbicki A, Wijns W, Windecker S, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreaun D, Faerstrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tenders M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J* 2013;**34**:2281–2329.
  250. Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R, Sulke N, Wieling W, Auricchio A, Lip GY, Almendral J, Kirchhof P, Aliot E, Gasparini M, Braunschweig F, Lip GY, Almendral J, Kirchhof P, Botto GL. Indications for the use of diagnostic implantable and external ECG loop recorders. *Europace* 2009;**11**:671–687.
  251. Macatrac-Costa MF, Arteaga-Fernandez E, de Brito FS, Darrieux F, de Melo SL, Scanavacca M, Sosa E, Hachul D. Evaluation of the autonomic function in patients with hypertrophic cardiomyopathy with and without syncope. *Arq Bras Cardiol* 2013;**100**:180–186.
  252. Gilligan DM, Nihoyannopoulos P, Chan WL, Oakley CM. Investigation of a hemodynamic basis for syncope in hypertrophic cardiomyopathy. Use of a head-up tilt test. *Circulation* 1992;**85**:2140–2148.
  253. Ravele A, Giada F, Bergfeldt L, Blanc JJ, Blomstrom-Lundqvist C, Mont L, Morgan JM, Raatikainen MJ, Steinbeck G, Viskin S, Kirchhof P, Braunschweig F, Borggrefe M, Hocini M, Della BP, Shah DC. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. *Europace* 2011;**13**:920–934.
  254. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CV, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr., Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr., Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. *J Am Coll Cardiol* 2003;**42**:1493–1531.



255. Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO III, Bonow RO, Maron BJ, Epstein SE. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. *Circulation* 1989;**80**:1259–1268.
256. Inada K, Seiler J, Roberts-Thomson KC, Steven D, Rosman J, John RM, Sobieszczek P, Stevenson WG, Tedrow UB. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol* 2011;**22**:41–48.
257. Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. *J Cardiovasc Electrophysiol* 2009;**20**:445–447.
258. Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with hypertrophic cardiomyopathy. *N Engl J Med* 1999;**341**:700–701.
259. Braunwald E, Brockenbrough EC, Frye RL. Studies on digitalis. V. Comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis. *Circulation* 1962;**26**:166–173.
260. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr., Morrow AG. Idiopathic hypertrophic subaortic stenosis. i) a description of the disease based upon an analysis of 64 patients. *Circulation* 1964;**30**:SUPPL-119.
261. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;**33**:2719–2747.
262. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Europace* 2010;**12**:1360–1420.
263. Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. *Br Heart J* 1970;**32**:804–811.
264. Stenson RE, Flamm MD Jr., Harrison DC, Hancock EW. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. *Am J Cardiol* 1973;**31**:763–773.
265. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. *Circulation* 1968;**38**:846–858.
266. Tendra M, Wycisk A, Schneeweiss A, Polonski L, Wodnicki J. Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. *Cardiology* 1993;**82**:335–342.
267. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2005;**45**:1251–1258.
268. Sherrid MV, Shetty A, Winsor G, Kim B, Musat D, Alviar CL, Homel P, Balaram SK, Swistel DG. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. *Circ Heart Fail* 2013;**6**:694–702.
269. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. *Circulation* 1981;**64**:437–441.
270. Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. *Circulation* 1979;**60**:1201–1207.
271. Bonow RO, Rosing DR, Epstein SE. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. *Eur Heart J* 1983;**4** Suppl F:57–65.
272. Spicer RL, Rocchini AP, Crowley DC, Vasiliades J, Rosenthal A. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. *Circulation* 1983;**67**:413–420.
273. Rosing DR, Idanpaan-Heikkilä U, Maron BJ, Bonow RO, Epstein SE. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. *Am J Cardiol* 1985;**55**:185B–195B.
274. Toshima H, Koga Y, Nagata H, Toyomasu K, Itaya K, Matoba T. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. *Jpn Heart J* 1986;**27**:701–715.
275. Betocchi S, Cannon RO III, Watson RM, Bonow RO, Ostrow HG, Epstein SE, Rosing DR. Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy. *Circulation* 1985;**72**:1001–1007.
276. Hopf R, Kaltenbach M. Effects of nifedipine and propranolol combined therapy in patients with hypertrophic cardiomyopathy. *Z Kardiol* 1987;**76** Suppl 3:105–112.
277. Menon SC, Ackerman MJ, Ommen SR, Cabalka AK, Hagler DJ, O'Leary PW, Dearani JA, Cetta F, Eidem BW. Impact of septal myectomy on left atrial volume and left ventricular diastolic filling patterns: an echocardiographic study of young patients with obstructive hypertrophic cardiomyopathy. *J Am Soc Echocardiogr* 2008;**21**:684–688.
278. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, Redwood DR. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. *Circulation* 1975;**52**:88–102.
279. Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. *Circulation* 1989;**80**:157–164.
280. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. *J Thorac Cardiovasc Surg* 1995;**110**:195–206.
281. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. *J Thorac Cardiovasc Surg* 1996;**111**:586–594.
282. Schonbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, Turina MI. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. *Ann Thorac Surg* 1998;**65**:1207–1214.
283. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy: long-term results after surgical therapy. *Thorac Cardiovasc Surg* 1999;**47**:213–218.
284. Ommen SR, Maron BJ, Olivetto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2005;**46**:470–476.
285. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. *Circulation* 2005;**111**:2033–2041.
286. Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DO, Blackstone EH. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. *Ann Thorac Surg* 2008;**85**:127–133.
287. Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilaraman M, Lytle BW, Lever HM. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. *Circulation* 2013;**128**:209–216.
288. Altarabsheh SE, Dearani JA, Burkhart HM, Schaff HV, Deo SV, Eidem BW, Ommen SR, Li Z, Ackerman MJ. Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. *Ann Thorac Surg* 2013;**95**:663–669.
289. Iacovoni A, Spirito P, Simon C, Iascone M, Di Dedda G, De Filippo P, Pentricci S, Boni L, Senni M, Gavazzi A, Ferrazzi P. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. *Eur Heart J* 2012;**33**:2080–2087.
290. Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy - the Mayo Clinic experience. *Nat Clin Pract Cardiovasc Med* 2007;**4**:503–512.
291. Kofflard MJ, van Herwerden LA, Waldstein DJ, Ruygrok P, Boersma E, Taams MA, Ten Cate FJ. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1996;**28**:197–202.
292. McIntosh CL, Maron BJ, Cannon RO III, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. *Circulation* 1992;**86**:1160–1167.
293. Reis RL, Bolton MR, King JF, Pugh DM, Dunn MI, Mason DT. Anterior-superior displacement of papillary muscles producing obstruction and mitral regurgitation in idiopathic hypertrophic subaortic stenosis. Operative relief by posterior-superior realignment of papillary muscles following ventricular septal myectomy. *Circulation* 1974;**50**:1181–1188.
294. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. *Circulation* 1995;**92**:1122–1127.
295. Kaple RK, Murphy RT, DiPaola LM, Houghtaling PL, Lever HM, Lytle BW, Blackstone EH, Smedira NG. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. *Ann Thorac Surg* 2008;**85**:1527–1535.
296. Stassano P, Di Tommaso L, Triggiani D, Contaldo A, Gagliardi C, Spampinato N. Mitral valve replacement and limited myectomy for hypertrophic obstructive cardiomyopathy: a 25-year follow-up. *Tex Heart Inst J* 2004;**31**:137–142.
297. Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. *J Thorac Cardiovasc Surg* 2004;**127**:481–489.

298. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. *Lancet* 1995;**346**:211–214.
299. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. *Clin Res Cardiol* 2007;**96**:864–873.
300. Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, Spencer WH III. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. *JACC Cardiovasc Interv* 2008;**1**:561–570.
301. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C. Survival after transcatheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. *Clin Res Cardiol* 2008;**97**:234–243.
302. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. *Circulation* 2008;**118**:131–139.
303. Sorajja P, Ommen SR, Holmes DR Jr., Dearani JA, Rihal CS, Gersh BJ, Lennon RJ, Nishimura RA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. *Circulation* 2012;**126**:2374–2380.
304. Ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. *Circ Heart Fail* 2010;**3**:362–369.
305. Durand E, Mousseaux E, Coste P, Pilliere R, Dubourg O, Trinquart L, Chatellier G, Hagege A, Desnos M, Lafont A. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. *Eur Heart J* 2008;**29**:348–355.
306. Iacob M, Pinte F, Tintoiu I, Cotuna L, Caroescu M, Popa A, Cristian G, Goleanu V, Greere V, Moscaliuc I, Neagoe G, Crisan P, Garjeu A, Chiriac L, Bolohan R, Murgu V, Lobont B, Filip S, Roates J, Hila G, Postolea E. Microcoil embolisation for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. *Kardiol Pol* 2004;**61**:350–355.
307. Gross CM, Schulz-Menger J, Kramer J, Siegel I, Pilz B, Waigand J, Friedrich MG, Uhlrich F, Dietz R. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes. *J Endovasc Ther* 2004;**11**:705–711.
308. Oto A, Aytemir K, Okutucu S, Kaya EB, Deniz A, Cil B, Peynircioglu B, Kabakci G. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. *J Interv Cardiol* 2011;**24**:77–84.
309. Lawrenz T, Borchert B, Leuner C, Bartelsmeier M, Reinhardt J, Strunk-Mueller C, Meyer ZV, Schloesser M, Beer G, Lieder F, Stellbrink C, Kuhn H. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients. *J Am Coll Cardiol* 2011;**57**:572–576.
310. Keane D, Hynes B, King G, Shiels P, Brown A. Feasibility study of percutaneous transvalvular endomyocardial cryoablation for the treatment of hypertrophic obstructive cardiomyopathy. *J Invasive Cardiol* 2007;**19**:247–251.
311. Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;**55**:823–834.
312. Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. *Eur Heart J* 2009;**30**:1080–1087.
313. Zeng Z, Wang F, Dou X, Zhang S, Pu J. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a meta analysis. *Int J Cardiol* 2006;**112**:80–84.
314. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. *Circ Cardiovasc Interv* 2010;**3**:97–104.
315. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. *Int J Cardiol* 2007;**119**:163–167.
316. Orme NM, Sorajja P, Dearani JA, Schaff HV, Gersh BJ, Ommen SR. Comparison of surgical septal myectomy to medical therapy alone in patients with hypertrophic cardiomyopathy and syncope. *Am J Cardiol* 2013;**111**:388–392.
317. Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis. Results in 27 patients. *J Cardiovasc Surg (Torino)* 1976;**17**:380–387.
318. Slade AK, Sadoul N, Shapiro L, Chojnowska L, Simon JP, Saumarez RC, Dodinot B, Camm AJ, McKenna WJ, Aliot E. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. *Heart* 1996;**75**:44–49.
319. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, Allison TG, Tajik AJ. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. *J Am Coll Cardiol* 1997;**29**:435–441.
320. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, Chojnowska L, Guize L, Gras D, Jeanrenaud X, Ryden L. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. *Eur Heart J* 1997;**18**:1249–1256.
321. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kievall RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). *Circulation* 1999;**99**:2927–2933.
322. Mickelsen S, Bathina M, Hsu P, Holmes J, Kusumoto FM. Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function. *J Interv Card Electrophysiol* 2004;**11**:47–53.
323. Gao YC, Li Y, Han ZH, Zhang XL, Zhao H, Jiang TY. [Transcatheter ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2007;**35**:333–336.
324. Qintar M, Morad A, Alhawasli H, Shorbaji K, Firwana B, Essali A, Kadro W. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. *Cochrane Database Syst Rev* 2012;**5**:CD008523.
325. Topilski I, Sherez J, Keren G, Copperman I. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. *Am J Cardiol* 2006;**97**:1769–1775.
326. Jeanrenaud X, Schlapfer J, Fromer M, Aebischer N, Kappenberger L. Dual chamber pacing in hypertrophic obstructive cardiomyopathy: beneficial effect of atrioventricular junction ablation for optimal left ventricular capture and filling. *Pacing Clin Electrophysiol* 1997;**20**:293–300.
327. O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, Al Shaikh S, Rahman SM, Arnous S, Jones S, McKenna WJ, Elliott P. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. *Heart* 2012;**98**:116–125.
328. Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, Nakajima T, Kawashiro N, Kawana M, Hagiwara N. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2011;**57**:2346–2355.
329. Efthimiadis GK, Pagourelis ED, Parcharidou D, Gossios T, Kamperidis V, Theofilogiannakos EK, Pappa Z, Meditskou S, Hadjimiltiades S, Pliakos C, Karvounis H, Styliadis IH. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. *Circ J* 2013;**77**:2366–2374.
330. Shah A, Duncan K, Winson G, Chaudhry FA, Sherid MV. Severe symptoms in mid and apical hypertrophic cardiomyopathy. *Echocardiography* 2009;**26**:922–933.
331. Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. *Br Heart J* 1989;**61**:178–181.
332. Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. *J Card Surg* 2012;**27**:443–448.
333. Kunkala MR, Schaff HV, Nishimura RA, Abel MD, Sorajja P, Dearani JA, Ommen SR. Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. *Ann Thorac Surg* 2013;**96**:564–570.
334. Gao XJ, Kang LM, Zhang J, Dou KF, Yuan JS, Yang YJ. Mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm and sustained ventricular tachycardia: a case report and literature review. *Chin Med J (Engl)* 2011;**124**:1754–1757.
335. Takeda I, Sekine M, Matsushima H, Hosomi N, Nakamura T, Ohtsuki T, Yamawaki T, Matsumoto M. Two cases of cerebral embolism caused by apical thrombi in mid-ventricular obstructive cardiomyopathy. *Intern Med* 2011;**50**:1059–1060.
336. Sato Y, Matsumoto N, Matsuo S, Yoda S, Tani S, Kasamaki Y, Takayama T, Kunimoto S, Saito S. Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm: evaluation of possible causes of aneurysm formation. *Yonsei Med J* 2007;**48**:879–882.
337. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitzer J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiger A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012;**33**:1787–1847.
338. Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, Lipson LC, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment

- of hypertrophic cardiomyopathy: III. Effects of long-term administration. *Am J Cardiol* 1981;**48**:545–553.
339. Rogers DP, Marazia S, Chow AW, Lambiase PD, Lowe MD, Frenneaux M, McKenna WJ, Elliott PM. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. *Eur J Heart Fail* 2008;**10**:507–513.
  340. Kato TS, Takayama H, Yoshizawa S, Marboe C, Schulze PC, Farr M, Naka Y, Mancini D, Maurer MS. Cardiac transplantation in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2012;**110**:568–574.
  341. Biagini E, Spirito P, Leone O, Picchio FM, Cocco F, Ragni L, Lofiego C, Grigioni F, Potena L, Rocchi G, Bacchi-Reggiani L, Boriani G, Prandstraller D, Arbustini E, Branzi A, Rapezzi C. Heart transplantation in hypertrophic cardiomyopathy. *Am J Cardiol* 2008;**101**:387–392.
  342. Ragni L, Biagini E, Picchio FM, Prandstraller D, Leone O, Berardini A, Perolo A, Grigioni F, di Diodoro L, Gargiulo G, Arbustini E, Rapezzi C. Heart transplantation in infants with idiopathic hypertrophic cardiomyopathy. *Pediatr Transplant* 2009;**13**:650–653.
  343. Coutu M, Perrault LP, White M, Pelletier GB, Racine N, Poirier NC, Carrier M. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. *J Heart Lung Transplant* 2004;**23**:413–417.
  344. Maron MS, Kalsmith BM, Udelsion JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. *Circ Heart Fail* 2010;**3**:574–579.
  345. Wynne E, Bergin JD, Ailawadi G, Kern JA, Kennedy JL. Use of a left ventricular assist device in hypertrophic cardiomyopathy. *J Card Surg* 2011;**26**:663–665.
  346. Topilsky Y, Pereira NL, Shah DK, Boilson B, Schirger JA, Kushwaha SS, Joyce LD, Park SJ. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. *Circ Heart Fail* 2011;**4**:266–275.
  347. Bourmayan C, Razavi A, Fournier C, Dussault JC, Baragan J, Gerbaux A, Gay J. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. *Am Heart J* 1985;**109**:1311–1316.
  348. Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. *Br Heart J* 1982;**48**:204–212.
  349. Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Webb-Peploe MM. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. *Br Heart J* 1986;**56**:544–553.
  350. Udelsion JE, Bonow RO, O'Gara PT, Maron BJ, Van Lingen A, Bacharach SL, Epstein SE. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. *Circulation* 1989;**79**:1052–1060.
  351. Pacileo G, De Cristofaro M, Russo MG, Sarubbi B, Pisacane C, Calabro R. Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function. *Can J Cardiol* 2000;**16**:146–152.
  352. Maron BJ, Olivetto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, Bongioanni S, Spirito P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;**39**:301–307.
  353. Pisters R, Lane DA, Nieuwlaar R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;**138**:1093–1100.
  354. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. *J Am Coll Cardiol* 1990;**15**:1279–1285.
  355. Cecchi F, Olivetto I, Monterege A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. *J Am Coll Cardiol* 1995;**26**:1529–1536.
  356. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermsillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanan F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedronone in high-risk permanent atrial fibrillation. *N Engl J Med* 2011;**365**:2268–2276.
  357. Di Donna P, Olivetto I, Delcree SD, Caponi D, Scaglione M, Nault I, Montefusco A, Girolami F, Cecchi F, Haissaguerre M, Gaita F. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. *Europace* 2010;**12**:347–355.
  358. Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM, Rea RF, Shen WK, Powell BD, Ommen SR, Monahan KH, Haroldson JM, Packer DL. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol* 2008;**19**:1009–1014.
  359. Gaita F, Di Donna P, Olivetto I, Scaglione M, Ferrero I, Montefusco A, Caponi D, Conte MR, Nistri S, Cecchi F. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2007;**99**:1575–1581.
  360. Kilicaslan F, Verma A, Saad E, Themistoclakis S, Bonso A, Ravele A, Bozbas H, Andrews MW, Beheiry S, Hao S, Cummings JE, Marrouche NF, Lakkireddy D, Wazni O, Yamaji H, Saenz LC, Saliba W, Schweikert RA, Natale A. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. *Heart Rhythm* 2006;**3**:275–280.
  361. McCready JW, Smedley T, Lambiase PD, Ahsan SY, Segal OR, Rowland E, Lowe MD, Chow AW. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. *Europace* 2011;**13**:355–361.
  362. Chen MS, McCarthy PM, Lever HM, Smedira NG, Lytle BL. Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2004;**93**:373–375.
  363. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med* 2009;**360**:2066–2078.
  364. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;**361**:1139–1151.
  365. Gomez-Outes A, Terleira-Fernandez AL, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. *Thrombosis* 2013;**2013**:640723.
  366. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. *Heart* 2006;**92**:785–791.
  367. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1999;**33**:1596–1601.
  368. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. *N Engl J Med* 1988;**318**:1255–1257.
  369. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1986;**7**:701–704.
  370. Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw DB. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. *Br Heart J* 1980;**43**:245–251.
  371. Joseph S, Balcon R, McDonald L. Syncope in hypertrophic obstructive cardiomyopathy due to asystole. *Br Heart J* 1972;**34**:974–976.
  372. Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y, Imaizumi T. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. *Am J Cardiol* 1998;**82**:774–778.
  373. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. *J Am Coll Cardiol* 2005;**45**:1076–1080.
  374. D'Andrea A, Caso P, Severino S, Cuomo S, Capozzi G, Calabro P, Cice G, Ascione L, Scherillo M, Calabro R. Prognostic value of intra-left ventricular electro-mechanical asynchrony in patients with hypertrophic cardiomyopathy. *Eur Heart J* 2006;**27**:1311–1318.
  375. Maron BJ, Casey SA, Hurrell DG, Aeppli DM. Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. *Am J Cardiol* 2003;**91**:1195–1198.
  376. Cecchi F, Olivetto I, Monterege A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. *Heart* 1998;**79**:331–336.
  377. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. *J Am Coll Cardiol* 2000;**36**:2212–2218.
  378. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance. *J Am Coll Cardiol* 1986;**8**:57–65.
  379. Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. *Europace* 2007;**9**:817–822.
  380. Olivetto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelsion JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2005;**46**:480–487.
  381. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. *Circulation* 1990;**82**:1995–2002.
  382. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boccorz S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the

- implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J* 2000;**21**:2071–2078.
383. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC, Tu JV, Alter DA. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. *J Am Coll Cardiol* 2003;**41**:1573–1582.
384. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. *J Am Coll Cardiol* 2003;**42**:1687–1713.
385. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011;**124**:e783–e831.
386. O'Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, Elliott PM. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. *Heart* 2013;**99**:534–541.
387. O'Mahony C, Lambiase PD, Rahman SM, Cardona M, Calcagnino M, Quarta G, Tsovolas K, Al Shaikh S, McKenna WJ, Elliott P. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. *Europace* 2012;**14**:724–733.
388. Kiernan TJ, Weivoda PL, Somers VK, Ommen SR, Gersh BJ. Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy. *Pacing Clin Electrophysiol* 2008;**31**:1253–1258.
389. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. *Br Heart J* 1985;**53**:412–416.
390. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, Thiene G, Iliceto S. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. *Heart* 2007;**93**:708–710.
391. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. *J Am Coll Cardiol* 1989;**13**:1283–1288.
392. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA III, Favale S, Piccinino M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. *JAMA* 2007;**298**:405–412.
393. Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterlinski M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczynska-Mazuruk R, Ruzyllo W, Swzed H. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. *J Cardiovasc Electrophysiol* 2010;**21**:883–889.
394. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, Ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. *Circ Heart Fail* 2012;**5**:552–559.
395. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson M, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. *Eur Heart J* 2005;**26**:1422–1445.
396. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. *Heart* 2009;**95**:709–714.
397. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. *Heart Rhythm* 2005;**2**:814–819.
398. Quin EM, Cuoco FA, Forcina MS, Coker JB, Yoe RH, Spencer WH III, Fernandes VL, Nielsen CD, Sturdivant JL, Leman RB, Wharton JM, Gold MR. Defibrillation thresholds in hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol* 2011;**22**:569–572.
399. Roberts BD, Hood RE, Saba MM, Dickfeld TM, Saliaris AP, Shorofsky SR. Defibrillation threshold testing in patients with hypertrophic cardiomyopathy. *Pacing Clin Electrophysiol* 2010;**33**:1342–1346.
400. Nagai T, Kurita T, Satomi K, Noda T, Okamura H, Shimizu W, Suyama K, Aihara N, Kobayashi J, Kamakura S. QRS prolongation is associated with high defibrillation thresholds during cardioverter-defibrillator implantations in patients with hypertrophic cardiomyopathy. *Circ J* 2009;**73**:1028–1032.
401. Cha YM, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, Weivoda PL, Trusty JM, Friedman PA, Hammill SC, Rea RF, Shen WK. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol* 2007;**18**:483–487.
402. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA III, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W. Reduction in inappropriate therapy and mortality through ICD programming. *N Engl J Med* 2012;**367**:2275–2283.
403. Braunschweig F, Boriani G, Bauer A, Hatala R, Herrmann-Lingen C, Kautzner J, Pedersen SS, Pehrson S, Ricci R, Schaliq MJ. Management of patients receiving implantable cardiac defibrillator shocks: recommendations for acute and long-term patient management. *Europace* 2010;**12**:1673–1690.
404. Bardy GH, Smith WM, Hood MA, Crozier IG, Meltan IC, Jordaens L, Theuns D, Park RE, Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, Spitzer SG, Ardashev AV, Odoro A, Boersma L, Maass AH, Van Gelder IC, Wilde AA, van Dessel PF, Knops RE, Barr CS, Lupo P, Cappato R, Grace AA. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med* 2010;**363**:36–44.
405. Jarman JW, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. *Europace* 2013;**15**:1158–1165.
406. Olde Nordkamp LR, Dabiri AL, Boersma LV, Maass AH, de Groot JR, van Oostrom AJ, Theuns DA, Jordaens LJ, Wilde AA, Knops RE. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. *J Am Coll Cardiol* 2012;**60**:1933–1939.
407. Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB, Hood M, Pedersen S, Kaab S, Murgatroyd F, Reeve HL, Carter N, Boersma L. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. *Eur Heart J* 2014.
408. Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. *Circulation* 2007;**115**:773–781.
409. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA III, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2013;**61**:1527–1535.
410. Decker JA, Rossano JW, Smith EO, Cannon B, Clunie SK, Gates C, Jefferies JL, Kim JJ, Price JF, Dreyer WJ, Towbin JA, Denfield SW. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. *J Am Coll Cardiol* 2009;**54**:250–254.
411. Ostman-Smith I, Wettrell G, Keeton B, Riesenfeld T, Holmgren D, Ergander U. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. *Cardiol Young* 2005;**15**:632–642.
412. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. *J Am Coll Cardiol* 2011;**58**:1007–1013.
413. Wilson WR, Greer GE, Grubb BP. Implantable cardioverter-defibrillators in children: a single-institutional experience. *Ann Thorac Surg* 1998;**65**:775–778.
414. Kaski JP, Tome Esteban MT, Lowe M, Sporton S, Rees P, Deanfield JE, McKenna WJ, Elliott PM. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. *Heart* 2007;**93**:372–374.
415. Efthimiadis GK, Giannakoulas G, Parcharidou DG, Pagourelis ED, Kouidi EJ, Spanos G, Kamperidis V, Gavrielides S, Karvounis H, Styliadis I, Parcharidis GE. Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy. *Int J Cardiol* 2011;**153**:179–184.
416. Berrueto A, Vatasescu R, Mont L, Sitges M, Perez D, Papiashvili G, Vidal B, Francino A, Fernandez-Armenta J, Silva E, Bijnsens B, Gonzalez-Juanatey JR,

- Brugada J. Biventricular pacing in hypertrophic obstructive cardiomyopathy: a pilot study. *Heart Rhythm* 2011;**8**:221–227.
417. Savage DD, Seides SF, Maron BJ, Myers DJ, Epstein SE. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. *Circulation* 1979;**59**:866–875.
418. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, Fragola PV, Chiarella F, Zoni-Berisso M, Branzi A. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. *Circulation* 1994;**90**:2743–2747.
419. Morner S, Johansson B, Henein M. Arrhythmogenic left ventricular apical aneurysm in hypertrophic cardiomyopathy. *Int J Cardiol* 2011;**151**:e8–e9.
420. Bordignon S, Chun KR, Schmidt B. Epicardial ablation of monomorphic ventricular tachycardia storm in hypertrophic cardiomyopathy. *Europace* 2013;**15**:346.
421. Wong KC, Qureshi N, Jones M, Betts TR. Epicardial ablation of monomorphic ventricular tachycardia in a case of hypertrophic cardiomyopathy with apical aneurysm. *Europace* 2013;**15**:296.
422. Dukkupati SR, d'Avila A, Soejima K, Bala R, Inada K, Singh S, Stevenson WG, Marchlinski FE, Reddy VY. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. *Circ Arrhythm Electrophysiol* 2011;**4**:185–194.
423. Sorajja P, Nishimura RA, Gersh BJ, Dearani JA, Hodge DO, Wiste HJ, Ommen SR. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. *J Am Coll Cardiol* 2009;**54**:234–241.
424. Todiere G, Aquaro GD, Piaggi P, Formisano F, Barison A, Masci PG, Strata E, Bacigalupo L, Marzilli M, Pingitore A, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2012;**60**:922–929.
425. Olivotto I, Montereggi A, Mazzuoli F, Cecchi F. Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy. *G Ital Cardiol* 1999;**29**:11–19.
426. Sorajja P, Allison T, Hayes C, Nishimura RA, Lam CS, Ommen SR. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. *Am J Cardiol* 2012;**109**:1494–1498.
427. Regitz-Zagrosek V, Blomstrom LC, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Lung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *Eur Heart J* 2011;**32**:3147–3197.
428. Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers Lives: Reviewing Maternal Deaths to make motherhood safer – 2003–2005. The seventh report on confidential enquiries into maternal deaths in the United Kingdom. 2008.
429. Silversides CK, Sermer M, Siu SC. Choosing the best contraceptive method for the adult with congenital heart disease. *Curr Cardiol Rep* 2009;**11**:298–305.
430. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, Kells CM, Bergin ML, Kiess MC, Marcotte F, Taylor DA, Gordon EP, Spears JC, Tam JW, Amankwah KS, Smallhorn JF, Farine D, Sorensen S. Prospective multicenter study of pregnancy outcomes in women with heart disease. *Circulation* 2001;**104**:515–521.
431. Autore C, Conte MR, Piccininno M, Bernabo P, Bonfiglio G, Bruzzi P, Spirito P. Risk associated with pregnancy in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002;**40**:1864–1869.
432. Avila WS, Amaral FM, Ramires JA, Rossi EG, Grinberg M, Bortolotto MR, Mady C, Krieger JE, Zugaib M. Influence of pregnancy on clinical course and fetal outcome of women with hypertrophic cardiomyopathy. *Arq Bras Cardiol* 2007;**88**:480–485.
433. Thaman R, Varnava A, Hamid MS, Firoozi S, Sachdev B, Condon M, Gimeno JR, Murphy R, Elliott PM, McKenna WJ. Pregnancy related complications in women with hypertrophic cardiomyopathy. *Heart* 2003;**89**:752–756.
434. Krul SP, van der Smagt JJ, van den Berg MP, Sollie KM, Pieper PG, Spaendonck-Zwarts KY. Systematic review of pregnancy in women with inherited cardiomyopathies. *Eur J Heart Fail* 2011;**13**:584–594.
435. Schuler PK, Herrey A, Wade A, Brooks R, Peebles D, Lambiasi P, Walker F. Pregnancy outcome and management of women with an implantable cardioverter defibrillator: a single centre experience. *Europace* 2012;**14**:1740–1745.
436. Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, Vliegen HW, van Dijk AP, Voors AA, Yap SC, van Veldhuisen DJ, Pieper PG. Predictors of pregnancy complications in women with congenital heart disease. *Eur Heart J* 2010;**31**:2124–2132.
437. Lui GK, Silversides CK, Khairy P, Fernandes SM, Valente AM, Nickolaus MJ, Earing MG, Aboulohn JA, Rosenbaum MS, Cook S, Kay JD, Jin Z, Gersony DR. Heart rate response during exercise and pregnancy outcome in women with congenital heart disease. *Circulation* 2011;**123**:242–248.
438. Tadmor OP, Keren A, Rosenak D, Gal M, Shaia M, Hornstein E, Yaffe H, Graff E, Stern S, Diamant YZ. The effect of disopyramide on uterine contractions during pregnancy. *Am J Obstet Gynecol* 1990;**162**:482–486.
439. Magee LA, Downar E, Sermer M, Boulton BC, Allen LC, Koren G. Pregnancy outcome after gestational exposure to amiodarone in Canada. *Am J Obstet Gynecol* 1995;**172**:1307–1311.
440. Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. *Drug Saf* 1999;**20**:85–94.
441. Tromp CH, Nanne AC, Pernet PJ, Tukkie R, Bolte AC. Electrical cardioversion during pregnancy: safe or not? *Neth Heart J* 2011;**19**:134–136.
442. Walker D, Kaur N, Bell R, Walker F. Hypertrophic obstructive cardiomyopathy and pregnancy: University College London Hospital experience. *Minerva Anestesiol* 2007;**73**:485–486.
443. Pelliccia A, Maron MS, Maron BJ. Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy. *Prog Cardiovasc Dis* 2012;**54**:387–396.
444. Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. *Circulation* 2006;**114**:1633–1644.
445. Spirito P, Pelliccia A, Proschan MA, Granata M, Spataro A, Bellone P, Caselli G, Biffi A, Vecchio C, Maron BJ. Morphology of the "athlete's heart" assessed by echocardiography in 947 elite athletes representing 27 sports. *Am J Cardiol* 1994;**74**:802–806.
446. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. *N Engl J Med* 1991;**324**:295–301.
447. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete's heart in women. Echocardiographic characterization of highly trained elite female athletes. *JAMA* 1996;**276**:211–215.
448. Biffi A, Maron BJ, Culasso F, Verdile L, Fernando F, Di Giacinto B, Di Paolo FM, Spataro A, Delise P, Pelliccia A. Patterns of ventricular tachyarrhythmias associated with training, deconditioning and retraining in elite athletes without cardiovascular abnormalities. *Am J Cardiol* 2011;**107**:697–703.
449. Biffi A, Maron BJ, Di Giacinto B, Porcaccia P, Verdile L, Fernando F, Spataro A, Culasso F, Casasco M, Pelliccia A. Relation between training-induced left ventricular hypertrophy and risk for ventricular tachyarrhythmias in elite athletes. *Am J Cardiol* 2008;**101**:1792–1795.
450. Wilson MG, Sharma S, Carre F, Charron P, Richard P, O'Hanlon R, Prasad SK, Heidebuechel H, Brugada J, Salah O, Sheppard M, George KP, Whyte G, Hamilton B, Chalabi H. Significance of deep T-wave inversions in asymptomatic athletes with normal cardiovascular examinations: practical solutions for managing the diagnostic conundrum. *Br J Sports Med* 2012;**46** Suppl 1:i51–i58.
451. Konno T, Fujino N, Hayashi K, Uchiyama K, Masuta E, Katoh H, Sakamoto Y, Tsubokawa T, Ino H, Yamagishi M. Differences in the diagnostic value of various criteria of negative T waves for hypertrophic cardiomyopathy based on a molecular genetic diagnosis. *Clin Sci (Lond)* 2007;**112**:577–582.
452. Corrado D, Pelliccia A, Heidbuechel H, Sharma S, Link M, Basso C, Biffi A, Buja G, Delise P, Gussac I, Anastasakis A, Borjesson M, Bjornstad HH, Carre F, Deligiannis A, Dugmore D, Fagard R, Fagard R, Hoogsteen J, Mellwig KP, Panhuyzen-Goedkoop N, Solberg E, Vanhees L, Drezner J, Estes NA III, Iliceto S, Maron BJ, Peidro R, Schwartz PJ, Stein R, Thiene G, Zeppilli P, McKenna WJ. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. *Eur Heart J* 2010;**31**:243–259.
453. Afonso LC, Bernal J, Bax JJ, Abraham TP. Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. *JACC Cardiovasc Imaging* 2008;**1**:787–800.
454. Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1987;**10**:733–742.
455. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. *Circulation* 2002;**105**:944–949.
456. Maron BJ, Pelliccia A, Spataro A, Granata M. Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. *Br Heart J* 1993;**69**:125–128.
457. Papadakis M, Carre F, Kervio G, Rawlins J, Panoulas VF, Chandra N, Basavarajaiah S, Carby L, Fonseca T, Sharma S. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin. *Eur Heart J* 2011;**32**:2304–2313.
458. Sheikh N, Papadakis M, Carre F, Kervio G, Panoulas VF, Ghani S, Zaidi A, Gati S, Rawlins J, Wilson MG, Sharma S. Cardiac adaptation to exercise in adolescent athletes of African ethnicity: an emergent elite athletic population. *Br J Sports Med* 2013;**47**:585–592.
459. Pagourelas ED, Efthimiadis GK, Kouidi E, Zorou P, Giannoglou G, Deligiannis A, Athyros VG, Karagiannis A, Geleris P. Efficacy of various "classic" echocardiographic and laboratory indices in distinguishing the "gray zone" between athlete's heart

- and hypertrophic cardiomyopathy: a pilot study. *Echocardiography* 2013;**30**: 131–139.
460. Gruner C, Ivanov J, Care M, Williams L, Moravsky G, Yang H, Laczay B, Siminovich K, Woo A, Rakowski H. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. *Circ Cardiovasc Genet* 2013;**6**:19–26.
  461. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. *JAMA* 1996;**275**:1507–1513.
  462. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *Am J Med* 2003;**115**:41–46.
  463. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. *JAMA* 2004;**292**: 2343–2349.
  464. Skudicky D, Sareli P, Libhaber E, Candy G, Radevski I, Valtchanova Z, Tshele E, Thijs L, Wang JG, Staessen JA. Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial. *Circulation* 2002;**105**:830–836.
  465. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif PC, Smith BA, Dahlof B. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. *Circulation* 2009;**119**:530–537.
  466. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. *Lancet* 2009;**374**:525–533.
  467. Pewsner D, Juni P, Egger M, Battaglia M, Sundstrom J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. *BMJ* 2007;**335**:711.
  468. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. *Am Heart J* 2002;**144**: 530–537.
  469. Tang W, Devereux RB, Rao DC, Oberman A, Hopkins PN, Kitzman DW, Arnett DK. Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. *Am Heart J* 2002;**143**:854–860.
  470. Brady TM, Fivush B, Flynn JT, Parekh R. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. *J Pediatr* 2008;**152**: 73–78.
  471. Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD, Ostman-Smith I, Casadei B, Watkins H, Neubauer S. Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2005;**7**:551–558.
  472. Sipola P, Magga J, Husso M, Jaaskelainen P, Peuhkurinen K, Kuusisto J. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. *Eur Radiol* 2011;**21**:1383–1389.
  473. Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, Paetsch I. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. *Am J Cardiol* 2010;**106**:1016–1022.
  474. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. *Hypertension* 2005;**45**:412–418.
  475. Gerds E, Okin PM, Boman K, Wachtell K, Nieminen MS, Dahlöf B, Devereux RB. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. *Am J Hypertens* 2012;**25**:678–683.
  476. Cuspidi C, Negri F, Muesan ML, Capra A, Lonati L, Milan A, Sala C, Longo M, Morganti A. Prevalence and severity of echocardiographic left ventricular hypertrophy in hypertensive patients in clinical practice. *Blood Press* 2011;**20**:3–9.
  477. Fogari R, Mugellini A, Destro M, Corradi L, Lazzari P, Zoppi A, Preti P, Derosa G. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. *Diabet Med* 2012;**29**:24–31.
  478. Peterson GE, de Backer T, Contreras G, Wang X, Kendrick C, Greene T, Appel LJ, Randall OS, Lea J, Smogorzewski M, Vagaonescu T, Phillips RA. Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease. *Hypertension* 2013;**62**:518–525.
  479. Vinereanu D, Florescu N, Sculthorpe N, Tweddel AC, Stephens MR, Fraser AG. Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue Doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes. *Am J Cardiol* 2001;**88**: 53–58.
  480. Kato TS, Noda A, Izawa H, Yamada A, Obata K, Nagata K, Iwase M, Murohara T, Yokota M. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. *Circulation* 2004;**110**:3808–3814.
  481. Faber L, Heemann A, Surig M, Michalowski Z, Gleichmann U, Klempt HW. Outflow acceleration assessed by continuous-wave doppler echocardiography in left ventricular hypertrophy: an analysis of 103 consecutive cases. *Cardiology* 1998;**90**: 220–226.
  482. Zywicki K, Jenni R, Pelliikka PA, Faeh-Gunz A, Seifert B, Attenhofer Jost CH. Dynamic left ventricular outflow tract obstruction evoked by exercise echocardiography: prevalence and predictive factors in a prospective study. *Eur J Echocardiogr* 2008;**9**:665–671.
  483. Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. *Circulation* 1978;**58**:402–408.
  484. Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ. Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. *Am J Cardiol* 2005;**96**:270–275.
  485. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. *N Engl J Med* 1987;**317**: 787–792.
  486. Siegel D, Cheitlin MD, Black DM, Seeley D, Hearst N, Hulley SB. Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. *Am J Cardiol* 1990;**65**:742–747.
  487. Hennersdorf MG, Strauer BE. Arterial hypertension and cardiac arrhythmias. *J Hypertens* 2001;**19**:167–177.
  488. Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, Ackerman MJ. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofibrillar mutations. *Mayo Clin Proc* 2006;**81**:459–467.
  489. Konishi C, Shiraishi J, Muraguchi N, Ohtsuki K, Inoue M, Tatsumi T, Azuma A, Matsuura H. Beneficial effect of cibenzoline on left ventricular pressure gradient with sigmoid septum. *Circ J* 2004;**68**:968–971.
  490. Ranasinghe I, Yeoh T, Yiannakis J. Negative inotropic agents for the treatment of left ventricular outflow tract obstruction due to sigmoid septum and concentric left ventricular hypertrophy. *Heart Lung Circ* 2011;**20**:579–586.
  491. Tuseth N, Cramariuc D, Rieck AE, Wachtell K, Gerds E. Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy). *Blood Press* 2010;**19**:140–144.
  492. Dweck MR, Joshi S, Murigu T, Gulati A, Alpendurada F, Jabbour A, Maceira A, Roussin I, Northridge DB, Kilner PJ, Cook SA, Boon NA, Pepper J, Mohiaddin RH, Newby DE, Pennell DJ, Prasad SK. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2012;**14**:50.
  493. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivas G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Jung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J* 2012;**33**:2451–2496.
  494. Di Tommaso L, Stassano P, Mannacio V, Russolillo V, Monaco M, Pinna G, Vosa C. Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy. *J Thorac Cardiovasc Surg* 2013;**145**:171–175.
  495. Kar AK, Roy S, Panja M. Aortic regurgitation in hypertrophic cardiomyopathy. *J Assoc Physicians India* 1993;**41**:576–578.
  496. Shiota T, Sakamoto T, Takenaka K, Amano K, Hada Y, Hasegawa I, Suzuki J, Takahashi H, Sugimoto T. Aortic regurgitation associated with hypertrophic cardiomyopathy: a colour Doppler echocardiographic study. *Br Heart J* 1989;**62**: 171–176.
  497. Roberts WC, Kishel JC, McIntosh CL, Cannon RO III, Maron BJ. Severe mitral or aortic valve regurgitation, or both, requiring valve replacement for infective endocarditis complicating hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1992;**19**: 365–371.
  498. Brown PS Jr., Roberts CS, McIntosh CL, Clark RE. Aortic regurgitation after left ventricular myotomy and myectomy. *Ann Thorac Surg* 1991;**51**:585–592.
  499. Sasson Z, Prieur T, Skrobik Y, Fulop JC, Williams WG, Henderson MA, Gresser C, Wigle ED, Rakowski H. Aortic regurgitation: a common complication after surgery for hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 1989;**13**:63–67.
  500. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano JL. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). *Eur J Echocardiogr* 2010;**11**:307–332.

501. Spirito P, Rapezzi C, Bellone P, Betocchi S, Autore C, Conte MR, Bezante GP, Bruzzi P. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. *Circulation* 1999;**99**:2132–2137.
502. Alessandri N, Pannarale G, del Monte F, Moretti F, Marino B, Reale A. Hypertrophic obstructive cardiomyopathy and infective endocarditis: a report of seven cases and a review of the literature. *Eur Heart J* 1990;**11**:1041–1048.
503. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, de Jesus AM, Thilen U, Lekakis J, Lengyel M, Muller L, Naber CK, Nihoyannopoulos P, Moritz A, Zamorano JL. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. *Eur Heart J* 2009;**30**:2369–2413.
504. Vijgen J, Botto G, Camm J, Hoijer CJ, Jung W, Le Heuzey JY, Lubinski A, Norekval TM, Santomauro M, Schalij M, Schmid JP, Vardas P. Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. *Eur J Cardiovasc Nurs* 2010;**9**:3–14.
505. Smith D, Toff W, Joy M, Dowdall N, Johnston R, Clark L, Gibbs S, Boon N, Hackett D, Aps C, Anderson M, Cleland J. Fitness to fly for passengers with cardiovascular disease. *Heart* 2010;**96** Suppl 2:ii1–16.
506. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2009;**54**:201–211.